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Dr. Mark Joseph Daly                                                                    Elizabeth Jeffries Rossin 
The proteomic landscape of human disease: construction and evaluation of 
networks associated to complex traits 
Abstract 
Genetic mapping of complex traits has been successful over the last decade, with 
over 2,000 regions in the genome associated to disease. Yet, the translation of these 
findings into a better understanding of disease biology is not straightforward. The true 
promise of human genetics lies in its ability to explain disease etiology, and the need to 
translate genetic findings into a better understanding of biological processes is of great 
relevance  to  the  community.  We  hypothesized  that  integrating  genetics  and  protein-
protein  interaction  (PPI)  networks  would  shed  light  on  the  relationship  among  genes 
associated to complex traits, ultimately to help guide understanding of disease biology. 
First,  we  discuss  the  design,  testing  and  implementation  of  a  novel  in  silico 
approach (“DAPPLE”) to rigorously ask whether loci associated to complex traits code 
for proteins that form significantly connected networks. Using a high-confidence set of 
publically available physical interactions, we show that loci associated to autoimmune 
diseases code for proteins that assemble into significantly connected networks and that 
these networks are predictive of new genetic variants associated to the phenotypes in 
question. 
Next,  we  study  variation  in  the  electrocardiographic  QT-interval,  a  heritable 
phenotype that when prolonged is a risk factor for cardiac arrhythmia and sudden cardiac 
death. We show that a large proportion of QT-associated loci encode proteins that are 
members of complexes identified by immunoprecipitations in mouse cardiac tissue of      
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proteins  known  to  be  causal  of  Mendelian  long-QT  syndrome.  For  several  of  the 
identified proteins, we show they affect cardiac ion channel currents in model organisms. 
Using replication genotyping in 17,500 individuals, we use the complexes to identify 
genome-wide significant loci that would have otherwise been missed.  
Finally,  we  consider  whether  PPIs  can  be  used  to  interpret  rare  and  de  novo 
variation discovered through recent technological advances in exome-sequencing. We 
report a highly connected network underlying de novo variants discovered in an autism 
trio  exome-sequencing  effort,  and  we  design,  test  and  implement  a  novel  statistical 
framework (“DAPPLE/SEQ”) to analyze rare inherited variants in the context of PPIs in 
a way that significantly boosts power to detect association.      
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1  Introduction     
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1.1  Genetic Mapping in Human Disease 
Studying DNA variation of people affected by heritable disorders is one of the most 
promising  approaches  to  identifying  the  cellular  causes  of  many  human  diseases. 
Especially for diseases whose etiology is largely unknown, finding potentially causal 
genes can help reveal proteins and pathways to target with therapeutics. The search for 
such  genetic  variation  has  been  particularly  successful  in  rare  and  highly  penetrant 
genetic disorders that are caused by severe mutations in DNA: classic examples of such 
diseases  include  hemochromatosis,  cystic  fibrosis  and  phenylketonuria[1].  For  these 
diseases, single nucleotide changes in particular genes lead to deficient or altered proteins 
that then result in a cascade of physiological outcomes, ultimately culminating in the 
medical sequelae that define the disease. Understanding the cellular processes that have 
gone awry is relevant to patients’ medical treatment – for example, understanding that 
phenylketonuria  is  caused  by  a  lesion  the  gene  encoding  phenylalanine  hydroxylase 
directly translates to phenylalanine-lowering recommendations that drastically minimize 
damage; likewise, knowing that cystic fibrosis is caused by a primary defect in chloride 
transport has helped steer recent design of treatment toward drugs that will specifically 
focus on chloride ions. Therefore, we study human genetics to understand disease biology 
with the goal ultimately being novel therapeutic design. 
One  of  the  goals  of  the  last  decade  has  been  to  apply  these  concepts  to  more 
common and genetically complex diseases. A complex trait is defined as one that is 
influenced by many low-pentrant DNA variants as well as the environment such that the 
familial clustering of the trait does not follow a clear and predictable inheritance pattern.      
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For  most  complex  diseases,  we  do  not  understand  the  bulk  of  the  underlying 
pathophysiology, though many of these traits are clearly heritable. Since the early 1900s, 
medical doctors and scientists have compared monozygotic twins to dizygotic twins to 
estimate the proportion of phenotypic variance observed in such complex traits that is due 
to genetics. For many continuous traits – height, body mass index, blood lipid levels – as 
well as dichotomous traits – autoimmune disease, Type 2 diabetes and psychiatric disease 
–  twin  studies  have  consistently  revealed  a  striking  degree  of  heritability  (typically 
ranging from 30-90%). This observation is what gives the field of human genetics (and in 
particular complex trait genetics) hope: identifying genetic risk variants is a reliable and 
unbiased means of gaining insight into the relevant genes and biological processes.  
Identifying  genes  for  Mendelian  and  complex  traits  alike  requires  genetic 
mapping, i.e. the identification and localization of genes that underlie phenotypes [2]. 
Genetic mapping is accomplished by correlating DNA variation that is nearby to the 
disease-causing mutation – single nucleotide polymorphisms (SNPs), microsatellite and 
minisatellites, copy number variation, etc – with phenotype. The fundamental concept of 
genetic mapping involves two observations: DNA gets passed on in blocks and only 
rarely undergoes recombination, and this recombination occurs at “hotspots”, such that 
there are places in the genome that are much more likely to endure a recombination event 
than  others.  The  first  observation  is  what  led  to  linkage  mapping:  rare  and  highly 
deleterious alleles could be tracked in families by correlating genomic markers (DNA 
variation) with phenotype, since variants close to the disease-causing mutation will rarely 
recombine and those that are far will do so more often – thus allowing for positional 
mapping of the disease region. The second observation means that correlation between      
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nearby  variants  bounded  by  recombination  hotspots  will  persist  from  ancestors  many 
generations ago since recombination between them will be rare. This phenomenon is 
known as linkage disequilibrium (LD), and LD is harnessed in genome-wide association 
studies  (GWAS),  discussed  below.  Both  linkage  and  GWAS  require  being  able  to 
systematically assay a set of variants throughout the genome. 
The earliest attempts at linkage mapping were carried out by Surtevant in the 
early 1900s in Drosophila, when he realized that he could map the linear order of genes 
by tracking patterns of correlations between genotype and phenotype in fly crosses, with 
the assumption that meiotic cross-overs would lead to association only between markers 
physically  near  to  the  phenotype-causing  mutation  (also  known  as  “positional 
cloning”)[3]. Though successful in model organisms where predetermined crosses could 
be carried out, such an approach was met with significant difficulties in humans for most 
of the 20
th century due to small pedigrees and lack of systematic markers throughout the 
genome. Linkage in families became feasible around 1980 when Botstein and colleagues 
proposed the idea of using restriction fragment length polymorphisms (a type of variant 
that disrupts a restriction enzyme cut site and is therefore easy to assay) throughout the 
genome  to  systematically  map  human  genes  associated  with  disease[4].  This 
breakthrough  in  methodology  led  to  the  mapping  of  the  Huntington’s  gene  on 
chromosome 4 in 1983[5] followed by the systemic documentation of dense genome-
wide  polymorphic  sites  and  the  subsequent  mapping  of  now  over  2,000  Mendelian 
diseases[6]. Disease and study characteristics that aided in successful linkage mapping 
included highly penetrant causal genetic variants (as is the case in the aforementioned 
diseases like cystic fibrosis), causal variants that are rare in the population, relatively      
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little  environmental  influence  on  the  phenotype,  large  families  and  minimal  locus 
heterogeneity. Linkage analysis works very well with Mendelian phenotypes for these 
reasons.  
As the number of Mendelian phenotypes successfully mapped through linkage 
rose, however, it quickly became clear that this approach was woefully underperforming 
in more common complex phenotypes that clearly exhibited a heritable component. As 
discussed, these traits are unlike Mendelian phenotypes in that they are highly polygenic 
(many risk variants throughout the genome), influenced by environment, and contributed 
to by genetic variants of individually very low effect on phenotype. These factors are 
what make such traits ill-suited for linkage analysis. 
  Association  analysis  in  large  samples  of  individuals  –  comparison  of  allele 
frequencies in cases and controls rather than tracking genotypes and phenotypes in a 
family  –  offered  a  path  forward  because  it  was  much  better  powered  to  detect  such 
associations  of  weak  effects  due  to  the  fact  that  it  does  not  require  large  families. 
Association analysis differs from linkage in that it simply looks for differences in allele 
frequencies between cases and controls, rather than positionally mapping a linked region. 
It turns out that association studies for common variation ended up harnessing the same 
concept as linkage (i.e., variants close to the causal mutation will tend to associated with 
phenotype), but are fundamentally distinct in that they do not consider meiotic crosses in 
families. Rather, they use variants that tag regions of LD throughout the genome and that 
have  persisted  from  ancestors  many  generations  ago  and  undergone  relatively  little 
recombination. The first attempts at this were based on candidate gene studies where 
investigators  compared  variants  between  cases  and  controls  within  a  single  gene  of      
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interest,  such  as  the  mapping  of  the  human  leukocyte  antigen  locus  to  autoimmune 
disease [7] and the association between variants at APOE and Alzheimers disease[8]. The 
success  of  these  types  of  studies  were  limited  and  results  were  often  not  replicable, 
however,  since  they  relied  on  candidate  gene  selection,  they  counted  nominal 
significance (p<0.05) as definitive without controlling for multiple testing and they could 
not control for population sub-structure, which we now know to be a major confounder of 
association studies (“population stratification”)[2]. 
The challenge to expanding beyond single genes was that it was not feasible to 
sequence every genome in a cohort of individuals to document all the variants therein. 
Fortunately,  in  the  1990s,  a  systemic  genome-wide  association  approach  to  studying 
genetic  variation  associated  to  disease  on  a  genome-wide  scale  without  the  need  for 
sequencing was proposed that involved harnessing the LD previously described. A few 
key  developments  made  such  a  proposal  possible:  (1)  the  discovery  of  widespread 
correlation between SNPs throughout the genome and the presence of a limited set of 
haplotypes  at  a  given  locus,  which  precluded  the  need  to  fully  sequence  someone’s 
genome [9]; (2) the cataloging of common human genetic variation and the correlations 
therein in 2005 through the completion of The HapMap Project[10]; (3) the engineering 
of  microarray  technology  –  high-throughput  arrays  that  facilitated  cheaply  testing 
hundreds of thousands of variants at a time[11]; and (4) the development of statistical 
methodology to analyze such large amounts of data and control for technical artifacts and 
biases therein as well as methodology for imputation of non-typed SNPs, which allowed 
for meta-analyses across many individual studies[12].       
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The  proposal  to  study  genetic  variation  on  a  genome-wide  scale  (GWAS: 
genome-wide association study) therefore involved focusing on a particular subset of 
variation:  common  SNPs.  Common  SNPs  are  defined  as  those  whose  minor  allele 
frequency is > 1%. In the European population, there are 10 million such sites in the 
genome at which individuals’ genotypes vary [13]. These sites comprise about 90% of an 
individual’s  heterozygous  sites  throughout  their  genome[2].  Practically  speaking,  this 
type  of  variation  is  extremely  convenient  because,  as  described,  there  is  widespread 
correlation  among  common  variants  due  to  their  being  relatively  old  in  evolutionary 
history and recombination happening mostly at hotspots. This means that only a subset of 
variants needs to be genotyped in a given study to serve as a proxy for the rest, and 
microarray technology can easily allow for cheap, direct genotyping of these hundreds of 
thousands (and now a million) SNPs. 
Beyond  practicality,  however,  there  are  theoretical  arguments  grounded  in 
population genetics that predict the genetic architecture of common disease to be at least 
in part due to common variation (hence the so-called “common-variant common-disease” 
hypothesis). This argument includes the typical late onset of many common diseases that 
precludes causal alleles from strong natural selection, causal alleles being neutral in the 
past  and  only  now  having  an  effect  due  to  recently  introduced  changes  in  living 
situations, recent population expansion allowing detrimental alleles to rise in frequency 
and phenomena such as heterozygote-advantage [2].  
Perhaps more satisfying arguments for common variation playing a role in the 
etiology of common diseases are empirical ones. First, if the majority of causal variants 
for common disease were rare and highly penetrant, the linkage era would have seen      
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more success in mapping of common diseases (unless these diseases are typically caused 
by a single highly penetrant mutation in one of many possible genes, though so far there 
is  no  evidence  for  this  model).  Second,  the  genome-wide  association  era  of  the  last 
decade  has  seen  major  breakthroughs  in  the  identification  of  thousands  of  common 
variants associated to complex traits. Many dichotomous traits, such as Type 1 and 2 
diabetes and inflammatory bowel disease, have seen a rapid expansion in the number of 
loci definitively associated to disease[14–21]. Likewise, huge success has been met by 
those studying quantitative traits in population cohorts, such as blood lipid levels, human 
height and body-mass index[22–26]. The National Human Genome Research Institute 
has cataloged over 5,000 common variants found to be associated to complex traits or 
diseases [27]. The loci discovered to date have identified common variants at previously 
known genes where variants of much stronger effect had been identified through linkage 
but  also  have  identified  numerous  novel  genes  that  implicate  potential  pathogenic 
mechanisms that would never have been suspected. In age-related macular degeneration, 
complement  factor  H  was  identified  to  bear  common  variation  that  predisposes  to 
disease; in Crohn’s disease, ATG16L1 and IRGM, two genes known to play a role in 
cellular autophagy, are independently implicated; and regulatory variation near SORT1 
was found to predispose to higher blood LDL levels [16,28–30].  These are examples 
where GWAS has proven to be a powerful method to pinpoint genes and processes (and 
in the aforesaid cases specific variants) that are implicated in disease that would have 
otherwise been missed. 
With the discovery of associated common SNPs, a few fundamental and for the 
most part universal observations have been made.      
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•  The effect sizes of risk variants are small. While there are a cases where the 
effect size is observed to be ≥ 2 (such as IL23R in Crohn’s[18], SORT1 in blood-
lipid levels[31], APOE in Alzheimer’s disease[8] and CFH in age-related macular 
degeneration[32]), most lie between 1.1 and 1.5[2].  
•  Complex traits are extremely polygenic. A disease with substantial heritability 
and risk alleles individually of low effect is likely polygenic, i.e. phenotypes are 
contributed  to  by  risk  alleles  of  small  effect  at  many  genes  throughout  the 
genome.  In  Schizophrenia,  for  example,  a  significant  inflation  in  association 
exists across thousands of common variant loci. Importantly, this inflation was 
replicated  in  family  studies,  precluding  the  possibility  of  it  being  driven  by 
population stratification [33,34]. Subsequently, Yang et al. showed that much of 
the heritability for human height is explained by alleles of very weak effect that 
have yet to reach genome-wide significance[25]. Therefore, while the risk alleles 
discovered to date explain only a portion of the heritability, it may be the case for 
some complex traits that there are many more common variants of even lower 
effect  that  contribute  to  disease  (though  additional  sources  of  variation  not 
captured – rare variation, structural variation and epigenetic variation – are likely 
to contribute to the genetic architecture as well. Rare variation is discussed in 
section 1.2).  
•  Most associated regions implicate many genes and have not yet been fine-
mapped. SNPs tag large regions of disequilibrium where continuous blocks of 
DNA that are between recombination hotspots are passed on together and rarely 
recombined. Thus, association at a particular SNP implicates not only the SNPs in      
 
  10 
LD with the lead SNP but also any other type of variant nearby, such as another 
SNP or a CNV (as was the case with IRGM in Crohn’s disease)[29]. These blocks 
can be 100s of kilobases in size, and contain up to 25 genes (median of 3 genes, 
distribution shown in Figure 1.1). In a very small number of cases, fine-mapping 
has led to the unambiguous identification of a causal variant; for the vast majority 
of associations discovered to date, however, the causal gene is not known (though 
in  a  few  cases  may  be  suspected).  This  limiting  factor  is  what  prevents  the 
translation of these genetic discoveries to biological mechanism and ultimately to 
improving therapeutic design.  
 
Figure 1.1 Distribution of number of genes per locus. 7,496 SNPs were downloaded from the 
NHGRI GWAS catalog, of which 5,924 were in LD with genes. The wingspan of a SNP was 
defined by the SNPs in r
2 > .5 of the lead SNP and further extended to the nearest recombination 
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hotspots. Genes that overlap the defined wingspan were counted as part of the locus (see Chapter 
2).
•  The same locus can be implicated by rare and common variants. In many 
cases, common variants of modest effect were identified at the same locus that 
known highly penetrant mutations have been identified as causal of an extreme 
version  of  the  common  phenotype.  For  example,  a  SNP  with  minor  allele 
frequency of 11% at LDLR has been identified in a study of blood-lipid levels, 
complementary to the more rare and deleterious mutation in the same gene known 
to cause familial hypercholesterolemia[31,35]; 4 independent common variants 
that have been found to be associated with variation in the cardiac QT-interval are 
near genes that are causal of the rare Mendelian long-QT syndromes [36,37]; and 
common variants near FGFR4 were found to influence human height, where rare 
mutations in a similar growth-related gene (FGFR3) cause the Mendelian disease 
achondroplasia [38]. 
•  Most  associations  are  not  at  coding  variants  but  rather  are  in  intergenic 
regions. The majority of common variant associations that have been identified 
have no evidence of a nearby coding variant, suggesting that many genetic risk 
factors for common disease will interfere with gene expression rather than the 
protein itself[39]. This idea has been further supported by a number of expression 
quantitative-trait locus (eQTL) studies, where the allele of a SNP correlates with 
the expression of a gene in cis nearby, suggesting that it may interfere with the 
activity of transcription factors[40,41].      
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•  The  genes  implicated  in  associated  regions  fall  into  pathways.  Pathway 
analysis  –  the  study  of  genes  that  co-occur  in  documented  pathways  or  are 
connected in the biological literature – is an area of study that has been widely 
explored and has suggested that genes associated through GWAS tend to fall in 
cohesive pathways. Well-established methods include the GSEA, the Set-Screen 
test, MAGENTA, FORGE, ALIGATOR and INRICH[42–46]. Though distinct in 
their underlying methodology, each method tests a set of defined pathways or 
gene  groups  (using  databases  like  KEGG,  REACTOME,  Gene  Ontology, 
TargetScan,  PANTHER  and  OMIM)  for  enrichment  in  association  beyond 
random expectation, controlling for confounders like LD and gene size[6,47–49]. 
Though these approaches are inherently constrained by our limited knowledge of 
gene  function  and  how  genes  should  be  grouped  into  pathways,  they  have 
nonetheless indentified potentially relevant biological pathways[50]. For example, 
cell  adhesion  molecules  have  been  shown  to  be  significantly  enriched  in 
associations to schizophrenia and bipolar disorder, pointing at synaptic formation 
as a potential biological lead underlying the etiology of schizophrenia[51].  
There is a slowly growing set of instances where the preliminary GWAS scan has 
identified  not  only  an  associated  locus  but  also  a  specific  variant  that  has  relevant 
biological  findings  and  is  likely  driving  the  association  signal.  For  example,  the 
ATG16L1  T300A  variant  associated  to  Crohn’s  disease  was  found  to  be  the  most 
associated  SNP  in  the  region  and  also  suggested  to  be  causal:  ATG16L1  is  a  gene 
involved in cellular autophagy (the removal of intracellular contents) and this particular      
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variant  was  shown  to  impair  the  process  of  selective  autophagy  associated  with  the 
removal of Salmonella typhi bacteria in human epithelial cells[30].  
The  vast  majority  of  identified  loci,  however,  do  not  point  to  specific  causal 
variants or even causal genes. As shown in Figure 1.1, associated regions can contain 
multiple genes, making the problem even harder. With this in hand, it is clear that the 
next phase of GWAS should be focused on identifying important genes and pathways 
that are implicated by the genetic findings so far. However, while pathway analysis has 
promise, not all genes can be assigned to pathways and not all pathways are known. This 
thesis  will  discuss  the  use  of  protein-protein  interaction  data  (which  can  be 
experimentally produced on a broad scale and without the requirement of pre-determined 
processes)  to  begin  to  elucidate  some  of  the  biological  networks  or  complexes  that 
underlie genetic associations to complex traits.  
1.2  Exome sequencing and discovery of rare variants 
Most GWAS arrays are not designed to capture rare alleles. As the identification of new 
common-variant  loci  with  substantial  effect  size  has  tapered  off  for  many  traits, 
investigators have begun to wonder about rarer variation and are therefore turning to 
sequencing in order to capture this class of variant. A rare allele is defined as a minor 
allele frequency of <1% [52]. Most alleles in the population are rare, while common 
variants  (though  comprising  most  of  the  heterozygous  sites  of  an  individual)  are 
relatively  few.  The  etiology  of  this  distribution  is  that  variants  enter  the  population 
spontaneously fairly rapidly (~40 de novo SNPs per individual[53]), but are quickly lost 
via genetic drift or are even more rapidly lost if they are deleterious. Some – both benign      
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and  deleterious  –  will  be  passed  on  to  progeny  and  persist  at  low  levels  before 
disappearing and thus populate the rare alleles present in humans, though very few will 
rise to a frequency considered common. The size of the existing pool of rare variants in 
the population has been further enhanced by the recent population expansion, which will 
naturally expand with it the number of rare alleles[52].  
The reasons for testing rare variation for association to disease are many and have 
elicited lively debates among investigators. It is worth discussing three of the motivations 
behind this work. 
•  Fine-mapping  the  causal  gene  in  a  common  variant  associated  locus. A s  
discussed, common allele associations are hampered by long ranges of linkage 
disequilibrium,  which  leads  to  10s-100s  of  SNPs  being  implicated  under  one 
signal  and  multiple  genes  to  consider ( Figure  1.1).  It  is  possible  to  fine-map 
causal common alleles through conditional analysis (i.e., hold allele A fixed and 
test allele B to see if the signal from B is independent from A), but in regions 
where r
2 is close to 1 between associated SNPs, it can be impossible. Furthermore, 
common SNP associations do not necessarily implicate that a SNP nearby is the 
causal variant; SNPs can tag other types of genetic variation that may not have 
been captured such as CNVs or indels. On the other hand, since rare variation 
usually represents alleles that arose on a haplotype relatively recently, they are 
typically not in appreciable linkage disequilibrium with many surrounding SNPs. 
Therefore, if one can detect association to a rare allele (which is admittedly more 
difficult to do than for common alleles, see power discussion below), it is likely 
(though not always) that the rare allele itself – and not surrounding alleles in LD –      
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is the causal variant. If rare alleles affect the same gene in the region (i.e., the 
gene influences the phenotype through both common and rare variation in the 
population), this comes in handy: detection of rare associated alleles could help 
pinpoint the causal gene in a region of common-variant association [54]. 
•  Rare alleles are more likely to be deleterious. As discussed, one of the reasons 
that an allele may be rare in the population is if it confers reduced fitness and 
therefore is not able to rise in frequency. One would then predict that these types 
of  alleles  –  since  their  age  precludes  having  been  weeded  out  due  to  natural 
selection  –  may  be  enriched  for  deleterious  events,  and  in  fact  it  has  been 
observed that rare CNVs are more likely to affect whole genes than common ones 
and  rare  SNPs  are  more  likely  to  be  non-synonymous  than  their  common 
counterparts[52]. 
•  Heritability. Though thousands of common variant loci have been discovered to 
be significantly associated across hundreds of traits, most of the results do not 
explain  the  majority  of  estimated  heritability  within  each  phenotype. 
Undoubtedly,  alleles  across  the  entire  frequency  spectrum  will  contribute  to 
disease. The relative proportion of heritability explained by common versus rare 
alleles  remains  an  open  question  and  probably  depends  on  the  particular  trait 
being studied. Nonetheless, it is possible that rare variation might fill some of the 
gap in heritability that many diseases in medical genetics currently face. 
For the reasons discussed in section 1.1, the field has up until now focused on 
identifying association to SNPs whose allele frequency is > 1%. With the recent advent 
of  better  and  more  affordable  sequencing  technology,  it  is  now  possible  to  test  for      
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variants below the 1% threshold. Many groups have focused initially on coding SNPs, 
since the functional consequence of these variants is easier to interpret and the alleles 
themselves likely carry a higher effect (which decreases the number of samples needed to 
assay).  However, as the cost of sequencing decreases even further, groups will likely 
move to whole-genome sequencing, though the interpretation of rare, non-coding variants 
poses a new challenge. 
Thus, investigators have embarked on targeted-, whole-exome- and sometimes 
whole-genome-sequencing studies. Targeted re-sequencing, wherein regions associated 
to  disease  through  common  variants  are  deeply  sequenced,  has  the  promise  of  fine-
mapping  the  causal  common  variant  and  identifying  low-frequency  (and  potentially 
greater effect) variants that may help fine-map causal genes. Whole-exome or whole-
genome studies have the added benefit of identifying associated variants that point to 
novel  regions/genes,  especially  for  those  traits  for  which  fewer  common  variant 
associations have been documented (such as autism[55]). 
  Still, it is important to keep in mind the challenges that we face when looking for 
rare variants of low-effect. A common misconception is that through exome-sequencing, 
one will identify functional variants (i.e., missense, non-sense or splice-site) that will be 
easily  interpretable  as  to  their  relevance  to  disease.  On  the  contrary,  in  a  sample  of 
individuals,  many  neutral  or  disease-irrelevant  rare  coding  variants  will  vastly  out-
number the alleles that might be relevant to disease.  One promising avenue forward is to 
analyze these rare events as groups in the context of genes or groups of genes to improve 
our ability to identify causal variants. Chapter 4 will briefly review the existing rare-
variant analysis strategies and will introduce the idea of integrating sequencing data with      
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protein-protein interaction data in order to find networks of proteins affected by rare 
variation that would have otherwise been missed by studying each variant separately. 
1.3  Protein-protein interaction data 
1.3.1  From association to disease mechanism 
 
Whether studying common or rare variants, the true promise of human genetics 
lies in its ability to reveal novel disease mechanisms to be targeted by therapeutics. As 
discussed in sections 1.1 and 1.2, it is only for a subset of discovered GWAS loci so far 
that the causal gene is known, and an even smaller set where the implicated mechanism is 
known. It has previously been observed that genes causal of Mendelian diseases code for 
proteins that are part of the sample protein complex[56–59]. The hypothesis being tested 
in this thesis is that genetic variants predisposing to complex disease affect a common 
and limited set of cellular processes. Studying genes in the contexts of the biological 
networks through which they exert their effect is thus of utmost importance. Here, we 
rigorously test whether probing physical interactions among the products of associated 
genes offers a direct route to unraveling disease etiology. 
1.3.2  Protein-protein interactions 
Protein-protein  interactions  (PPI)  represent  the  main  functional  units  in  the 
majority  of  cellular  processes.  They  are  the  driving  events  in  signal  transduction, 
formation of macromolecular machinery, transportation of one protein by another to a 
different  compartment  of  the  cell,  modification  of  proteins  by  phosphorylation, 
acetylation or ubiquitination, scaffolding of structures, and so on. The protein-protein      
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interaction  is  the  ultimate  work  unit  of  almost  all  cellular  processes.  The  scientific 
community  has  therefore  built  a  field  around  discovering  and  documenting  these 
interactions on a proteome-wide scale in a number of different model organisms and has 
been very successful in doing so, particularly in yeast but also in humans[47,60–66]. The 
hope is that these connectivity networks will provide a snapshot of the various processes 
going on in the cell. 
The two main types of interactions are pair-wise interactions and macromolecular 
protein complexes. Each individual pairwise interaction can be furthermore categorized 
as stable or transient. Stable interactions are ones that persist over a period of time, such 
as a membrane scaffolding protein that organizes and clusters membrane ion channels, 
while transient interactions are ephemeral, such as a kinase phosphorylating a substrate. 
Typically, it is easier to capture stable interactions experimentally; therefore, most PPI 
experiments will be biased toward stable interactions. Macromolecular complexes are 
multiple proteins that bind to create a larger functional unit; RNA polymerase, comprised 
of multiple proteins that bind together to carry out transcription, is a classic example.  
1.3.3  Protein-protein interaction experimental strategies 
Different experimental approaches have been developed to capture PPIs. These 
can  largely  be  broken  down  into  genetic  and  biochemical  approaches[67].  Genetic 
approaches typically refer to transcriptional complementation assays, such as yeast two-
hybrid  (Y2H),  while  biochemical  approaches  refer  to  affinity  technologies,  such  as 
affinity  purification  followed  by  mass-spectrometry  (APMS).  As  discussed  in  section 
1.3.5 and shown in Figure 1.3, nearly 80% of the evidence for interactions in large PPI 
databases are from Y2H or affinity technology.      
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The Y2H method was original developed in 1989 by Fields and Song and was 
based on the observation that eukaryotic transcription factors have a modular structure, 
consisting of a DNA-binding domain and an activation domain responsible for recruiting 
transcriptional proteins such as RNA polymerase[68]. While different systems have been 
developed since its original inception, the yeast protein Gal4 construct is far-and-above 
the most common transcriptional complementation system used to date. Y2H involves 
transfecting yeast with plasmids that encode the two proteins of interest, each fused to 
one of to the two domains of Gal4. If the two proteins stably bind in yeast, the now-
functional Gal4 recognizes a specific DNA sequence and activates transcription through 
recruiting RNA polymerase II [69]. The gene being transcribed can be used as a read-out, 
such as a His reporter gene. 
The benefit of the Y2H system is that it is easily scaled up and may recapitulate 
the cellular milieu, especially when studying yeast proteins. However, when studying 
human  proteins  heterologously  expressed  in  yeast,  sources  of  false  positives  or  false 
negatives  include  post-translational  modifications  that  are  different  and  may  interfere 
with  the  interaction,  additional  proteins  present  in  yeast  that  positively  or  negatively 
affect the interaction, inability of bait and prey to localize to the nucleus, poor folding of 
the bait and prey or needed proteins/molecules are not present[70]. The accuracy of the 
Y2H  system  has  therefore  been  debated.  An  early  study  that  compared  a  handful  of 
interaction datasets to a gold standard of protein complexes discovered fairly low quality 
of the Y2H data[71]. In contrast, more recently, Y2H-reported interactions were deemed 
to  be  of  high  quality  when  compared  to  gold-standard  sets  of  binary  interactions, 
claiming that the previously reported comparison erroneously included protein complex      
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data [72]. Ultimately, Y2H should be interpreted as one source of interaction information 
that  together  with  other  approaches  may  contribute  to  a  high-confidence  set  of 
interactions. 
More  recently,  mammalian-2-hybrid  systems  have  been  developed  to  better 
approximate an in vivo setting for the tested interaction. These systems have extended the 
Y2H concept to two parts of a protein that together lead to a quantifiable signal – such as 
a split beta-glycosidase enzyme complementation system that leads to conversion of a 
substrate into a quantifiable product (such as X-gal, which turns blue after cleavage) [69]. 
The mammalian system relieves some of the problems in yeast, such as creating a more 
relevant cellular milieu. 
The other main category of PPI experimental strategies is biochemical. In vitro 
biochemical  experiments  include  phage  display  (display  of  a  bait  protein  on  a 
bacteriophage  that  then  adheres  to  a  prey  protein  immobilized  on  a  surface),  co-
immunoprecipitation of recombinant proteins, or protein chips (immobilized recombinant 
proteins  on  a  surface)[67].  Much  like  Y2H,  these  approaches  usually  assay  binary 
interactions. In vivo (or less in vitro) biochemical approaches refer to the purification of 
endogenous protein complexes in cells. These typically use primary antibodies directed at 
the bait, ligands specific to the bait or affinity tags. Affinity purification (AP) refers to the 
process of purifying an endogenous protein of interest along with its interaction partners. 
Though there are many different flavors of AP, most are based on the purification of a 
protein from cell extracts (usually tissue culture but whole organs can also be used) along 
with its interaction partners[70]. Sources of variability in the different methods include 
the affinity protein – such as an antibody specific to the bait protein versus an antibody      
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specific to a peptide-tagged recombinant protein – and cell lysis conditions as well as 
whether the process is one-step or tandem[73]. The tandem method (Tandem Affinity 
Purification) employs a dual purification system whereby the protein is dual-tagged such 
that it can be purified twice in order to reduce the number of proteins purified non-
specifically; one example is using a tag consisting of a protein A-calmodulin fused bait 
protein that will bind to IgG first followed by calmodulin beads and is very popular since 
all yeast open reading frames are available TAP-tagged[74]. In higher eukaryotes where 
these libraries are not available, HA-, FLAG- and Myc- tandem affinity purification is 
used  though  it  requires  over-expression  of  the  fusion  protein[75].  Since  tandem 
purification  is  biased  toward  stable  interactions,  one-step  purification  techniques  are 
ideally preferred because they will include weaker and more transient interactions. In 
addition, methods that do not require over-expression are preferred since over-expression 
can lead to non-physiologic interactions. 
  In  AP-MS,  quantitative  mass  spectrometry  is  then  used  after  the  affinity 
purification to indentify interaction partners. Mass spectrometry is traditionally used to 
identify the elemental composition of a sample, such as a purified protein and its binding 
partners. Quantitative mass spectrometry (q-MS) is a recent and critical advance in the 
field of proteomics: rather than simply knowing the identity of a molecule, q-MS uses 
stable isotope labeling of peptides or proteins in order to quantify their abundance. This 
technological advance has been revolutionary to the field of protein-protein interactions: 
it allows for the quantitative comparison between a specific bait and a control (such as a 
non-specific antibody or unrelated protein), which can then be used to rule out non-
specific binding partners[76]. This precludes the need for extensive purification, which      
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had been previously required and resulted in the inability to perform high-throughput 
experiments.  Additionally,  with  q-MS,  one-step  purification  methods  can  now  be 
employed that may identify weaker, more transient interactions than two-step approaches 
(such as TAP-tagging).  
  To ensure the capture of weaker, more transient interactions that would be missed 
in the washing steps of one- or two-step APMS, chemical cross-linking can be employed. 
Through the formation of covalent bonds, such as through the use of a His-Bio tag, weak 
interactions are stabilized and the protein of interest, along with its binding partners, can 
be purified[70]. 
  Other  methods  include  fluorescence-based  approaches  (such  as  Flourescence 
Resonance  Energy  Transfer),  2D  gene-electrophoresis,  synthetic  lethality,  and  x-ray 
chrystallography, among others [77,78]. Ultimately, meta-databases (such as STRING 
and  InWeb[62,79])  that  collect  multiple  different  sources  of  evidence  to  create  a 
confidence score for each interaction are likely to be the most useful.      
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Table 1.1 Categories of protein-protein interaction experiments. Controlled vocabulary was 
downloaded from the IntAct database website[63] and the top two levels of the ontology are 
shown. Column 1 lists the broadest PPI categories and column 2 lists specific examples of each 
category.  
Category  Examples 
Biophysical  Neutron diffraction 
  Light scattering 
  Circular dichroism 
  Intermolecular force 
  Scintillation proximity assay 
  Molecular sieving 
  Neutron fiber diffraction 
  isothermal titration calorimetry 
  surface plasmon resonance 
  Nuclear magnetic resonance 
  Filter trap assay 
  Mass spectrometry studies of complexes 
  Small angle neutron scattering 
  Electron resonance 
  Amplified luminescent proximity homogeneous assay 
  Electron diffraction 
  X-ray crystallography 
   Fluorescence technology 
Genetic Inference  Random spore analysis 
   Synthetic genetic analysis 
Protein Complementation Assay  Transcriptional complementation assay 
  3 hybrid method 
  Cytoplasmic complementation assay 
  Bimolecular fluorescence complementation 
   Membrane bound complementation assay 
Biochemical  Cross-linking study 
  Comigration in gel electrophoresis 
  Cosedimentation 
  Footprinting 
  Affinity technology 
  Chromatography technology 
   Enzymatic study 
Imaging Techniques  Electron microscopy 
  X-ray tomography 
  Light microscopy 
  Fluorescence microscopy 
  Confocal microscopy 
  Atomic force microscopy 
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1.3.4  Protein-protein interaction databases 
  There are over 25 publically available databases that collect published protein-
protein interactions. Examples of such databases are YPD (the first to use this approach), 
MINT,  BIND,  HPRD,  DIP,  MIPS,  IntAct,  BioGrid,  among  others[60,61,63–66,80]. 
Almost all databases are built through literature curation, whereby expert curators sift 
through the scientific literature and report interactions and the controlled vocabulary that 
represents their experiment type (see Table 1.1 for an example of vocabulary). IntAct, 
one  of  the  PPI  databases,  has  articulated  a  very  detailed  ontology  that  generally 
represents the full spectrum of codes used by other databases[63]. There are ~50 different 
categories  of  experiments  to  detect  PPIs,  and  many  more  sub-categories. 
Overwhelmingly,  transcriptional  complementation  assays  and  affinity  technologies 
comprise  the  majority  of  documented  interactions.  For  example,  in  MINT,  86%  of 
interactions are categorized as either “two hybrid pooling approach,” “tandem affinity 
purification,” “two hybrid,” “anti-tag coimmunoprecipitation,” “pull-down,” or “anti-bait 
coimmunoprecipitation”[61]. 
  These databases are incredibly powerful because they extract knowledge from the 
full body of published literature. Rather than having to invest time and money in building 
interaction networks de novo for each protein of interest, investigators can begin their 
search by studying what has already been done. 
  The drawback to these databases is that there is no weighting scheme for the 
reliability of interactions. As discussed in section 1.3.3, false positives can arise in Y2H 
experiments  due  to  failure  of  yeast  to  provide  the  appropriate  cellular  milieu  for 
eukaryotic proteins. Likewise, affinity technologies can result in false positives due to      
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non-specific binding of the affinity antibody to non-bait proteins. Furthermore, a recent 
study  that  compared  these  databases  identified  surprisingly  little  overlap  among 
them[81]. As a result, groups have begun to address this issue by generating probabilistic 
meta-databases  that  pool  PPIs  and  assign  a  confidence  score  to  reflect  the  presumed 
reliability of the interaction.   
1.3.5  InWeb Database 
  The  meta-database  that  is  used  throughout  this  thesis  is  the  InWeb  database 
developed by Lage et al. in 2007. InWeb is a probabilistic database of reported protein-
protein interactions [24,31] that combines interactions from MINT, BIND, IntAct, KEGG 
annotated protein-protein interactions (PPrel), KEGG Enzymes involved in neighboring 
steps (ECrel), Reactome, GRID, DIP, MPact, DOMINO, and HPRD [53-61]. All human 
interaction data were pooled, and to increase the coverage of interactions, interolog data 
(the  transfer  of  protein  interactions  between  orthologous  protein  pairs  in  different 
organisms)  from  the  Inparanoid  database  were  included  by  transferring  from  17 
eukaryotic  organisms,  similar  to  Lehner  and  Fraser[82,83].  The  distribution  of 
interactions categorized by species is show in Figure 1.2.       
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Figure 1.2 Distribution of interactions in InWeb categorized by species. 
As  mentioned,  InWeb  uses  a  probabilistic  weighting  scheme  to  assign  each 
interaction a confidence score that combines three measurements: topology, scale and 
reproducibility. Topology refers to the sub-network surrounding the interaction of interest 
and was implemented using a topological scoring method described in de Lichtenberg et 
al. that assigns a raw score (RS) from zero to -∞ according to: 
€ 
RS = −log((NS1 +1)⋅ (NS2 +1)) 
where NS1 and NS2 are the number of non-shared interaction partners of proteins 1 and 
2[84]. This score will be closer to zero as the number of non-shared partners decreases. 
Scale refers to the total number of interactions reported in the publication reporting the 
particular interaction of interest. Small-scale experiments were up-weighted because they 
typically  provide  multiple  sources  of  evidence  for  an  interaction,  unlike  large-scale 
screens [85]. Finally, reproducibility refers to the number of independent publications 
that reported the interaction, with the assumption that more independent reports of an 
interaction indicates better reliability. Topology, scale and reproducibility are combined 
using the following score: 
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€ 
Score =
RS
1/log(iint)
i=1
N
∑
 
where iint is the number of interactions reported in the i
th publication for an interaction of 
interest. Confidence therefore increases as this score increases (approaches zero). This 
score was calibrated against 35,000 high-confidence human interactions and shown to 
reliably call these gold-standard interactions as high-confidence[62]. Version 3.0 of this 
database contains 428,430 interactions, 169,810 of which are deemed high-confidence, 
non-self interactions across 12,793 proteins. High-confidence is defined by a signal to 
noise threshold as determined by the calibration step.  
  The distribution of experiments that contribute to InWeb is shown in Figure 1.3. 
As expected from the majority of experiments that go into the smaller databases, affinity 
technology  and  protein  complementation  assays  are  the  most  abundant  experimental 
evidence source in the database. The main difference between the entire set (blue bars) 
and the high-confidence set (gold bars) are that the high-confidence set has a higher 
protein-complementation  to  affinity  ratio.  Manual  inspection  of  a  subset  of  these 
publications reveals that often while the interaction is documented as Y2H, for example, 
it is typically a smaller publication with multiple lines of evidence for the interaction[62].       
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Figure 1.3 Distribution of experiment types in the InWeb database. Experimental evidence 
codes were gathered for all interactions in InWeb and grouped according to a broader category, if 
possible (typically evidence codes were similar to those listed in column 2 of Table 1.1).  
!"DQVLHQWïFR#[SUHVVLRQ
$RRWS"%&!%&'
()*+,
JHQHWLFLQWHU$HUHQFH
FRORFDOL]DWLRQ
FKURPDWRJ"-.K\WHFKQRORJ\
FURVVïOLQNLQJVWXG\
FRVHGLPHQWDWLRQFRPLJ"DWLRQ
LPDJLQJWHFKQLTXHV
%&$HUUHGE\DXWKRURUFX"DWRU
HQ]\PDWLFVWXG\
%&!#"DFWLRQSUHGLFWLRQ
SKHQRW\SLFHQKDQFHPHQW
ELRSK\VLFDO
*&/%/R
*&YLWUR
PDVVVSHFWURPHW"0
XQVSHFLILHG
SURWHLQFRPSOHPHQWDWLRQDVV-0
DIILQLW\WHFKQRORJ\
1HUFHQWRI2RWDO(YLGHQFH
343 345 346 347 348 349 34:
+LJKïFRQILGHQFHLQWH"DFWLRQV
$OOLQWH"DFWLRQV     
 
  29 
Finally, the distribution of the number of independent publications per interaction 
for the InWeb database (blue bars) and the same data for the high-confidence set (gold 
bars) is shown in Figure 1.4. As expected, the high-confidence set has a higher mean 
number of publications per interaction. 
 
Figure 1.4 Number of publications per interaction in the InWeb database.  
 
  The  binding  degree  distribution  (see  section  1.4)  of  the  InWeb  database  is 
characteristic of biological networks in that there are many proteins with one or two 
interactions  and  few  proteins  with  many  interactions[86].  The  distribution  of  binding 
degrees  for  proteins  in  the  high-confidence  set  (which  is  the  set  used  in  future 
discussions) is shown in Figure 1.5. The database is very interconnected, as evidenced by 
an average clustering coefficient (C) of 0.261 (see section 1.4 for definition C)[87].  
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Figure 1.5 Binding degree distribution of InWeb high-confidence interactions. The number 
of high-confidence interaction partners was summed for each protein and plotted; outliers (>3 
standard deviations away) were removed for plotting purposes. 
1.4  Network analysis strategies: describing and evaluating networks 
In this thesis, we combine lists of binary PPIs into networks, and it is therefore 
important to define the descriptive terms used to describe them. Note that the descriptions 
provided here are specific to this work but can take on more general meanings in graph 
theory.  
The term “global network” refers to the entire PPI database, such as the InWeb 
database, which can also be represented as a large network. A sub-network refers to a 
subset of the global network. Sub-networks are usually what one observes – for example, 
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10 connected proteins of interest associated to autoimmunity represent a sub-network 
within the global network InWeb. The following terms are used throughout this thesis or 
in the field of network analysis to describe networks: 
•  Network,  graph,  database:  These  words  are  used  interchangeably,  though 
“database” is specifically a global term. 
•  Node: A protein in the network 
•  Edge: Evidence of two proteins interacting. Networks can be represented with 
weighted or binarized edges, depending on whether the strength of interaction is 
relevant. Binarizing networks eases the calculation and interpretation of many 
network statistics, and therefore this thesis will use binary edges. Additionally, 
edges  can  be  unidirectional  (as  in  an  enzyme  acting  on  a  substrate)  or 
bidirectional (a ligand binding its receptor). In this thesis, we will consider all 
interactions to be bidirectional.  
•  Binding degree: The number of edges incident at a protein in a network. 
•  Average clustering coefficient: The cliquishness of a network, i.e. the average 
probability that a node’s binding partners bind each other. In a protein-protein 
interaction database, this is typically high. 
•  Diameter: The farthest distance between nodes in the network.  
•  Shortest-path: For two nodes of interest, the fewest number of edges between 
them. 
•  Power-law: The term used to describe a degree distribution that follows P(k) =  
k
-ϒ where ϒ>0. Typically, biological networks follow the power-law (as opposed 
to a poisson degree distribution, which a classic random network will follow).      
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•  Sub-graph, sub-network: A subset of the global database. 
•  Size: The number of nodes in a network. 
•  Connectivity:  A  broad  term  used  to  describe  the  connectedness  of  networks. 
Various  statistical  measurements  on  networks  can  be  referred  to  broadly  as 
connectivity. 
Typically, these are the terms used to describe both global and sub-networks, although 
many  of  them  (average  clustering  coefficient,  diameter,  degree  distribution)  are  used 
more often to describe global networks. It is important to note that it is not readily clear 
which measurements are best to use, or that a sufficient set of terms exist to describe a 
network[88]. The relevance of the terms listed here are that they comprise important 
characteristics to match if generating randomized networks for comparison. In Chapter 2, 
we will define additional measurements specific to sub-networks.  
  If we can describe a network with the aforesaid terms, why do we need to analyze 
it? Network analysis is a broad term that refers not only to determining metrics used to 
describe  networks  but  also  to  methods  to  determine  the  significance  that  should  be 
applied to local areas of connectivity. In the context of this thesis, the reason to evaluate 
networks (rather than simply describe) is to determine which ones we should care about. 
For example, for the sub-network built from 10 autoimmune proteins, what values of 
connectivity  (such  as  the  number  of  connections)  are  significantly  above  chance 
expectation? Network connectivity will behave like any other statistic: there exists a null 
distribution (albeit one that is not straightforward to estimate) that is expected simply 
from random networks, and network analysis can be used to estimate this null distribution 
and assign significance to sub-networks.      
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  When evaluating whether a sub-network is significantly interconnected, the goal 
is to compare it to randomized, matched networks. The earliest randomized graph model 
is the Erdös-Rényi random graph, which is simply the set of edges between randomly 
drawn pairs of nodes[89]. In 1959, Gilbert then proposed the model E=pN(N-1)/2, where 
E is the number of edges, p is the probability of two nodes connecting, and N is the 
number of nodes. Another model, the “geometric graph,” is built by distributing points 
randomly  in  space  and  connecting  any  two  points  that  are  below  a  set  distance  ε 
apart[89].  These  three  random  graphs  allow  for  analytic  calculations  of  expected 
connectivity.  Permutation  approaches,  on  the  other  hand,  build  random  graphs  by 
permuting the existing database. Edge shuffling refers to random edge permutation with 
degree preservation (i.e., randomly permute edges but keep each protein’s binding degree 
the same)[86]. Node randomization refers to randomly drawing nodes from the larger 
database to create a random graph. Variants on node randomization preserve degree by 
sampling nodes of the same degree distribution as the ones in the observed sub-network. 
  The described approaches to random graph generation each fail to recapitulate 
many of the global properties of real protein-protein interaction networks. Both the ER 
and  geometric  graph  will  have  a  different  global  degree  distribution  and  average 
clustering coefficient, and the Gilbert approach also has a different degree distribution. 
Global edge-shuffling will indeed match the degree distribution but will have a much 
lower global average clustering coefficient; random node selection will fail to match the 
properties of the observed network, since random nodes are not likely to share the same 
degree  distribution.  Node  randomization  that  specifically  selects  nodes  matched  on 
observed degree distribution is theoretically ideal but practically constrained, since there      
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is usually a limited number of possible permutations that will match the observed degree 
distribution. Chapter 2 introduces a novel permutation scheme to randomize networks 
matched on degree distribution and average clustering coefficient that is not limited by 
permutation possibilities. 
1.5  Summary 
The  hypothesis  being  tested  here  is  that  both  common  and  rare  genetic  variation 
associated to disease affect a common and limited set of cellular processes, and that 
introducing PPI data to genetic association results will help identify networks underlying 
risk variation. So far, we have broadly introduced efforts to identify common variants 
associated  to  disease  through  GWAS,  recent  sequencing  efforts  to  search  for  rare 
variation,  protein-protein  interactions  and  the  experiments  used  to  generate  them  and 
finally how PPI databases are built and analyzed. Chapters 2-4 of this thesis will delve 
more deeply into historical methods to integrate genetic and PPI data as well as introduce 
novel statistical approaches to integrating PPI data from both public databases as well as 
direct experiments with genetic data from GWAS and sequencing studies. 
In chapter 2, we discuss the design, testing and implementation of a novel in silico 
approach (“DAPPLE”[87]) to rigorously ask whether loci associated to complex traits 
code  for  proteins  that  form  significantly  connected  networks.  In  chapter  3,  we  study 
protein  complexes  associated  to  variation  in  the  electrocardiographic  QT-interval,  a 
heritable  phenotype  that  when  prolonged  is  a  risk  factor  for  cardiac  arrhythmia  and 
sudden cardiac death. In chapter 4, we consider whether PPIs can be used to interpret rare 
and  de  novo  variation  discovered  through  recent  technological  advances  in  exome-     
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sequencing. Ultimately, we hope that this thesis convinces its readers that considering 
genetic variants in the context of the biological networks through which they exert their 
effect is a promising step forward in complex trait genetics. 
    
 
2  Disease Association Protein-Protein Link Evaluator 
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2.1  Abstract 
 
Genome-wide  association  studies  (GWAS)  have  defined  over  150  genomic  regions 
unequivocally containing variation predisposing to immune-mediated disease. Inferring 
disease biology from these observations, however, hinges on our ability to discover the 
molecular  processes  being  perturbed  by  these  risk  variants.    It  has  previously  been 
observed that different genes harboring causal mutations for the same Mendelian disease 
often physically interact. We sought to evaluate the degree to which this is true of genes 
within  strongly  associated  loci  in  complex  disease.  Using  sets  of  loci  defined  in 
rheumatoid arthritis (RA) and Crohn’s disease (CD) GWAS, we build protein-protein 
interaction (PPI) networks for genes within associated loci and find abundant physical 
interactions  between  protein  products  of  associated  genes.  We  apply  multiple 
permutation approaches to show that these networks are more densely connected than 
chance expectation. To confirm biological relevance, we show that the components of the 
networks tend to be expressed in similar tissues relevant to the phenotypes in question, 
suggesting the network indicates common underlying processes perturbed by risk loci.  
Furthermore,  we  show  that  the  RA  and  CD  networks  have  predictive  power  by 
demonstrating  that  proteins  in  these  networks,  not  encoded  in  the  confirmed  list  of 
disease associated loci, are significantly enriched for association to the phenotypes in 
question in extended GWAS analysis. Finally, we test our method in 3 non-immune traits 
to  assess  its  applicability  to  complex  traits  in  general.  We  find  that  genes  in  loci 
associated to height and lipid levels assemble into significantly connected networks but 
did not detect excess connectivity among Type 2 Diabetes (T2D) loci beyond chance.      
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Taken together, our results constitute evidence that for many of the complex diseases 
studied  here,  common  genetic  associations  implicate  regions  encoding  proteins  that 
physically  interact  in  a  preferential  manner,  in  line  with  observations  in  Mendelian 
disease. 
2.2  Introduction 
Common genetic variants in over 200 genomic loci have now been unequivocally 
associated  to  immune-mediated  diseases  by  genome-wide  association  studies 
(GWAS)[15–17,19,20,23,90–97].  It  is  presumed  that  these  associations  represent 
perturbations  to  a  common  but  limited  set  of  underlying  molecular  processes  that 
modulate risk to disease. The next challenge – and the great promise of human genetics – 
is  the  identification  of  these  disease-causing  pathways  so  they  may  be  targeted  for 
diagnostics and therapeutic intervention. 
In  identifying  such  processes,  there  are  difficulties  in  both  (i)  identifying  the 
specific genes at (and how they are molecularly impacted by) each association and (ii) 
inferring  disease-causing  mechanisms  from  the  set  of  identified  genes.  Linkage 
disequilibrium blocks containing disease-associated SNPs can be hundreds of kilobases 
in size, and some contain tens of genes to consider. Genes are often informally implicated 
in  pathogenesis  by  their  proximity  to  the  most  associated  marker,  their  biological 
plausibility, or simply their being the only protein-coding gene in the region.  In reality, 
however,  it  is  only  a  very  small  subset  of  confirmed  GWAS  associations  for  which 
specific functional variants have been proven experimentally.       
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More systematic approaches have been applied to connect genes to a common 
process with the use of independent data, such as Gene Set Enrichment Analysis (GSEA) 
and Gene Relationships Across Implicated Loci (GRAIL) [45,90,98,99]. Both approaches 
identify  connections  between  genes  based  on  descriptive  categories  that  outline  the 
theorized underlying pathogenesis. However, these concepts are often general, so that 
specific hypotheses and molecular pathways can be difficult to define and are somewhat 
limited to established knowledge bases. 
Observations of interactions between the products of protein-coding genes offer 
the most direct route to identifying pathogenic processes. It has been shown in a number 
of  Mendelian  diseases  that  genes  causal  of  a  particular  phenotype  tend  to  physically 
interact [62,100–102]. This has been confirmed in the model organism C. elegans, where 
RNAi knock-down of germline genes correlated highly with their products interacting in 
yeast-two hybrid experiments[102]. A classic example of a human Mendelian disease that 
recapitulates this model is Fanconi Anemia (FA), an autosomal recessive disorder linked 
to at least 13 loci, at least 8 of which function together in a DNA repair complex [100]. 
Protein-protein interaction (PPI) data has also been used to formulate hypotheses about 
co-expressed genes as well as cancer genes [103,104]. We note that previous attempts to 
use PPI data to prioritize candidate genes in Mendelian disorders have been successful as 
was the case with the published tool Prioritizer [59]. We therefore set out to test such an 
approach in complex disease.  
Investigators have rapidly populated databases of such protein-protein interactions 
over the past decade. The reported interactions in PPI databases stem from both small, 
directed  investigations  and  high-throughput  experiments,  primarily  yeast  two-hybrid      
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screens and affinity purification followed by mass spectrometry [105]. These data are 
inherently noisy: beyond technical false positives and negatives, experiments in vitro may 
report interactions that do not occur in vivo simply because the proteins involved never 
overlap spatially or temporally. To mitigate the noisiness of PPI databases, we extract 
networks from “InWeb”, assembled in 2007 by Lage et al [62]. InWeb is a database of 
169,810  high-confidence  pair-wise  interactions  involving  12,793  proteins  (human 
proteins and their orthologs). Lage et al. define high-confidence interactions as those seen 
in  multiple  independent  experiments  and  reported  more  often  in  lower-throughput 
experiments [62]. To further restrict the data to biologically plausible interactions, we 
overlay mRNA expression information to confirm co-expression of binding partners; this 
correlates with co-localization, similar phenotype and participation in a protein complex 
[106,107]. 
Assessing the significance of networks built from PPI data is challenging for two 
reasons:  first,  overall  connectivity  is  a  function  of  the  binding  degree  (number  of 
connections in the database for a given protein) of proteins within the network. Thus, the 
apparent density of a network could simply be due to the lack of specificity with which 
its constituents bind in vitro. Second, certain processes are more extensively studied, so 
more connections between proteins involved in them may be reported (see Figure 2.1; 
immune  proteins  are  reported  in  more  publications  and  have  a  higher  mean  binding 
degree). This confounds our effort to assess connectivity of associated loci if there is a 
bias in the data. From a genetic standpoint, a common randomization method would 
involve sampling SNPs from the genome matched for the appropriate parameters (such as      
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gene density and protein binding degree). This method becomes highly limited if the 
disease loci contain genes that are better studied than the randomly sampled SNPs.  
 
Figure 2.1 Immune proteins comprise a disproportionate portion of the PPI literature. For 
each protein, we enumerated the number of unique publications in which it is reported. Using a 
publically available expression dataset of 55 immune tissues[108], we then categorized proteins 
as  “immune”  or  “non-immune”.  Genes  in  the  top  2%  of  expression  for  at  least  2  of  the  55 
immune tissues were deemed immune genes; their proteins were then deemed immune-proteins. 
The distribution of publications for immune proteins is significantly more than the background 
distribution (Kolmogorov-Smirnov p-value <2E-16). 
Therefore, we apply a permutation method that is robust to non-specific binding 
and  differences  in  publication  density.  We  perform  a  within-degree  node-label 
permutation that is carried out as follows: a random network is built that has nearly the 
exact same structure as the original InWeb network, only the node labels (i.e. the protein 
names) are randomly re-assigned to nodes of equal binding degree; this method assumes 
a null distribution of connectivity that is entirely a function of the binding degree of 
individual proteins. Random networks will have the same size, number of edges and per-
protein binding degree as InWeb; we build 50,000 different random networks. With this      
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method, we are able to test the non-randomness of an observed sub-network conditional 
on the exact binding degree distribution of the observed disease proteins.  
Others have used PPI data in complex disease to understand epistatic loci or to 
build a network of interacting proteins from associated loci [109–111]. The novelty of 
our method lies not in the idea that PPI data can be used to help understand genetic loci 
associated to disease, but rather in that we have developed a broadly-applicable method 
to statistically evaluate the degree to which non-random PPI networks emerge from loci 
associated to complex disease and to leverage from this insight about causal proteins in 
large loci [109,110]. We show this to be the case in a number of diseases.  
  Here, we use this methodology to evaluate whether genes in loci associated to five 
complex traits are significantly connected via protein-protein interactions. We report an 
algorithm to build and assess PPI networks using the InWeb database and find robust, 
statistically  significant  networks  underlying  associations  to  RA,  CD,  height  and  lipid 
levels,  which  we  suggest  as  representative  of  the  underlying  pathogenic  molecular 
processes. We then perform several detailed analyses on the RA and CD networks to 
confirm  that  they  contain  true  biological  insight  into  disease.    We  use  independent 
mRNA expression data to show that the prioritized associated proteins we propose as 
interacting are co-expressed in relevant immune tissues, supporting a plausible biological 
setting for our findings as well as the validity of the reported protein-protein interactions. 
Lastly,  by  analyzing  more  recent  GWAS  meta-analysis  results,  we  show  that  these 
networks  contain  components  that  show  significant  evidence  of  further  genetic 
associations: proteins interacting with multiple associated network members and encoded 
elsewhere in the genome themselves carry an excess of association to disease in the latest      
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meta-analyses of each of these diseases. Our method, available for download, generates 
an experimentally tractable hypothesis of the molecular underpinnings of pathogenesis.  
2.3  Methods 
2.3.1  Network construction and evaluation pipeline 
We construct and evaluate networks of disease loci as outlined in Figure 2.2. We 
first  define  associated  proteins  as  gene  products  encoded  in  genomic  loci  harboring 
variants  associated  to  disease  (Figure  2.2A-B;  see  Materials  and  Methods  for  locus 
definition). We construct networks of protein-protein interactions representing proteins as 
nodes connected by an edge if there is in vitro evidence of interaction (InWeb high-
confidence  interaction  set).  We  build  direct  networks,  in  which  any  two  associated 
proteins can be connected by exactly one edge, and indirect networks, where associated 
proteins can be connected via common interactor proteins (not encoded in associated 
loci)  with  which  the  associated  proteins  each  share  an  edge.  We  restrict  direct  and 
indirect interactions to only those between proteins encoded in distinct associated loci.  
We then calculate several metrics to evaluate network properties. These metrics 
can be divided into two categories: an edge metric and node metrics. The edge metric is 
the direct network connectivity parameter defined as the number of edges in the direct 
network. We interpret direct network connectivity as the frequency with which different 
loci harbor proteins that directly bind each other, regardless of how they assemble; direct 
network connectivity is therefore our most straightforward metric. Node metrics include 
the  following:  associated  protein  direct  connectivity  and  associated  protein  indirect 
connectivity  which  refer  to  the  number  of  distinct  loci  an  associated  protein  can  be      
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connected to directly and indirectly, respectively, and common interactor connectivity 
which  refers  to  the  average  number  of  proteins  in  distinct  loci  bound  by  common 
interactors in indirect networks. We interpret all three node metrics as descriptive of the 
type of network that was constructed: a stream of connections (such as the network A-B-
C-D-E) will likely have low and insignificant node metrics despite a significant edge 
metric, whereas a more tightly clustered network might be enriched for both edge and 
node metrics. We assess the statistical significance of the various connectivity parameters 
using a within-degree node-label permutation strategy that controls for variation in the 
degree to which certain proteins are studied or behave in vitro (Figure 2.2C). As we are 
interested in the processes underlying disease, we also define the gene encoding the top-
scoring protein in each locus as most likely to be causal for association (Figure 2.2D). 
We then use tissue expression data to test whether our nominated candidate genes are 
enriched in the same tissue(s) and therefore participate in a network that is biologically 
feasible  (Figure  2.2E).  With  this  approach,  we  aim  to  construct  plausible  models  of 
biological networks underlying pathogenesis.      
 
  45 
 
Figure 2.2 Pictorial outline of methodology. A. Genes overlapping the wingspan of associated 
SNPs are defined, and these genes code for associated proteins. B. Associated proteins are used 
to recover direct and indirect networks. Direct networks (left) are built from direct interactions 
between associated proteins according to the InWeb database (colored proteins). Connections 
between proteins within the same locus are not considered. Indirect networks (right) are built by 
allowing connections between associated proteins through a protein elsewhere in the genome 
(grey). Various network parameters to quantify connectivity, defined in the text, are assigned. C. 
Random networks are built from a within-degree node-label permutation method. An empirical 
distribution is constructed for each network parameter and used to evaluate the significance of 
networks.  D. U s i n g  t h e  s a m e  p e r m u t a t i o n  m e t h o d  t o  s c o r e  i n d i v i d u a l  p r o t e i n s ,  a  s u b s e t  o f  
proteins per locus is nominated as candidates for harboring causal variants (red circles). Scores 
used  to  nominate  candidates a re  Bonferroni  corrected  for  the  number  of  possible  candidates Figure 2.2 (continued)     
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within  each  locus.  E. C a n d i d a t e  g e n e s  f r o m  D  ( n o m i n a l  p -values  used)  are  tested  for  co-
expression.  
2.3.2  Network analysis 
The goal of building random networks is to compare disease networks to what is 
expected  given  the  binding  degrees  of  associated  proteins.  In  order  for  the  random 
networks to represent appropriate comparisons, they must mimic the original networks in 
their overall structure; furthermore, the binding degree of any one protein in a random 
network should be close to its value in the original network. As was discussed in section 
1.4, many of the existing algorithms to generate random networks do not achieve this 
matching. As such, we used a within-degree node-label permutation method and built 
random networks whose network topology, as measured by clustering coefficient and 
conformity to the Power Law, is close to the original network and whose individual 
proteins have the same degree of binding as in the original network [86,112].  
We  define  the  original  PPI  network  G  (the  InWeb  network)  to  have  a  node 
corresponding to each protein known to participate in a protein-protein interaction, where 
an edge represents such interaction. Let G have n vertices and E edges. Let G0 be a 
random graph with the same set of nodes as G and randomly-assigned edges. Moreover, 
for every node i0 in G0 deg(i0) = deg(i) where deg(i0) is the binding degree of node i0. The 
algorithm  for  generating  a  graph  G0  from  a  given  graph  G  involves  two  steps,  a 
permutation step and a switching step.      
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Permutation Step: Let k1, k2, k3, ..., km be the sequence of all possible node 
degrees in G and let Ki be the set of vertices that have degree ki with 1 ≤ i ≤ m. The 
following procedure permutes sets of same degree nodes 1,000 times: 
1. Repeat the following 1,000 times: 
2. For every set Ki, 1 ≤ i ≤ m 
(a) Choose randomly two vertices a and b. 
(b) Swap its positions in set Ki. 
The permutation step has a high impact in randomizing graph G but it has one 
limitation: the algorithm cannot perturb nodes that have unique degrees. The presence of 
high degree nodes in the network, often referred to as “hubs,” that have unique degrees 
creates several situations where our method cannot permute.  Let Gunique be the union of 
sub-networks consisting of high-degree nodes and their edges. In order to completely 
randomize graph G we apply an edge permutation algorithm for network Gunique. 
Switching Step: The edge permutation algorithm starts from a given network and 
involves carrying out a series of switching steps whereby a pair of edges (A−B, C−D) is 
selected at random and the ends are exchanged to give (A−D , B−C) or (A−C , B−D). 
The exchange is only performed if it generates no multiple edges or self-edges. The entire 
process is repeated some number E times, where E is the number of edges in Gunique. The 
switching algorithm is used as a second step in our method, continuing the randomization 
process of graph G after the permutation step. It is applied only to Gunique graph defined 
by  the  set  of  nodes  with  unique  degrees  and  their  edges.  The  following  procedure 
perturbs Gunique.      
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While there are nodes unvisited: 
(a) Choose randomly edges A−B and C−D 
(b) If A−D and B−C do not exist  
i. Add edges A−D and B−C to G0 
ii. Remove edges A−B and C−D from G0 
 
The benefit of the permutation method used is that we repeat the entire process to 
generate 50,000 permuted networks matched for size, binding degree of proteins within it 
and overall network structure. As we show in the candidate gene section, this method 
importantly  allows  us  to  score  individual  proteins  in  the  network,  in  addition  to  the 
network as a whole.  
2.3.3  Evaluation of Permutation Method 
  To test whether this permutation method created random networks that matched 
the InWeb network in overall properties, we computed the binding degree distribution 
and the clustering coefficient for each random network. The binding degree distribution 
of  the  InWeb  network,  which  is  scale-free,  follows  the  power  law,  and  the  random 
networks should too if they are structured like the InWeb network [62,86,106]. Because 
we permute within-degree, the distribution should be identical; indeed, we found that the 
random networks follow the power law and their distribution, which fits k
-1.7 (where k is 
equal to a given binding degree), are equivalent to the InWeb network. Secondly, the 
average clustering coefficient, Cavg, which is the probability that two binding partners of a 
vertex are connected, was computed for all nodes in the random networks and the InWeb      
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network. We found that the InWeb average clustering coeffecient was close to that of the 
random  networks:  Cavg  for  the  InWeb  network  was  0.261  and  the  mean  Cavg  for  the 
random  networks  was  0.197.  The  difference  is  due  to  the  small  amount  of  edge 
permutation that we perform on nodes with unique degrees. 
  Next, we tested the distribution of p-values that the permutation method reported 
for randomly selected groups of 30 SNPs (to roughly mimic RA and CD loci sets). If the 
permutation method correctly tested the null hypothesis, then the distribution of p-values 
for each metric should be uniform. For 50 such random groups of SNPs, we find via a χ
2 
test  for  uniform  distribution  that  the  network  connectivity,  the  common  interactor 
connectivity, and the associated protein indirect connectivity fit what is expected under a 
uniform distribution (p = 0.923, p = 0.787 and p = 0.896). The associated protein direct 
connectivity is skewed towards non-significant p-values (p = 1), and thus the p-value 
distribution for this metric is less uniform. However, the skew towards p=1 for random 
SNPs indicates that for this metric, the permutation method would be more likely to call a 
false negative rather than a false positive.  
2.3.4  Nomination of candidate genes within loci. 
We applied an iterative scoring method to nominate candidate genes in multigenic 
loci.  The  goal  of  the  approach  is  to  identify  a  subset  of  candidate  genes  per  locus 
(preferably one candidate gene although risk variants, if regulatory, could feasibly affect 
multiple  genes)  that  are  more  highly  connected  to  disease  loci  than  by  chance  via 
permutation, or that score the highest compared to other proteins in the locus.      
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For a given gene in a multigenic locus, we identify whether it participates in the 
direct network only, the indirect network only, or both. If it participates in the direct 
network, we enumerate the number of distinct loci it connects to, D, and compare this 
number to the values obtained in permuted networks Di for the i
th permutation. The 
number of successes, S, is enumerated, where S=1 if Di is greater than or equal to D, 
otherwise S equals 0. After 50,000 permutations, the direct score for that protein is 
therefore: 
€ 
S 0:Di <D
1:Di ,≥D
i=1
50000
∑
50000
 
Equation 2.1 
If  the  protein  participates  in  the  indirect  network,  we  perform  a  similar 
enumeration. A caveat to the indirect connections is that unlike direct connections, a 
protein can indirectly connect to another protein in multiple ways and to a locus in even 
more ways. Based on the biological assumption that more indirect connections suggests 
more  relatedness  (functionally  speaking),  we  would  like  to  up-weight  additional 
connections; as such, the indirect binding score I between a protein and another locus is 
the maximum number of indirect connections to a protein in that locus over all proteins in 
that  locus.  We  compare  I  to  the  values  Ii  obtained  in  permuted  networks  for  the  i
th 
permutation. The number of successes, S, is enumerated, where S=1 if Ii is greater than or 
equal to I, otherwise S equals 0. After 50,000 permutations, the indirect score for that 
protein is therefore: 
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€ 
S 0:Ii <I
1:Ii ,≥I
i=1
50000
∑
50000
 
Equation 2.2 
 
If a protein participates in both networks, the direct and indirect scores are Bonferroni 
corrected for two tests and the best score is assigned.  
  Thus, each protein emerges with a final score that is used to nominate candidate 
genes within a locus; this score is further Bonferroni corrected for the number of possible 
candidates in that locus. In the text we distinguish between genes that achieve a corrected 
p < 0.05 from those that only achieve nominal significance. Nominal significance refers 
to significance after correcting for 2 tests (where applicable) but without correction for 
the number of genes in a locus; however, when building final networks (Figure 2.8) we 
use nominally significant genes. Genes in single-gene loci are automatically nominated if 
they participate in either network, but are only included as “candidates” if they achieved 
p < 0.05. This process is iterated until convergence where upon genes scoring p < 0.05 
are nominated as the definitive causal gene, and all other genes in that locus are removed 
for the next iteration.  
  To  validate  that  p-values  are  comparable  across  proteins,  we  tested  for  a 
correlation between prioritization p-value and binding degree. Such a correlation would 
indicate that the network significance assigned to individual proteins is mainly a function 
of representation in InWeb rather than relevance to disease processes. First, we selected 
25 sets of 30 random gene-containing SNP wingspans, built random networks and ran      
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them  through  the  pipeline  using  5,000  permutations.  We  then  evaluated  the  p-values 
assigned to individual proteins (1046 proteins in total across all random networks). The 
R
2 between binding degree and –log(p) was 0.000094 (p=0.757). We then collected the 
scores for proteins from all 5 complex traits discussed here (408 proteins in total) and R
2 
was 0.0065 (p=0.104). These results are shown in Figure 2.3. We therefore conclude that 
p-values  assigned  to  proteins  are  not  confounded  by  the  degree  to  which  they  are 
represented in the database. 
 
Figure 2.3 Correlation between prioritization p-value and binding degree. We show that 
there is no correlation between prioritization p-values given to genes and their representation in 
the database. We show this in randomized networks (A) and in the disease networks (B). 
This analysis pipeline, which we call Disease Association Protein-Protein Link 
Evaluator  (DAPPLE),  is  available  for  download  at 
http://www.broadinstitute.org/mpg/dapple.      
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2.4  Results 
2.4.1  Gene products encoded in associated loci interact 
We first tested DAPPLE on the Mendelian disease Fanconi Anemia (FA) as a proof of 
principle. We input 9 of the FA genes and found 23 connections among them; compared 
to 50,000 random networks, the FA network is enriched for connectivity (direct network 
connectivity  p  <<  2×10
-5,  Figure  2.4).  The  associated  protein  direct  connectivity, 
associated  protein  indirect  connectivity  and  common  interactor  connectivity  were  all 
significantly enriched (p < 1 × 10
-5, p = 0.00150, p = 0.00373, respectively). These results 
agree with the current understanding of FA pathogenesis[56]. The network is shown in 
Figure 2.4.  
 
 
Figure  2.4 F a n c o n i a  A n e m i a  n e t w o r k .  As  a  benchmark  analysis,  we  tested  the  method  on 
Fanconia Anemia, a Mendelian disorder caused by genes that code for interacting proteins. 9 of 
the 13 FA genes were in the InWeb database. We found that the direct network connectivity was 
23,  which  is  many  more  than  expected  by  chance  (p<<2E-5).  The  associated  protein  direct 
!"#$%&
!"#$"&
!"#$'&
!"#$(&
!"#$)&
!"#$$&
!"#$*+& !"#$,&
!"#$!&Figure 2.4 (continued)     
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connectivity, associated protein indirect connectivity and common interactor connectivity were all 
significantly enriched (p<2E-5, p = 0.004, p = 0.009, respectively). These results agree with the 
current understanding of FA pathogenesis. FA Network is shown. 
We then set out to test our method on two autoimmune diseases that are both 
complex  traits.  Recent  GWA  studies  in  autoimmune  and  inflammatory  diseases  have 
been particularly successful at determining loci encoding risk to disease, with over 100 
loci described to date [15–17,90,92,93]. We investigated rheumatoid arthritis (RA) and 
Crohn’s  disease  (CD)  and  built  networks  from  proteins  encoded  in  25  and  27  gene-
containing associated loci, respectively. As described above, we built direct and indirect 
networks for each set of loci, evaluated the significance of the 4 network metrics to assess 
the probability that such networks could arise by chance, and we nominated candidate 
genes by assessing network participation. We followed up our results by assessing tissue 
co-expression as a test for the biological feasibility. 
We  were  able  to  connect  20/27  loci  for  RA  and  12/25  loci  for  CD  in  direct 
networks, strongly suggesting functional connections between proteins encoded in the 
associated regions. When compared to 50,000 random networks, we found that the direct 
network connectivity (the number of direct network edges) was statistically significant 
(27 for each disease; PRA = 3×10
-4, PCD = 1.11×10
-3; Figure 2.5) as was the associated 
protein  direct  connectivity ( Figure  2.5,  PRA  =  0.02,  PCD  =  0.00305).  Thus  disease-
associated  loci  encode  directly  interacting  proteins  beyond  chance  expectation, 
suggesting that risk variants may act on suites of proteins involved in the same process.
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Figure 2.5 RA and CD direct networks are significantly interconnected. The direct network 
connectivity, associated protein direct connectivity, associated protein indirect connectivity and 
common interactor connectivity were enumerated for the disease networks and 50,000 random 
networks. A histogram is plotted to represent random expectation, and the disease network is 
shown by an arrow for A. RA and B. CD. From left to right and top to bottom, the connectivity p-
values are: RA - 0.00031, 0.02000, 2.9734E-5, 6.9380E-5; CD - 0.00111, 0.00336, 0.00023, 
0.00014.  
We were then able to connect all but one gene-containing associated loci in each 
disease by expanding our networks to include common interactors (26/27 in RA; 24/25 in 
CD).  The  associated  protein  indirect  connectivity  was  significantly  enriched  in  both 
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diseases (Figure 2.5, p = 3.0×10
-5 in RA, p = 2.3×10
-4 for CD), as was the common 
interactor connectivity (Figure 2.5, p = 7 × 10
-5 for RA and p = 1.4×10
-4 for CD). 
Our  approach  controls  for  biases  in  the  data:  using  the  high-confidence 
interactions  from  InWeb  addresses  laboratory  artifacts,  and  node-label  permutation 
accounts  for  ascertainment  biases  due  to  differing  levels  of  knowledge  on  biological 
processes for those proteins present in InWeb (Figure 2.1). We show empirically that 
priority scores given to proteins have no correlation with the degree to which they are 
represented in the database (Figure 2.3). A fundamental limitation of any functional data 
is that genes for which data are missing will not be considered. This applies to similar 
methods, including expression data that can be limited to genes represented on specific 
arrays or ontology analyses that are restricted to well characterized genes. Here, proteins 
that are entirely absent from the filtered InWeb data are not considered in our analysis 
(see Discussion). It is important to note that these genes cannot be ruled out as potentially 
affected by causal variation since we have no power to make such a conclusion. We note, 
however,  that  the  loci  we  have  considered  here  (for  the  5  complex  traits)  have  the 
majority of their genes present in the high-confidence InWeb database (median inclusion 
of 81.5%). 
2.4.2  Alternate network analysis 
To ensure the robustness of our significance, we tested two alternative methods: 
we (1) built networks from randomly selected SNPs and (2) permuted all the edges, 
rather than only networks of nodes with unique degrees (see section 1.4 for discussion of 
network  randomization  methods).  We  carried  this  out  in  CD  and  RA.  Permuting  the      
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SNPs requires that the randomly chosen loci be matched for gene content as well as 
average binding degree of encoded proteins; method 1 is thus severely limited by the 
strict  matching  criteria,  making  this  method  unsuitable,  and  additionally,  it  does  not 
easily  allow  for  scoring  of  individual  proteins.  Thus,  we  permuted  1000  times  and 
remove permutations for which the binding degree distribution of proteins in randomly 
selected  loci  was  different  (binding  degree  was  greater  or  less  than  the  mean  of  the 
disease proteins’ binding degrees plus or minus 10, respectively, and the protein with the 
highest binding degree was more than the disease protein with the highest binding degree 
plus 20). Method 2 involves randomly shuffling the edges such that the number of edges 
per protein is preserved but the identity of binding partners is changed.  Overall, the 
significance is replicated, though the SNP matching to a lesser extent: for RA, the direct 
network connectivity, associated protein direct connectivity, associated protein indirect 
connectivity and the common interactor connectivity p-values were p = 0.005, = 0.013, = 
0.07, and = 0.06, respectively. For CD, the same p-values were p = <0.001, = 0.003, 
<0.001, and = 0.033. In the case of edges shuffling, the RA p-values were p = <0.001, = 
0.013, <0.001, and <0.001 while the CD p-values were p = <0.001, <0.001, <0.001, and = 
0.001. While we were encouraged to see persistent significance, SNP permutation may 
not be robust in the presence of extremes of gene density or protein binding degree at 
some loci, and edge permutation does not preserve the network structure of InWeb.  
2.4.3  RA and CD networks identify new proteins enriched for association 
In  aggregate,  these  results  suggest  that  the  observations  of  connectivity  in 
Mendelian diseases are recapitulated in both RA and CD and that common risk variants      
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predisposing  to  these  diseases  may  impact  sets  of  interacting  proteins.  Given  the 
significant connectivity of common interactors in the indirect networks for RA and CD, 
we  speculated  that  common  interactors  might  themselves  be  affected  by  previously 
undescribed risk variation. To test this, we consulted association data for each disease in 
the available data from meta-analyses, which for RA was in a newly completed meta-
analysis and for CD was the same study that yielded the 30 loci[16,113]. We assigned 
each recombination hotspot-bounded linkage-disequilibrium (LD) block in the genome 
an association score that represents the maximum score in that block corrected for the 
number  of  independent  SNPs  therein  using  logistic  regression.  Genes  were  assigned 
association scores based on the blocks they overlap; this score distribution can then be 
compared to the scores of all gene-containing blocks in the genome (for both diseases, we 
removed the MHC from this analysis due to LD properties). Using this method, we found 
that  common  interactors  expressed  in  the  same  tissues  as  associated  proteins  in  our 
networks (see below) were encoded in regions with evidence of association significantly 
in  excess  to  what  is  expected  in  gene-containing  regions.  In  RA,  the  distribution  of 
common interactor scores was skewed toward higher association (one-tailed rank sum p = 
1.7×10
-5) and in CD, we saw similar enrichment (p = 6.5×10
-4). This observed skew 
suggests that the common interactors themselves may harbor risk variants; we therefore 
considered the regions they overlap as candidates for replication (see section 2.4.6).   
2.4.4  Extending Analysis to Height, Lipids and Type 2 Diabetes 
  To test whether the observed significant connectivity seen in RA and CD was 
present  in  non-immune  complex  traits,  we  tested  our  method  on  three  traits:  human      
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height, blood lipid concentration (both LDL and HDL) and Type 2 Diabetes (T2D). We 
used 37 replicated gene-containing loci associated with human height, 18 with blood lipid 
levels and 36 with T2D [19–24,95–97]. The loci associated to height and lipids each 
contain proteins that assemble into significantly connected direct networks (Figure 2.6, 
direct network connectivity p = 1×10
-4 and p = 1.9×10
-4 for each disease, respectively; see 
Figure  2.6  for  significance  of  other  3  parameters).  In  the  height  network,  19/42  loci 
participated in the direct network and 34/42 participate in the indirect networks, but only 
the direct network connectivity and the common interactor connectivity were significantly 
greater than chance. In the lipids network, 11/19 participated in the direct network and 
16/19 in the indirect; all node metrics except the common interactor connectivity were 
significantly enriched.  9/37 T2D loci participated in the direct network and 34/37 in the 
indirect network; however, 3/4 metrics were not greater than chance expectation and only 
one was slightly enriched (Figure 2.6, direct network connectivity p = 0.44960; see Figure 
2.6 for significance of other 3 parameters).       
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Figure 2.6 Network parameters for Height, Lipids, and T2D. We show the expected random 
distribution in relation to the disease network (arrow) for each of the 4 parameters (direct network 
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connectivity,  associated  protein  direct  connectivity,  associated  protein  indirect 
connectivity,common interactor connectivity) for height (A), lipids (B), and T2D (C). Permuted 
networks  were  generated  use  the  within-degree  node-label  permutation  method.  Connectivity 
parameter scores are as follows, from left to right and top to bottom. Height: 1e-04, 0.8446, 
0.192,  <2E-5.  Lipids:  0.00018,  0.01810,  0.00092,  0.13537.  T2D:  0.41698,  0.23713,  0.03202, 
0.2371.
 
We therefore conclude that the PPI connectivity seen in two autoimmune diseases 
can  be  generalized  to  other  complex  trait  loci  (height-  and  lipid-associated  regions), 
though we could not confirm the significance of the T2D network.  
Our results suggest that functionally connected proteins reside in regions of the 
genome associated to disease risk. Permutation analysis revealed that these connections 
are  in  excess  compared  to  what  is  expected  given  the  binding  profiles  of  associated 
proteins. For RA and CD, other proteins interacting with the associated proteins also 
show evidence of association beyond chance expectation. Cumulatively, these findings 
suggest  that  risk  to  the  complex  disease/traits  studied  here  is  spread  over  functional 
groups of proteins, directly analogous to observations in Mendelian traits.  
2.4.5  Prioritizing proteins in associated loci reveals likely pathogenic tissues 
An  obstacle  to  interpreting  GWA  results  stems  from  the  difficulty  in  identifying  the 
genes within associated regions influenced by risk variants. Candidate genes are often 
selected  based  on  proximity  to  most  associated  markers  and  miscellaneous  forms  of      
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previous knowledge. We therefore asked whether our observations could lead us to a 
principled, data-driven approach to selecting candidate genes by assessing their role in 
our networks. As shown Figure 2.2 and described in detail in section 2.3.2, we used an 
iterative optimization method to assign priority scores to associated genes based on the 
network participation of their encoded proteins. We nominate genes that achieve the best 
score within their locus as the candidates for influencing disease risk. We describe the 
results in detail here for RA and CD; see Table 2.1 and Table 2.2 for scores assigned to 
RA and CD. 
We were able to nominate candidate genes in 12/21 RA loci encoding multiple 
genes  (Table  2.1).  Examples  of  candidate  genes  in  RA  were  IL2RA,  CD40,  CD28, 
PTPN22,  CTLA4  and  TRAF1.    We  accomplished  the  same  task  in  CD,  nominating 
candidate  genes  in  10/18  multi-genic  loci.  Candidates  included  JAK2,  STAT3, 
IL23R/IL12RB2, PTPN2, MST1R and AIRE. For both diseases, genes in single-gene loci 
are also scored, though they are automatically considered the candidate gene (but not 
necessarily part of the underlying mechanism). It is important to note that we do not 
expect high-scoring proteins in every locus; we only expect high scores for those proteins 
that may participate in the common process(es) detected via enrichment in connections. 
RA and CD, like most complex diseases, most likely have many underlying processes, 
not all of which are captured here.   
 
Table 2.1 RA candidate genes proposed through permutation. Each protein that participated 
in the direct and/or indirect network was assigned a permutation p-value corresponding to the 
likelihood  of  seeing  the  degree  of  connectivity  observed  by  chance.  A  protein's  score  was Table 2.1 (continued)     
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Bonferroni corrected for the number of genes in its locus and for two tests if it participated in 
both the direct and indirect network (Pnominal reflects the first correction). For tissue enrichment 
analysis and plotting of networks, we used the nominal p-value. Here, the permutation process is 
iterated twice, and the second iteration removes proteins in a locus that score p > 0.05 if any 
protein in that locus scored p < 0.05. Columns from left to right: SNP, number of genes in locus, 
gene,  nominal  p-value,  corrected  p-value,  second  iteration  nominal  p-value,  second  iteration 
corrected p-value. *NA indicates that the gene was not included in the second iteration, either 
because it was filtered after the first or because its participation depended on a protein that was 
filtered. Second iteration scores are only used to nominate candidate genes if no gene in the locus 
achieved p<0.05 the first time around. 
Rheumatoid arthritis 
SNP 
# Genes 
in 
Locus  Gene  P1nominal  P1corrected  P2nominal  P2corrected 
rs3218253  2  IL2RB  1.6E-04  3.2E-04  1.0E-05  2.0E-05 
rs2476601  6  PTPN22  1.4E-04  8.4E-04  1.7E-05  1.0E-04 
rs10919563  1  PTPRC  4.0E-05  4.0E-05  2.0E-05  2.0E-05 
rs3087243  1  CTLA4  8.0E-05  8.0E-05  1.0E-04  1.0E-04 
rs4750316  1  PRKCQ  2.0E-06  2.0E-06  2.0E-04  2.0E-04 
rs1980422  2  CD28  5.6E-04  1.1E-03  2.3E-04  4.7E-04 
Rs540386  4  TRAF6  7.3E-03  2.9E-02  6.7E-04  2.7E-03 
rs11586238  1  CD2  1.3E-03  1.3E-03  1.0E-03  1.0E-03 
rs3761847  6  TRAF1  2.9E-03  1.7E-02  1.9E-03  1.1E-02 
rs2812378  2  DCTN3  2.2E-03  4.4E-03  2.1E-03  4.1E-03 
rs12746613  3  HSPA6  4.2E-03  1.3E-02  2.5E-03  7.4E-03 
rs4810485  4  CD40  3.7E-03  1.5E-02  3.0E-03  1.2E-02 
rs7574865  2  STAT1  8.9E-03  1.8E-02  4.3E-03  8.6E-03 
rs12746613  3  FCGR2A  7.0E-03  2.1E-02  5.9E-03  1.7E-02 
rs3766379  4  CD48  1.6E-02  6.2E-02  1.3E-02  5.2E-02 
rs2395175  11  HLA-DRB5  2.1E-02  2.0E-01  1.5E-02  1.5E-01 
rs2395175  11  HLA-DQA2  2.1E-02  2.1E-01  1.5E-02  1.6E-01 
rs2395175  11  FKBPL  1.7E-02  1.7E-01  1.6E-02  1.6E-01 
rs7574865  2  STAT4  2.8E-02  5.5E-02  2.0E-02  4.0E-02 
rs5029937  1  TNFAIP3  2.2E-02  2.2E-02  2.1E-02  2.1E-02 
rs3890745  4  HES5  2.7E-02  1.0E-01  2.3E-02  8.9E-02 Table 2.1 (continued)     
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Rheumatoid arthritis 
SNP 
# Genes 
in 
Locus  Gene  P1nominal  P1corrected  P2nominal  P2corrected 
rs2395175  11  HLA-DQA1  4.4E-02  3.9E-01  3.5E-02  3.2E-01 
rs2395175  11  HLA-DQB1  5.0E-02  4.3E-01  4.1E-02  3.7E-01 
rs2104286  4  IL15RA  5.7E-02  2.1E-01  5.1E-02  1.9E-01 
rs1678542  20  MARS  9.2E-02  8.6E-01  5.8E-02  7.0E-01 
rs6822844  3  IL21  6.3E-02  1.8E-01  6.0E-02  1.7E-01 
rs2104286  4  IL2RA  7.6E-02  2.7E-01  6.3E-02  2.3E-01 
rs2395175  11  PBX2  7.1E-02  5.6E-01  6.5E-02  5.3E-01 
rs1678542  20  ARHGAP9  9.1E-02  8.5E-01  7.1E-02  7.7E-01 
rs1678542  20  DCTN2  0.12  0.93  0.08  0.80 
rs6822844  3  IL2  0.10  0.27  0.09  0.24 
rs3890745  4  PEX10  0.09  0.32  0.09  0.31 
rs13031237  2  REL  0.13  0.23  0.10  0.19 
rs1678542  20  CDK4  0.12  0.93  0.12  0.92 
rs1678542  20  CTDSP2  0.18  0.98  0.17  0.97 
rs1678542  20  SLC26A10  0.23  0.99  0.21  0.99 
rs1678542  20  AGAP2  0.23  0.99  0.22  0.99 
rs10865035  1  AFF3  0.29  0.29  0.26  0.26 
rs3761847  6  PSMD5  0.30  0.88  0.27  0.85 
rs13031237  2  PEX13  0.30  0.51  0.28  0.49 
rs3766379  4  CD244  0.32  0.79  0.31  0.77 
rs2736340  2  BLK  0.35  0.58  0.33  0.55 
rs12746613  3  FCGR3A  0.38  0.77  0.34  0.71 
rs3761847  6  GSN  0.38  0.94  0.35  0.92 
rs548234  2  ATG5  0.41  0.65  0.37  0.61 
rs3890745  4  TNFRSF14  0.43  0.90  0.39  0.86 
rs2395175  11  AGER  0.42  1.00  0.41  1.00 
rs540386  4  RAG1  0.43  0.89  0.41  0.88 
rs2736340  2  GATA4  0.73  0.93  0.71  0.92 
rs4810485  4  NCOA5  0.86  1.00  0.84  1.00 
rs1678542  20  PIP4K2C  0.14  0.95  1.00  1.00 
rs1678542  20  DDIT3  1.00  1.00  1.00  1.00 
rs1678542  20  INHBE  1.00  1.00  1.00  1.00 
rs1678542  20  METTL1  1.00  1.00  1.00  1.00 
rs1678542  20  GLI1  1.00  1.00  1.00  1.00 
rs1678542  20  R3HDM2  1.00  1.00  1.00  1.00 
rs1678542  20  XRCC6BP1  1.00  1.00  1.00  1.00 
rs1678542  20  DTX3  1.00  1.00  1.00  1.00 
rs1678542  20  INHBC  1.00  1.00  1.00  1.00 
rs1678542  20  OS9  1.00  1.00  1.00  1.00 Table 2.1 (continued)     
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Rheumatoid arthritis 
SNP 
# Genes 
in 
Locus  Gene  P1nominal  P1corrected  P2nominal  P2corrected 
rs1678542  20  TSFM  1.00  1.00  1.00  1.00 
rs1678542  20  AVIL  1.00  1.00  1.00  1.00 
rs1678542  20  KIF5A  1.00  1.00  1.00  1.00 
rs2104286  4  RBM17  1.00  1.00  1.00  1.00 
rs2104286  4  PFKFB3  1.00  1.00  1.00  1.00 
rs2395175  11  NOTCH4  1.00  1.00  1.00  1.00 
rs2395175  11  AGPAT1  1.00  1.00  1.00  1.00 
rs2395175  11  HLA-DRB1  1.00  1.00  1.00  1.00 
rs2395175  11  GPSM3  1.00  1.00  1.00  1.00 
rs3761847  6  RAB14  1.00  1.00  1.00  1.00 
rs3761847  6  FBXW2  1.00  1.00  1.00  1.00 
rs3761847  6  C5  1.00  1.00  1.00  1.00 
rs3766379  4  LY9  1.00  1.00  1.00  1.00 
rs3766379  4  ITLN1  1.00  1.00  1.00  1.00 
rs3890745  4  MMEL1  1.00  1.00  1.00  1.00 
rs4810485  4  MMP9  1.00  1.00  1.00  1.00 
rs4810485  4  ZNF335  1.00  1.00  1.00  1.00 
rs540386  4  RAG2  1.00  1.00  1.00  1.00 
rs540386  4  FLJ14213  1.00  1.00  1.00  1.00 
rs6822844  3  KIAA1109  1.00  1.00  1.00  1.00 
rs394581  1  RSPH3  1.00  1.00  1.00  1.00 
rs548234  2  PRDM1  1.00  1.00  1.00  1.00 
rs7528684  2  FCRL3  1.00  1.00  1.00  1.00 
rs7528684  2  CD5L  1.00  1.00  1.00  1.00 
rs3218253  2  TMPRSS6  0.15  0.28  NA  NA 
rs2476601  6  HIPK1  0.13  0.58  NA  NA 
rs1980422  2  RAPH1  0.44  0.69  NA  NA 
rs2476601  6  MAGI3  0.49  0.98  NA  NA 
rs2476601  6  RSBN1  1.00  1.00  NA  NA 
rs2476601  6  DCLRE1B  1.00  1.00  NA  NA 
rs2476601  6  OLFML3  1.00  1.00  NA  NA 
rs2812378  2  SIGMAR1  1.00  1.00  NA  NA 
 
 
Table 2.2 CD candidate genes proposed through permutation. See Table 2.1 for description. Table 2.2 (continued)     
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Crohn's Disease 
SNP 
# Genes 
in Locus  Gene  P1nominal  P1corrected  P2nominal  P2corrected 
rs744166  8  STAT5B  2.0E-03  1.6E-02  2.0E-04  1.6E-03 
rs744166  8  STAT5A  1.9E-04  1.5E-03  2.0E-04  1.6E-03 
rs10758669  2  JAK2  2.8E-04  5.6E-04  4.0E-04  8.0E-04 
rs2872507  17  CSF3  1.1E-03  1.9E-02  1.8E-03  3.0E-02 
rs11465804  2  IL23R  2.0E-03  4.0E-03  2.0E-03  4.0E-03 
rs11465804  2  IL12RB2  2.0E-03  4.0E-03  2.0E-03  4.0E-03 
rs10045431  1  IL12B  2.7E-03  2.7E-03  2.6E-03  2.6E-03 
rs2188962  8  IL5  1.5E-03  1.2E-02  3.4E-03  2.7E-02 
rs2188962  8  CSF2  4.3E-03  3.4E-02  4.0E-03  3.2E-02 
rs2188962  8  IL3  3.7E-03  2.9E-02  4.4E-03  3.5E-02 
rs744166  8  STAT3  3.4E-03  2.7E-02  5.6E-03  4.4E-02 
rs3197999  23  MST1R  3.1E-03  6.9E-02  6.6E-03  1.4E-01 
rs2188962  8  IRF1  1.3E-02  9.6E-02  9.9E-03  7.7E-02 
rs3197999  23  DAG1  1.1E-02  2.3E-01  1.9E-02  3.6E-01 
rs2872507  17  GRB7  7.9E-03  1.3E-01  1.9E-02  2.8E-01 
rs2542151  6  PTPN2  3.1E-02  1.7E-01  2.5E-02  1.4E-01 
rs762421  3  AIRE  2.0E-02  5.8E-02  2.6E-02  7.6E-02 
rs2066845  4  CYLD  3.1E-02  1.2E-01  3.0E-02  1.1E-01 
rs2476601  6  PTPN22  2.6E-02  1.5E-01  3.9E-02  2.1E-01 
rs2872507  17  IKZF3  3.9E-02  4.9E-01  4.0E-02  5.0E-01 
rs10995271  1  ZNF365  4.7E-02  4.7E-02  4.5E-02  4.5E-02 
rs3197999  23  TRAIP  0.07  0.81  0.07  0.79 
rs2872507  17  ERBB2  0.08  0.75  0.07  0.70 
rs3197999  23  BSN  0.08  0.84  0.07  0.83 
rs3197999  23  IP6K1  0.11  0.92  0.10  0.90 
rs3197999  23  GPX1  0.09  0.90  0.10  0.91 
rs2872507  17  FBXL20  0.11  0.87  0.10  0.84 
rs2542151  6  SPIRE1  0.14  0.59  0.13  0.57 
rs762421  3  PFKL  0.20  0.48  0.15  0.39 
rs2872507  17  PPP1R1B  0.20  0.98  0.18  0.97 
rs11190140  2  ENTPD7  0.20  0.36  0.19  0.35 
rs3197999  23  CELSR3  0.23  1.00  0.20  0.99 
rs3197999  23  PRKAR2A  0.25  1.00  0.22  1.00 
rs3828309  1  ATG16L1  0.64  0.64  0.23  0.23 
rs3197999  23  CAMKV  0.27  1.00  0.26  1.00 
rs11584383  3  CACNA1S  0.28  0.63  0.26  0.60 
rs3197999  23  QARS  0.33  1.00  0.30  1.00 
rs744166  8  TUBG1  0.35  0.97  0.30  0.94 
rs2872507  17  CACNB1  0.36  1.00  0.33  1.00 
rs17582416  3  CREM  0.38  0.76  0.35  0.72 
rs2872507  17  PERLD1  0.39  1.00  0.36  1.00 
rs11584383  3  KIF21B  0.45  0.83  0.44  0.83 Table 2.2 (continued)     
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Crohn's Disease 
SNP 
# Genes 
in Locus  Gene  P1nominal  P1corrected  P2nominal  P2corrected 
rs2476601  6  MAGI3  0.48  0.98  0.46  0.98 
rs1456893  1  IKZF1  0.48  0.48  0.47  0.47 
rs11747270  2  DCTN4  0.53  0.78  0.53  0.78 
rs2188962  8  RAD50  0.57  1.00  0.54  1.00 
rs744166  8  ATP6V0A1  0.57  1.00  0.56  1.00 
rs17582416  3  CUL2  0.61  0.94  0.58  0.93 
rs7746082  1  PRDM1  0.67  0.67  0.65  0.65 
rs2188962  8  P4HA2  0.68  1.00  0.66  1.00 
rs11584383  3  C1orf106  0.70  0.97  0.67  0.97 
rs2476601  6  HIPK1  0.78  1.00  0.78  1.00 
rs17582416  3  CCNY  0.79  0.99  0.79  0.99 
rs11190140  2  GOT1  0.84  0.98  0.84  0.97 
rs6908425  1  E2F3  0.89  0.89  0.87  0.87 
rs2066845  4  SNX20  1.00  1.00  1.00  1.00 
rs2066845  4  NKD1  1.00  1.00  1.00  1.00 
rs2066845  4  NOD2  1.00  1.00  1.00  1.00 
rs2188962  8  SLC22A5  1.00  1.00  1.00  1.00 
rs2188962  8  SLC22A4  1.00  1.00  1.00  1.00 
rs2542151  6  SEH1L  1.00  1.00  1.00  1.00 
rs2542151  6  CEP76  1.00  1.00  1.00  1.00 
rs2542151  6  PSMG2  1.00  1.00  1.00  1.00 
rs2542151  6  CEP192  1.00  1.00  1.00  1.00 
rs2872507  17  ORMDL3  1.00  1.00  1.00  1.00 
rs2872507  17  MED1  1.00  1.00  1.00  1.00 
rs2872507  17  PSMD3  1.00  1.00  1.00  1.00 
rs2872507  17  RPL19  1.00  1.00  1.00  1.00 
rs2872507  17  CRKRS  1.00  1.00  1.00  1.00 
rs2872507  17  STARD3  1.00  1.00  1.00  1.00 
rs2872507  17  NEUROD2  1.00  1.00  1.00  1.00 
rs2872507  17  STAC2  1.00  1.00  1.00  1.00 
rs2872507  17  TCAP  1.00  1.00  1.00  1.00 
rs3197999  23  IMPDH2  0.23  1.00  1.00  1.00 
rs3197999  23  GMPPB  1.00  1.00  1.00  1.00 
rs3197999  23  RHOA  1.00  1.00  1.00  1.00 
rs3197999  23  ARIH2  1.00  1.00  1.00  1.00 
rs3197999  23  APEH  1.00  1.00  1.00  1.00 
rs3197999  23  WDR6  1.00  1.00  1.00  1.00 
rs3197999  23  MST1  1.00  1.00  1.00  1.00 
rs3197999  23  QRICH1  1.00  1.00  1.00  1.00 
rs3197999  23  IP6K2  1.00  1.00  1.00  1.00 
rs3197999  23  LAMB2  1.00  1.00  1.00  1.00 
rs3197999  23  USP4  1.00  1.00  1.00  1.00 Table 2.2 (continued)     
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in Locus  Gene  P1nominal  P1corrected  P2nominal  P2corrected 
rs3197999  23  NDUFAF3  1.00  1.00  1.00  1.00 
rs3197999  23  AMT  1.00  1.00  1.00  1.00 
rs744166  8  PTRF  1.00  1.00  1.00  1.00 
rs744166  8  PSMC3IP  1.00  1.00  1.00  1.00 
rs744166  8  MLX  1.00  1.00  1.00  1.00 
rs762421  3  DNMT3L  1.00  1.00  1.00  1.00 
rs11175593  1  SLC2A13  1.00  1.00  1.00  1.00 
rs11747270  2  RBM22  1.00  1.00  1.00  1.00 
rs2274910  2  LY9  1.00  1.00  1.00  1.00 
rs2274910  2  CD244  1.00  1.00  1.00  1.00 
rs2476601  6  RSBN1  1.00  1.00  1.00  1.00 
rs2476601  6  DCLRE1B  1.00  1.00  1.00  1.00 
rs2476601  6  AP4B1  1.00  1.00  1.00  1.00 
rs3764147  1  ENOX1  1.00  1.00  1.00  1.00 
rs4263839  1  TNFSF8  1.00  1.00  1.00  1.00 
rs7927894  2  C11orf30  1.00  1.00  1.00  1.00 
rs7927894  2  PRKRIR  1.00  1.00  1.00  1.00 
rs10758669  2  INSL6  0.55  0.80  NA  NA 
 
The core networks involving only these candidate genes represent our mechanistic 
predictions  of  pathways  underlying  pathogenesis  in  RA  and  CD.  From  a  statistical 
standpoint  the  final  networks  built  from  candidate  proteins  account  for  the  excess 
connectivity that we initially observed: the significance remains if we restrict multigenic 
loci to just these genes (direct network connectivity p < 2×10
-5 for RA and CD), while 
networks  built  from  the  remaining  non-prioritized  genes  are  less  significant  (direct 
network  connectivity  p  =  0.0368  and  p  =  0.993,  for  RA  and  CD  respectively).  The 
remaining significance in RA is most likely a sign of additional important proteins that 
did  not  make  the  cutoff.  From  a  biological  standpoint,  our  candidates  agree  with 
experimental  findings  in  the  few  cases  where  such  evidence  exists  [114–121].  We 
therefore show that the connectivity between associated loci in RA and CD is primarily      
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driven by a small subset of associated proteins encoded in those regions; this observation 
suggests that the interacting proteins – and the biological pathways they represent – may 
be the targets of risk variation. 
To  test  the  biological  plausibility  of  our  nominated  core  networks,  we  asked 
whether the candidate genes are co-enriched in subsets of particularly relevant tissues in a 
reference microarray dataset consisting of 14,184 transcripts measured in 55 immune, 8 
gastro-intestinal, 27 neuronal and 36 miscellaneous other tissues (126 total) [108]. These 
publicly available data are curated: expression intensities were converted to enrichment 
scores to reflect the enrichment of a gene in a tissue given its expression in all tissues. For 
each tissue, we compared the expression enrichment of RA and CD candidate genes to 
the rest of the genes in the genome using a one-tailed rank-sum test, resulting in a p-value 
for each tissue. A significant difference for a given tissue indicated that the genes in 
question were enriched for expression in that tissue compared to all genes in the genome. 
We  also  performed  the  same  analysis  for  the  remaining  non-prioritized  genes  in 
associated regions to test whether the network prioritization method identified genes that 
were enriched in tissues distinct from non-prioritized genes. For discussion purposes, we 
defined  “top”  tissues  as  tissues  achieving  p  <  0.1  (Figure  2.7  depicts  the  entire 
distribution of p-values). This analysis led to 3 main conclusions. First, we found that for 
each disease, enrichment only occurred in immunologically relevant tissues (Figure 2.7; 
strikingly, immune tissues are nearly all ranked higher than other tissues). Second, we 
found that this was not the case to such an extent for non-prioritized genes (Figure 2.7, 
black points). Third, we found that the non-prioritized genes had fewer tissues where we 
could detect enrichment (Figure 2.7, RA and CD candidate gene tissue scores are more      
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significant  than  tissue  scores  of  non-prioritized  genes).  We  formally  tested  this  by 
comparing the p-value distributions for candidate genes and non-prioritized genes using a 
one-tailed rank-sum test (p = 2.85×10
-7 for RA; p = 2.55×10
-4 for CD). Of the 11 top 
tissues for CD candidate genes, 7 are subgroups of T-cell lymphocytes; the analogous list 
for  RA  (21  tissues)  contains  a  mix  of  immune  tissues,  again  dominated  by  T-cell 
subgroups (Table 2.3). The top tissue compartment for both diseases is defined as CD4+ 
T-cells.      
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Figure 2.7 Candidate RA and CD genes are preferentially expressed in immune tissues. We 
obtained tissue expression data for 126 different cell types from a publicly available database, 
which was grouped into immune, gastrointestinal (GI), neuronal and 'other' [108]. For each tissue, 
we compared the expression of RA (A) and CD (B) candidate genes to the rest of the genes in the 
genome using a one-tailed rank-sum test, resulting in a p-value for each tissue (-log(p) is plotted 
on the y-axis). A significant difference for a given tissue indicated that the candidate genes were 
enriched for expression in that tissue compared to all genes in the genome. To test whether our Figure 2.7 (continued)     
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network prioritization identified genes that were co-enriched in specific tissues beyond what was 
expected from all genes in associated regions, we calculated the same p-values for the rest of the 
genes in RA and CD associated loci (i.e., the genes that weren't prioritized via our network 
permutations).  I n  t h i s  f i g u r e ,  w e  p l o t  t h e  t i s s u e  e n r i c h m e n t  s c o r e s  f o r  e a c h  t i s s u e  f o r  t h e  
candidate genes (purple) and the non-prioritized genes in the remaining regions of association 
(black). We indicate the category of tissue on the bottom: immune (red), GI (yellow), neuronal 
(green) and other (blue). We ordered the tissues by decreasing enrichment score of the candidate 
gene.
Table 2.3 RA and CD candidate genes are preferentially expressed in immune tissues. 
Expression data was downloaded from a publically available dataset [108]. The data had been 
previously converted into enrichment scores (see Materials and Methods). The enrichment scores 
of candidate genes in RA and CD were compared to the rest of the genome by a one-tailed rank-
sum test. The tissues that received a p-value of < 0.1 are shown. Of note, all tissues in this 
category for both RA and CD are immune, as shown in Figure 2.7.  
Rheumatoid arthritis  Crohn's disease 
Tissue  p-value  Tissue  p-value 
TonsilsCD4posTcells  1.21E-06  Tcellseffectormemory  0.0108 
Th1  3.60E-06  TcellsBAFFpos  0.0215 
TcellsCD57pos  5.74E-06  Treg  0.0402 
Treg  2.42E-05  Tcellscentralmemory  0.0472 
Lymphnode  4.58E-05  ThymicSPCD8posTcells  0.0525 
Th2  5.42E-05  PeripheralnaiveCD4posTcells  0.0624 
TcellsBAFFpos  0.000122  ThymicSPCD4posTcells  0.0637 
PeripheralCD8posTcells  0.000416  MacrophageLPS4h  0.0674 
Tcellscentralmemory  0.000548  MyeloidCD33pos  0.0822 
Tcellseffectormemory  0.000896  PeripheralCD8posTcells  0.0831 
Tonsils  0.003590  DC  0.0901 
ThymicSPCD8posTcells  0.005277     Table 2.3 (continued)     
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Rheumatoid arthritis  Crohn's disease 
Tissue  p-value  Tissue  p-value 
ThymicSPCD4posTcells  0.010418     
PeripheralnaiveCD4posTcells  0.011665     
NKCD56pos  0.017593     
Tcellsgammadelta  0.018660     
MacrophageLPS4h  0.029525     
DC  0.046402     
Spleen  0.048697     
DCLPS48h  0.063014     
ThymicCD4posCD8posCD3pos  0.091299     
 
2.4.6  Crohn’s Network Predicts New Loci 
  We hypothesized that a subset of proteins connected  to the core CD network 
(Figure 2.8B, the network built from prioritized genes in CD loci) might be near true 
causal variation. Having observed significant enrichment for association in the common 
interactors, we then chose a more conservative approach to propose candidate genes. We 
selected all proteins that connect directly to the core CD network only (21 genes) and 
filtered them on expression in the relevant tissues (Table 2.3). While this work was being 
prepared, a larger meta-analysis was completed and recently published that reports 39 
new loci associated to CD (295 overlapping genes) [18]. Of the 293 genes proposed by 
our method (small circles, Figure 2.8B), 10 were in newly associated regions (small red 
circles).  This  represents  a  statistically  significant  enrichment  compared  to  chance 
expectation based on random draws from all 21,718 genes (p = 0.001) as well as random 
draws from genes expressed in at least one of the CD-relevant tissues (p=0.01).       
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Figure 2.8 Final disease networks. Resultant networks built from candidate genes are depicted 
for RA and CD (A and B, respectively). Using only the candidate genes, we plotted the direct 
network as well as any other proteins connected to the direct network after filtering them on 
expression in any one of the tissues found to be specific to the core network. 610 such proteins 
connect to the RA network and 293 such proteins connect to the CD network. Large circles 
represent disease proteins, and small circles represent the connected proteins. Small red circles 
indicate proteins connected to the core network that were newly identified associated regions (10 
proteins in CD and 1 protein in RA). The large circles are colored by locus. 
 
  We performed a similar analysis in RA since the recent meta-analysis discovered 
6 new loci (18 new genes) [113]. Of the 610 genes proposed, 1 was among the 18 new 
genes (Figure 2.8A, small red circle). This does not represent a statistically significant 
enrichment. 
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2.4.7  Candidate gene networks suggest underlying biology 
The networks (Figure 2.8) suggest pathogenic mechanisms in agreement with current 
thinking  on  disease  etiology  and  propose  novel  roles  for  candidate  proteins  in  these 
pathways.  The  RA  network  (Figure  2.10)  appears  to  represent  signaling  cascades 
involved in the inhibition or stimulation of the NF-kB complex, a factor that activates 
transcription  of  genes  encoding  cytokines,  antibodies,  co-stimulatory  molecules  and 
surface  receptors  [119].  STAT4  encodes  a  transcription  factor  that  is  activated  upon 
engagement of cytokines, such as IL12 and interferon type I, with their receptors [119]. 
We show that not only does STAT4 show enrichment for connectivity, it is connected 
indirectly to a number of associated genes encoding surface receptor subunits that also 
achieve high network scores, such as IL12RB, IL2RA and PTPRC. TNFAIP3 (known as 
A20  in  mice)  is  a  cytoplasmic  zinc  finger  protein  that  inhibits  NF-kB  activity,  and 
knockout  mice  develop  widespread  and  ultimately  lethal  inflammation,  making  it  a 
plausible player in RA pathogenesis [122]. Also in the NF-kB pathway is associated 
protein  CD40,  which  scores  highly  in  our  networks  and  binds  TRAF6  and  TRAF1 
directly. CD40 is normally found on B cells but has also been shown to act as a co-
stimulatory molecule on T cells to augment CD28 response and activate NF-kB [123]. 
PTPN22, a gene with strong genetic support for harboring risk variants (including 
the  strongly  associated  R620W  coding  polymorphism),  has  been  shown  to  act  as  a 
negative  regulator  of  TCR  but  has  not  yet  been  definitively  linked  to  a  pathogenic 
mechanism [119,124]. Here, we place it in context of other highly associated proteins and 
suggest that it is part of a common mechanism.       
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Finally, the RA network places a number of other proteins that have not yet been 
formally studied in the context of the proposed network underlying RA; these include 
CD2 and CD48, as well as FCG2RA and PRKCQ, genes suspected of being causal but 
not formally placed in a mechanism with other associations. 
In  CD  the  core  of  the  candidate  network  (IL12B/IL23R/JAK2/STAT3;  Figure 
2.8B) corresponds to the interleukin-23 (IL23) signaling pathway. IL12B encodes p40, a 
component  of  the  heterodimeric  IL23.  The  IL23R  gene  encodes  one  half  of  the  also 
heterodimeric IL23 receptor. This receptor is a cell surface complex found on a variety of 
immune cells; on activation, it induces Janus Kinase 2 (Jak2) autophosphorylation, which 
in turn leads to the translocation of STAT3 to the nucleus to activate transcription of 
various pro-inflammatory cytokines [116]. IL23 signaling is necessary for the activation 
and maintenance of a subset of CD4
+ T cells acting as ‘inflammatory effectors’; these 
interleukin-17  responsive  T-cells  (Th17)  have  been  implicated  in  autoimmune 
inflammation in CD and experimental models of other autoimmune diseases [116]. We 
note that IL23 belongs to the interleukin 12 family of cytokines and both ligand and 
receptor  share  subunits  with  the  canonical  IL12-mediated  signaling  pathway,  which 
induces activation of regulatory T cells (Treg). 
The CD network suggests that other proteins participate in this pathway, including 
the tyrosine phosphatase encoded by PTPN2, a gene also associated to other autoimmune 
diseases [125]. Other proteins that are indirectly connected to this pathway include IRF1, 
which we score highly and that has separately been reported to activate transcription of 
IL12RB1 [126]. Furthermore, the common interactors that we prioritize for replication of 
association given their involvement in the CD network – including JAK1, STAT4, TYK2      
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and IL2RA – fall into the IL12 and IL23 signaling pathway (TYK2 and IL2RA were of the 
genes recently found to be in regions of association). 
The  CD  network  also  generates  new  hypotheses  about  potentially  important 
genes. We prioritize AIRE, an associated protein involved in T-cell development, which 
has not been extensively studied in the context of Crohn’s but could plausibly lead to 
autoimmunity. ZNF365, a gene that achieves a high permutation score, has been assumed 
to be the causal gene because it is the only gene to reside in the wingspan of its locus; 
however,  it  has  not  been  studied  as  part  of  the  core  network  described  here 
(IL23R/JAK2/STAT3 pathway). Finally, CSF2, IKZF3 and GRB7 are in the same large 
locus (17 genes) but achieve significant permutation scores; these genes have been less 
well studied in the context of CD. 
2.5  Discussion 
We have shown that proteins encoded in regions associated to RA, CD, height and lipids 
interact and that the networks they form are significantly connected when compared to 
random  networks.  In  CD  and  RA,  the  genes  encoding  prioritized  proteins  are 
preferentially expressed in immune tissues relevant to the pathogenesis of both diseases, 
while the rest of the genes in associated loci show less tissue preference. Furthermore, we 
can connect other associated proteins to these networks via common interactors, which 
appear to be encoded in genomic regions harboring further risk variants. Newly available 
data in CD allowed us to confirm that genes predicted to be near causal variation are 
indeed in regions now known to be associated to CD. We note that the conclusion of 
connectivity  could  not  be  extended  to  T2D,  and  we  hypothesize  that  the  lack  of      
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connectivity may be due to disparate underlying mechanisms that have yet to be well 
captured genetically. Though our aim was to build and analyze networks that emerge 
from replicated regions of association, we feel that a promising future direction may be to 
look more broadly for networks enriched in weaker signals of association. Evidence that 
this type of analysis may be helpful is that we pointed to a set of weaker CD association 
signals that were found to be true positives in a larger study. 
Our  results  have  several  implications  for  the  interpretation  of  genome-wide 
association studies: first, our ability to connect the majority of associated loci in a limited 
number  of  molecular  networks  suggests  that  these  represent  processes  underlying 
pathogenesis. Second, these networks are unbiased, in the sense that they do not rely on 
previous  classifications  of  gene  function  or  pathway  lists;  rather,  we  assemble  our 
networks from low-level functional genomics data and allow network structure, if any, to 
emerge.  Third,  our  approach  is  general;  we  have  demonstrated  it  using  interactions 
between protein products, but any relationship between genes or other genomic features 
(non-coding RNAs, enhancer elements, conserved regions etc.) may be used in the same 
fashion. Even more powerful, approaches combining such orthogonal data types will be 
rewarding. The limitation to using PPI data from a curated database such as InWeb is that 
proteins for which no high-confidence interactions exist will be left out of the analysis. 
As such, our analysis is limited to proteins present in the database. Additionally, while 
we controlled for the biases we observed, other undetected biases still may exist. 
Interestingly,  there  are  certain  cases  where  the  method  is  able  to  distinguish 
between proteins that are close in the genome and functionally very similar. In RA, the 
rs12746613 locus has 3 genes in the PPI database – FCG2RA, FCGR3A and HSP70B.      
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FCG2RA  achieved  a  nominal  p-value  of  0.00703,  whereas  FCGR3A  achieved  p  = 
0.38296. Similarly, in the large rs3197999 locus in CD, the method gave MST1R a p-
value of 0.0066 whereas MST1, the ligand of MST1R, achieved a p-value of 1. In these 
cases, the method is able to distinguish between functionally similar genes. There are 
times when it is unable to distinguish between functionally similar genes, however, such 
as  the  IL21/IL2  locus  in  RA,  the  STAT1/STAT4  locus  in  RA  and  the 
STAT3/STAT5A/STAT5B locus in CD.  
We note in passing that the candidate genes we nominate are on average the 
closest to the most associated SNP in each locus, even though proximity within the LD 
region was not considered in the PPI analysis (p = 0.005, Figure 2.9). This supports the 
theory that the majority of causal variation will be close to the association signal rather 
than anywhere in the region of LD. We also observed overlap between genes prioritized 
by this method and GRAIL, a text-mining approach that uses orthogonal data [98]. We 
depict this information, as well as overlap between prioritized genes and the presence of 
non-synonymous SNPs, in Figure 2.9.      
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Figure 2.9 Candidate genes are likely to be near to the associated SNP. Candidate genes 
within multigenic loci were prioritized as described. We defined the distance from a gene to the 
SNP that tags it as the shortest of two distances: the distance from its start codon to the SNP and 
its stop codon to the SNP. Genes within a SNP's wingspan are then given ranks as to how close 
they are to the SNP (closest gene, 2nd closest gene, and so on). These distances were collected for 
RA and CD and the distribution is shown (salmon bars). We compared this distribution to the 
distribution of 100 simulated distances as defined by random assignment of candidate genes in 
associated  loci  (black  hatched  bars).  The  distributions  are  significantly  different  (one-tailed 
Kolmogorov-Smirnov test p = 0.008).      
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Figure 2.10 Overlap of prioritized genes across methods. For each SNP, we compared the 
prioritized  genes  through  PPI  networks,  through  GRAIL  and  through  presence  of  non-
synonymous SNPs. We show the overlap for all SNPs, where two methods agree if at least one 
prioritized gene in the region is the same. 
In this chapter, we have studied 5 complex phenotypes, 4 of which show evidence 
of abundant PPI connections across loci. Our results therefore allow us to speculate that 
other complex diseases may behave in the same way and that genetic risk may be spread 
over the molecular processes that influence disease, rather than a single, catastrophic 
mutation as in Mendelian inheritance. In order to determine whether what we find here is 
expandable to complex disease in general, however, we would need to apply our method 
to  the  many  more  diseases  and  traits  to  which  regions  of  the  genome  have  been 
associated. Nonetheless, for the networks that emerge here, our approach identifies sets 
of proteins plausibly involved in pathogenesis, and the next step will be to identify what 
the molecular and phenotypic consequences of perturbing such processes are and how 
they relate to overall disease etiology.  
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2.6  Materials and Methods 
2.6.1  InWeb Database 
See  section  1.3.5  for  description.  The  data  we  used  is  available  at 
www.broadinstitute.org/mpg/dapple. 
2.6.2  Disease Loci 
30 CD SNPs were derived from the first CD meta analysis of which 25 contain genes 
[16]. 28 RA SNPs were derived from the most recent RA review of which 27 contain 
genes [94]. 42 Height SNPs were derived from a number of analyses of which 38 contain 
genes [23,24,97]. 19 blood lipid level SNPs were derived from a number of analyses of 
which all 19 contain genes [96]. Finally, 42 T2D SNPs were derived from a number of 
analyses of which 37 contain genes [19–21,95]. 
2.6.3  Translating SNPs to genes 
Hotspot  and  linkage  disequilibrium  (LD)  information  were  downloaded  from 
www.hapmap.org for CEU hg17 and hg18 to match the version in which associations 
were reported [127]. We defined the wingspan of a SNP as the region containing SNPs 
with  r
2>0.5  to  the  associated  SNP;  this  region  is  then  extended  to  the  nearest 
recombination  hotspot.  We  downloaded  the  Ensembl  human  gene  list  from  UCSC 
Genome Browser and collapsed isoforms into single genes [128]. We converted gene IDs 
from Ensemble to InWeb IDs. A gene’s residence in a locus is defined by whether 110kb 
upstream and 40kb downstream (to include regulatory DNA) of the coding region of the 
gene’s largest isoform overlaps the SNP wingspan[41].       
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2.6.4  Statistical Analysis 
All analyses, including building networks and evaluating significance, were carried out in 
R , Perl and Python and are available at www.broadinstitute.org/mpg/dapple.  
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3  Proteomic and genetic dissection of cardiac repolarization 
complexes 
 
The contents of this chapter are also represented as 2 submissions to Nature: 
Alicia Lundby*, Elizabeth J. Rossin*, Annette B. Steffensen, Christopher Newton-Cheh, 
Arne Pfeufer, et al. Proteomic and genetic dissection of cardiac repolarization protein 
complexes. In review at Nature. 
 
Arking et al. Novel genetic variants influencing myocardial repolarization highlight 
calcium signaling. (2011) In review at Nature. 
 
 
Individual contributions are listed at the end of the chapter.      
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3.1  Abstract 
Myocardial repolarization is reflected in the QT interval of the heart's electric cycle, and 
prolongation of this interval is a risk factor for sudden cardiac death and drug-induced 
arrhythmias. Mendelian long QT syndrome (LQTS) is caused by rare mutations in genes 
important for cardiac ion channel function [129]. A recent meta-analysis of genome-wide 
association  studies  (GWAS)  identified  35  loci  associated  with  modest  QT  interval 
variation in the general population, but for most loci the causal genes remain unknown. 
[36,37]. Despite the biomedical implications, this reflects our rudimentary knowledge of 
the  molecular  components  driving  cardiac  repolarization.  Here,  we  resolve  protein 
complexes based on five LQTS genes (KCNQ1, KCNH2, CACNA1C, SNTA1, CAV3) by 
label-free  quantitative  proteomics[130–132]  in  cardiac  tissue,  and  integrate  the 
complexes with GWAS data on QT interval variation from ~100,000 individuals. Twelve 
genes in genome-wide significant loci encode proteins in the complexes (PLN, ATP1B1, 
UNC45B, TRAP1, TTN, CCDC141, ATP2A2, CAV1, CAV2, GOT2, ACTR1A, MYL3; P = 
1.3e-6),  suggesting  that  these  genes  underlie  their  respective  association  signals. 
Electrophysiological recordings show that the protein encoded by ATP1B1 modulates ion 
channel function, and knock-down of the orthologous gene in zebrafish shortens cardiac 
repolarization. Guided by proteins in the complexes, 25 single nucleotide polymorphisms 
(SNPs)  are  chosen  for  hypothesis-driven  genotype  replication  in  >17,500  individuals. 
Three SNPs that would otherwise have been missed become genome-wide significant, 
including  one  at  SRL,  a  known  regulator  of  Ca
2+  uptake  through  interactions  with 
ATP2A2 at the protein level (rs10824026, P = 1.5e-9; rs889807, P = 1.2e-8; rs7498491, P      
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= 2.2e-8). Combining tissue-specific high-resolution proteomics with GWAS datasets, 
we show that 39% of common genetic variants associated with QT interval variation 
point to proteins in cardiac repolarization protein complexes. Furthermore, our approach 
illustrates a strategy for integrating and interpreting common and rare genetic variation 
using quantitative interaction proteomics.   
3.2  Introduction 
Modest prolongation of the QT interval duration is a quantitative heritable trait, 
and with the completion of the work described in the companion paper by Arking et al., 
GWAS  have  successfully  identified  35  loci  significantly  associated  with  QT  interval 
variation in the general population (≈1-4 msec/allele). In the majority of associated loci, 
large spans of linkage disequilibrium include many genes, and the exact genes underlying 
the signal remain to be identified and functionally characterized. Five of the common 
variant loci harbor Mendelian LQTS genes, which encode cardiac ion channels as well as 
proteins regulating the channel function (Figure 3.2A). Cardiac ion channels form large 
protein  complexes  and  their  function  is  greatly  modulated  by  auxiliary  subunits,  in 
addition to the control exerted by more dynamic interaction partners, such as protein 
kinases[133].    However,  the  exact  tissue-specific  composition  of  these  complexes  is 
largely unknown.  We hypothesized that some of the genetic contribution to QT interval 
variation  could  be  attributed  to  proteins  in  complexes  with  Mendelian  LQTS  gene-
encoded proteins (LQTS proteins hereafter), which is in accordance with results from in 
silico analyses from the companion paper by Arking et al. [manuscript in review].      
 
  87 
To initially test the strength of this hypothesis, we ran DAPPLE (described in 
Chapter 2) using the published loci as well as the known LQTS genes to see whether we 
could identify significant connectivity based on available public data[36,37]. Briefly, we 
seeded the network with the 12 known Mendelian LQTS genes and seven loci harboring 
common QT variants (but not Mendelian genes) previously identified[134]. Consistent 
with  the  known  relationships  among  several  of  the  Mendelian  genes,  significant 
interconnectivity  was  observed  (p=0.0006  for  the  direct  connections,  p=0.008  for  the 
indirect connections, Figure 3.1).  
 
Figure 3.1 Proteins associated to QT-interval variation are significantly interconnected with 
Mendelian LQTS proteins and predict 8 newly associated proteins. DAPPLE was seeded 
with 7 previously known loci harboring common QT variants (light green), 7 Mendelian LQTS 
!"#$$
%&'()
*+,-$
+./0
*+,1$
.,*$
%+,2.
.'3)
.'"454
%,'.4
+,6'4
.+6'7
*+,.5$
!.(24#0
,#&4
8+9'+.+,.4+
+4:;<444
++')5
#8'.3
'=,(+44
,6%4."
>8,%0
*+,?4
*+,&$
*+,&4
#8>0
@,+A25
"#,
!33#
%+,A5
%1$(45
@19*4
!"#$"%&'#()*+,
)*+,-.#%/
!"#$"%&'#-.#%/
0"1%/-'22.3&'4"$
546"7-&#4"7'34&#8-97.4"&#
.*."BFigure 3.1 (continued)     
 
  88 
genes (blue) and 5 genes associated to the QT-interval both through GWAS and LQTS (dark 
green). Other proteins connected to the network that are newly associated in the recent QT-IGC 
meta-analysis are shown in red. 
We identified 606 other proteins interacting directly with the seed proteins and found that 
8 of them were from 7 novel loci (loci newly associated via the companion paper by 
Arking et al.) at genome-wide significance (ATP2A2, CAV1, CAV2, PRKCA, SLC8A1, 
ATXN1,  ETF1,  SGOL2;  small  red  circles  in  Figure  3.1),  representing  significant 
enrichment compared to expectations under the null (hypergeometric P = 0.03).  This 
likely represents an underestimate of the true biologic interactors due to the fact that 
several proteins in associated loci are not present in the InWeb database. Similar to the 
analysis  described  in  section  2.4.3,  we  assigned  association  scores  to  all  interacting 
proteins not in the novel loci and tested for enrichment in association in those genes 
compared  to  all  genes  in  the  genome  from  non-associated  regions.  We  found  that 
interacting proteins were more associated than chance expectation (rank-sum p=0.00012), 
suggesting that they may represent true associations yet to be discovered. 
Encouraged  by  the  in  silico  results,  we  went  on  to  investigate  the  protein 
complexes associated with known LQTS proteins in an in vivo setting. We decided to 
explore a broad subset of the known LQTS proteins by affinity purification and mass 
spectrometry  and  integrated  these  with  data  on  SNPs  associated  with  QT  interval 
variation in the general population (Digure 3.2B). We chose three ion channels and two 
modulators of ion channel currents as targets for the proteomic analysis. These proteins 
correspond to Mendelian LQTS genes both present and absent in loci identified in GWA  
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studies of QT interval variation.  For the three ion channels chosen, mutations in KCNQ1 
and KCNH2 cause the two most common forms of LQTS (LQT1 and LQT2), whereas 
mutations in CACNA1C cause a rare, but severe, type of LQTS associated with autism 
(LQT8). KCNQ1 and KCNH2 associated mutations result in reduced current conduction 
by  the  voltage-gated  potassium  channels  Kv7.1[135]  and  Kv11.1[136],  respectively, 
whereas CACNA1C mutations impede voltage-independent inactivation of the Cav1.2 L-
type calcium channel[137]. The two ion channel regulators chosen, caveolin 3 (Cav3) 
encoded  by  CAV3  (LQT9)[138]
  and  α1-syntrophin  (Snta1)  encoded  by  SNTA1 
(LQT12)[139], have both been associated with LQTS via their influence on the Nav1.5 
ion  channel  (encoded  by  SCN5A),  but  they  represent  a  smaller  proportion  of  LQTS 
overall.  
 
Figure  3.2  General  design  and  experimental  workflow  of  our  integrated  genetic  and 
proteomic study. A. Left panel: Rare mutations in 12 genes can cause Mendelian LQTS. 
Five  of  the  Mendelian  genes  reside  in  loci  definitively  associated  with  QT  interval 
variation in the general population by genome-wide association studies (GWAS). Right 
panel: The LQTS genes encode five ion channels, Nav1.5 (SCN5A), Cav1.2 (CACNA1C), 
Kv7.1 (KCNQ1), Kv11.1 (KCNH2), and Kir2.1 (KCNJ2), mediating currents affecting 
the part of the cardiac action potential (black line) where the ion channels are drawn. The 
remaining  seven  LQTS  genes  encode  proteins  that  interact  with  the  illustrated  ion 
channels and affect their currents. We resolved protein complexes of the protein products 
of the LQT1, LQT2, LQT8, LQT9 and LQT12 causing genes (highlighted in red). B. Top 
panel: We performed quantitative interaction proteomics on the five LQTS proteins to Figure 3.2 (continued) 
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obtain complexes isolated from cardiac tissue. This was done by immunoprecipitating the 
five target LQTS proteins (baits) or control IgGs and analyzing the precipitated proteins 
by high-resolution tandem mass spectrometry. We identified proteins specifically and 
reproducibly binding to the LQTS target proteins, hereby resolving the protein complexes 
for  each  of  the  bait  proteins.  Middle  panel:  By  integrating  the  proteomics  data  with 
GWAS data on common variants associated with QT interval variation we investigate the 
protein complexes for genetic association to this trait. Lower panel: Guided by the protein 
complexes we i) annotated associated loci and carried out experimental follow up on 
specific candidate genes and ii) identified candidate SNPs for genetic replication. Figure 3.2 (continued) 
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3.3  Results 
Affinity-purification in combination with mass spectrometry is currently the most 
powerful  and  unbiased  experimental  method  to  identify  the  constituents  of  protein 
complexes[140,141]. We therefore applied this technique to identify interactors of the 
five  LQTS  proteins  from  mouse  cardiac  tissue.  We  isolated  protein  complexes  by 
immunoprecipitations (IP) from total cardiac lysates generated from male mice (strain 
C57BL6) and studied the composition of proteins physically associated with the LQTS 
proteins  by  high-resolution  and  quantitative  liquid  chromatography  tandem  mass 
spectrometry (LC-MS/MS) using non-specific immunoglobulin G (IgG) IPs as controls. 
We performed triplicate IPs of all LQTS proteins (baits) and compared them to matched 
IgG control IPs, as quantitative mass spectrometry can effectively discriminate between 
specific  and  non-specific  interactors  in  this  experimental  setting.  This  allowed  us  to 
identify proteins that specifically bound to the LQTS proteins by label-free quantification 
based  on  pair-wise  comparison  of  peptide  extracted  ion  chromatograms  (XICs)  and 
statistical significance analysis[130–132,142].  
As evident from Figure 3.3A this experimental approach co-precipitates a specific 
cluster of proteins with each LQTS protein, and the experimental triplicates yield highly 
reproducible results for protein intensities (Pearson correlation coefficients R>0.8 in all 
replicates). We identified proteins specifically interacting with the LQTS proteins by a 
combination of the t-test derived P-value and the observed fold-change in LQTS-protein-
to-control intensity ratios and calculated a significance curve separating specific from 
non-specific binders (Figure 3.3B)[130]. We defined the set of proteins surpassing a false  
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discovery rate cut-off at 0.05 as the bait protein complex, leading to protein complexes 
for each of the LQTS proteins.  
As expected, the bait proteins (Kv7.1, Kv11.1, Cav1.2, Cav3 or Snta1) are among 
the most abundant proteins in their respective protein complexes, measured both by the 
XIC-based protein intensity ratios as well as by spectral counts. The protein complexes 
identified encompass many of the known interaction partners of the bait proteins, but 
more  importantly  they  contain  multiple  novel  components.  We  identify  89  specific 
protein interactors for Cav1.2, 31 for Kv11.1, 117 for Kv7.1, 108 for Snta1 and 334 for 
Cav3. These numbers are comparable to those reported for a comprehensive analysis of 
members of the Cav2 channel family in rodent brain, where between 97 and 161 protein 
interactors  were  consistently  identified  for  the  respective  channel  members[143].  We 
then compared the interactors identified here with those reported in the literature. For 
each complex, all interaction partners were determined by searching the largest protein 
interaction databases for interaction partners, as described previously[62,106]. Literature 
derived interaction partners were then compared to interaction partners identified here, 
using a hypergeometric distribution. In this way we determined the probability of the 
observed  overlap  given  a  background  of  ~22,000  protein  coding  genes.  Four  of  five 
complexes  are  enriched  for  literature-derived  interaction  partners  (Kv7.1,  P=  6.0e-3; 
Cav1.2,  P  =  3.1e-5;  Cav3,  P  =  8.9e-3;  Snta1,  P  =  5.0e-4  using  a  hypergeometric 
distribution test)[62,106]. 
The consensus between our results and the literature are noteworthy given that the 
bait  proteins  are  widely  distributed  across  human  tissues  and  that  many  interactors 
reported in the literature are identified under experimental conditions not relevant to the  
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biology  of  the  cardiac  ion  channel  complexes  studied  here.  Moreover,  as  in  other 
quantitative  proteomics  screens  with  high  resolution  aimed  at  identifying  novel 
interactors, we do not expect perfect consensus with the literature [36,37]. For only one 
complex (Kv11.1) we observe no overlap with literature, which is consistent with the 
limited knowledge on the interactions of this protein compared to others tested in our 
screen.    
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Figure  3.3 Q u a n t i t a t i v e  i n t e r a c t i o n  p r o t e o m i c s  o f  f i v e  M e n d e l i a n  L Q T S  p r o t e i n s .  A. 
Hierarchical cluster analysis of proteins identified in immunoprecipitation experiments visualizes 
the experimental specificity and reproducibility. Proteins are color-coded according to their mass-
spectrometry signal intensity derived by summing the measured peptide XICs. The triplicates of 
the five target LQTS protein immunoprecipitations cluster together illustrating the reproducibility 
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and  the  highlighted  yellow  areas  indicate  that  each  group  of  triplicate  experiments 
immunoprecipitates a specific cluster of proteins. B. Volcano plots representing the bait versus 
IgG control IPs for the five target proteins. The volcano plots show negative logarithmized t-test 
derived  P-values  (-log10(P))  as  function  of  logarithmized  ratios  of  average  protein  intensities 
(log2) for the bait relative to control. A hyperbolic curve indicates a ratio significance P-value 
<0.05 and separates specific interacting proteins from unspecific ones. All points represent a 
protein with points in red being the bait proteins, points in yellow are those that specifically 
interact with the bait protein, and the blue points represent non-specific protein interactors. The 
immunoprecipitation experiments shown in this figure were the work of Alicia Lundby. 
In chapter 2 we showed that combining protein interaction data and GWAS data can 
contribute to deciphering the molecular networks driving complex phenotypes and lead to 
identification of new candidate genes [144]. Here we exploit this method to analyze the 
generated protein complexes in the context of GWAS data of common SNPs underlying 
QT interval variation in the general population. In a companion paper by Arking et al., 
the QT-IGC consortium completed a GWAS meta-analysis in >100,000 individuals of 
European ancestry and reported 35 genome-wide significant (GWS) loci associated to QT 
interval  variation  in  the  general  population,  which  together  define  loci  spanning  154 
genes. A locus is defined by identifying neighbor SNPs in linkage disequilibrium (r
2>0.5) 
to the associated SNP, and expanding to the nearest recombination hotspot as previously 
described [144]. Strikingly, twelve genes in the GWS loci (PLN, ATP1B1, UNC45B, 
TRAP1,  TTN,  CCDC141,  ATP2A2,  CAV1,  CAV2,  GOT2,  ACTR1A,  MYL3)  encode 
proteins in one or several complexes. To test the joint set of proteins (737 proteins in 
total, 436 unique proteins) derived from all complexes for containing more GWS hits  
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than  chance  expectation,  taking  into  account  that  multiple  GWS  proteins  were 
represented in more than one complex, we simulated random selections of 5 complexes 
(each of the same number of proteins represented in the individual complexes) from all 
genes in the genome. After 10,000,000 random draws, we calculated an empirical p-value 
for the probability of selecting 22 or more GWS hits (22 represents the fact that some of 
the  12  GWS  proteins  were  selected  multiple  times).  We  found  the  complexes  to  be 
significantly  enriched  for  GWS  genes  (P  =  1.3e-6).  The  results  for  the  individual 
complexes are shown in Table 3.1.  This provides a strong mechanistic link at the level of 
protein complexes between rare LQTS genes and a subset of genes in loci definitively 
associated with common QT interval variation in the general population. 
 
Table  3.1 E n r i c h m e n t  i n  a s s o c i a t i o n  a c r o s s  c o m p l e x e s .  E a c h  c o m p l e x  w a s  t e s t e d  f o r  
enrichment  in  proteins  associated  to  QT-interval  association  according  to  the  recent  QT-IGC 
meta-analysis. Column 1 – bait protein with both protein nomenclatures represented. Column 2 – 
number of proteins pulled down. Column 3 – number of complex proteins that could be tested for 
association (filter out X chromosome or failed gene ID matches). Column 4 – number of complex 
proteins  that  are  in  genome-wide  significant    (GWS)  loci.    Column  5  – b i n o m i a l  t e s t  f o r  
enrichment in GWS complex proteins. Column 6 – composite test for association of complex 
proteins not in GWS regions. 
Bait Protein 
N 
TOTAL 
N (after 
filtering)  N GWS 
GWS 
Enrichment 
subGWS 
Enrichment 
CAV3 (Cav3)  358  320  11  2.8E-04  1.9E-03 
CACNA1C (Cav1.2)  104  90  5  1.7E-03  2.7E-02 
KCNH2 (Kv11.1)  33  30  2  3.2E-02  5.4E-02 
KCNQ1 (Kv7.1)  125  116  3  9.7E-02  1.5E-01 
SNTA1 (Snta1)  117  103  1  6.2E-01  2.2E-01 
ALL  737  659  22  1.6E-06  1.50E-04 
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Because regions of the genome associated to QT interval variation are likely to 
code for heart-expressed genes, we considered the possibility that the association results 
(number of GWS proteins represented in the complexes as well as enrichment in sub-
genome-wide scores) were due to enrichment for association in heart-expressed proteins 
rather  than  complex-specific  proteins.  Based  on  organ-wide  proteomic  mapping  of 
phosphoproteins in rat hearts (unpublished data, Lundby et al), we collected a dataset of 
2000 proteins expressed in heart tissue. We assessed the likelihood of identifying 22 
GWS  proteins  in  a  random  selection  of  5  complexes  (each  of  the  same  number  of 
proteins represented in the individual complexes – 737 proteins in total). After 1,000,000 
permutations, we found the probability of selecting >=22 heart-expressed proteins to be 
0.0054, suggesting that our finding is indeed specific to complex proteins. 
The  ten  loci  contain  a  total  of  79  genes,  12  of  which  the  protein  complexes 
provide experimental support for. One of these is ATP1B1, which is in a locus defined by 
rs10919070 that is convincingly associated with QT interval variation (P = 1.11e-31), and 
the  protein  product  interacts  with  Kv11.1,  Cav1.2,  Kv7.1  and  Cav3.  Atp1b1  is  well 
characterized as a β-subunit for the Na
+,K
+-ATPase (ATP1A1), but Atp1a1 was not part 
of  any  of  the  protein  complexes,  suggesting  an  additional  unrecognized  function  of 
Atp1b1. We tested the effect of Atp1b1 on the Kv11.1 channel (encoded by KCNH2) by 
electrophysiological  measurements  of  heterologously  expressed  proteins  in  Xenopus 
laevis oocytes. Atp1b1 affects the current mediated by the Kv11.1 channel markedly 
(Figure  3.4B-D).  Co-expression  of  Atp1b1  shifts  the  peak  of  the  current-voltage 
relationship  by  10  mV  to  more  positive  potentials,  slows  the  channel  inactivation 
kinetics, and right-shifts the voltage-dependence of recovery from inactivation. These  
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data  clearly  show  that  Atp1b1  has  a  direct  functional  impact  on  the  Kv11.1  channel 
properties, and suggests a biological mechanism through which common genetic variants 
near or in ATP1B1 affects QT interval variation. To directly test the effect of ATP1B1 on 
cardiac  repolarization  we  used  optical  voltage-mapping  to  probe  cardiac 
electrophysiology of ATP1B1 zebrafish knockdown animals. Cardiac repolarization in 
zebrafish and humans is remarkably similar, and optical voltage-mapping enables high-
resolution  measurement  of  zebrafish  cardiac  repolarization  [145].  Morpholino 
knockdown of zebrafish ATP1B1a (ortholog of human ATP1B1) results in shorter action 
potential duration compared to wildtype (APD80 in ATP1B1a knockdown 256±20 msec 
versus controls 321±21 msec, P = 0.002, see Figure 3.4E-F), further supporting ATP1B1 
as the causal gene in the rs10919070 locus.  
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Figure  3.4 A n n o t a t i o n  o f  Q T -interval  variation  loci  and  electrophysiological 
characterization of Atp1b1-Kv11.1 interaction and ATP1B1 zebrafish knockdowns. A. We 
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used data on SNPs associated to QT interval variation from an expanded GWAS meta-analysis 
and replication in >100,000 individuals of European ancestry. Association Z-scores were derived 
for individual genes, and we depict the distribution of association Z-scores for genes represented 
in the complexes (grey bars) to a background distribution of all genes in the genome (black line). 
The  x-axis  represents  Z-scores  assigned  to  genes  corrected  for  SNP  density  and  linkage 
disequilibrium structure. The insert shows a zoom-in of the tail of the distribution, illustrating that 
the distribution is significantly enriched for genes at GWS loci (P = 1.3e-6, using permutation). 
B. One of the complex proteins in a GWS locus was Atp1b1, which has never been shown to 
affect  ion  channel  currents.  Representative  current  traces  recorded  from  Kv11.1  (left)  and 
Kv11.1+Atp1b1  (right)  proteins  heterologously  expressed  in  Xenopus  laevis o o c y t e s  b y  t w o -
electrode voltage clamp. Step currents were elicited using the depicted voltage clamp protocol 
with 1s pulses to test potentials ranging from −80 to +40 mV followed by deactivation (tail) 
current  measurements  at  −60  mV.  C. C u r r e n t -voltage  relationships  were  constructed  by 
normalizing the steady-state currents measured at the end of each voltage step to the maximum 
outward current and plotting it as function of the test potential. D. Channel inactivation kinetics 
was  evaluated  from  currents  elicited  from  the  indicated  pulse  protocol.  Inactivation  time 
constants measured at +60 mV are shown for Kv11.1 in absence or presence of Atp1b1. Data 
points are mean±SEM. E. Morpholino knockdown of zebrafish ATP1B1a resulted in shortened 
cardiac action potentials (APD80 = 256±20 msec) compared to carrier injected controls (APD80 
= 321±21 msec), n = 13 independent samples per condition. f) Superimposed normalized traces 
are shown for one representative sample for ATP1B1a knockdown (red) and control conditions 
(blue). * represents P<0.05. Parts B-F in this figure were the work of Annette B. Steffensen, Alicia 
Lundby, Moshe Rav Acha, Stacey N. Lynch and David Milan. 
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Similar  to  most  other  complex  phenotypes,  the  currently  identified  common 
genetic  variants  associated  with  QT  interval  variation  explain  only  a  minority  of  the 
heritability of this trait in the population. To investigate if other proteins in the complexes 
could be used to guide genetic replication experiments, we excluded genes from the 35 
loci definitively associated to QT interval variation and made a composite test of genetic 
association across the remaining genes represented in the complexes. We translated all 
identified  mouse  proteins  to  their  orthologous  human  genes  and  derived  a  set  of 
association Z-scores for each gene taking SNP density and linkage disequilibrium across 
and surrounding each gene into consideration[144]. Using a one-tailed Mann-Whitney 
rank-sum  test,  we  compared  the  distribution  of  association  scores  across  genes 
represented in the protein complexes to those for all genes in the genome. Even after 
excluding  the  12  genes  from  the  definitively  associated  loci,  we  find  that  protein 
complexes  are  significantly  enriched  for  association  (P  =  1.5e-4).  This  suggests  that 
subunits in the protein complexes point to genetic variants important for QT interval 
variation that have so far been missed. By combining genetic and proteomic evidence 
(association P<1e-4 or P<1e-3 and being identified as a highly abundant protein in one of 
the IPs), we selected 28 SNPs represented by proteins in the complexes for replication 
genotyping  in  four  cohorts  comprised  of  17,692  independent  samples  in  total.  The 
proteins that formed the basis for the SNP selection are depicted in Figure 3.6A (yellow 
circles), along with information on which of the cardiac protein complexes they were 
detected in (grey lines). We selected 28 SNPs to replicate that met the following criteria: 
they were in LD with a gene that codes for one of the proteins pulled down in the 5 
complexes, and either their association p-value was <1e-4 (23 SNPs) or it was <1e-3 as  
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well as the protein of interest passed a threshold for being abundantly present in one of 
the complexes (5 SNPs). The selected SNPs were then genotyped or looked up in four 
cohorts: 5,731 independent samples were genotyped in the SMART cohort, and betas, 
standard errors and p-values were collected for the 28 SNPs from the LifeLines cohort 
(n=4,865),  the  POSPER/PHASE  cohort  (n=5,135)  and  the  RS3  cohort  (n=1,961),  for 
which the QT interval duration had been measured (in milliseconds) but the results had 
not  been  included  in  the  QT-IGC  meta-analysis.  Each  analysis  performed  a  linear 
regression of the original QT measurement on genotype using RR-interval, age and sex as 
covariates. Individuals with QRS duration > 120 or history of myocardial infarction were 
removed. 3 SNPs were dropped due to failure in ≥ 3 of the 4 cohorts, leaving 25 SNPs 
that  were  successfully  tested.  The  meta-analysis  was  done  by  combining  betas  and 
standard  errors  using  the  software  METAL.  Of  those  tested,  18  were  directionally 
consistent (P = 0.02), 7 were nominally significant in the replication cohort (P = 0.0003), 
and 3 reached genome-wide significance when jointly analyzed with the recent QT-IGC 
meta-analysis  (VCL  –  rs10824026,  P  =  1.5e-9;  SRL  –  rs889807,  P  =  1.2e-8  and 
TUFM/EIF3C/EIF3CL – rs7498491, P = 2.2e-8, see Table 3.2).  
SRL encodes the sarcolemmal Ca
2+ binding protein sarcalumenin, which regulates 
Ca
2+ reuptake into the sarcoplasmic reticulum by interaction with the Ca
2+-ATPase 2 
(SERCA2)[146] encoded by the gene ATP2A2 which itself is in a locus significantly 
associated  to  QT  prolongation  (rs17483,  3x10
-12)  [Arking  et  al.,  in  submission].  The 
importance  of  SRL  in  cardiac  physiology  is  evident  from  knockout  mice,  in  which 
ventricular depolarization is prolonged[146]. Our data shows that SERCA2 and SRL both 
interact  with  Cav3,  and  that  SERCA2  also  interacts  with  the  LQTS  calcium  channel  
  104 
Cav1.2.  In  the  accompanying  paper  by  Arking  and  colleagues,  298  LQTS  patients 
without LQT1-3 mutations were screened for mutations in 6 genes. The gene encoding 
SERCA2  (ATP2A2)  was  found  to  have  stop  mutations,  and  SRL  was  found  to  have 
amino-acid  altering  mutations  that  were  likely  to  be  damaging  as  predicted  by  two 
independent  methods;  neither  ATP2A2  nor  SRL  had  damaging  mutations  in  >300 
matched  controls
  [Arking  et  al.,  in  submission].  VCL  encodes  a  cytoskeletal  protein, 
vinculin,  which  we  show  interacts  with  Cav3  and  Snta1.  Although  vinculin  has 
previously been related to dilated cardiomyopathy[147], it has never been found to be 
involved  in  QT  interval  variation.  Our  results  are  further  supported  by  morpholino 
knockdowns in zebrafish, where we show that VCL knockdown has a direct affect on 
cardiac repolarization in vivo (Figure 3.5).  
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Table 3.2 Genetic replication results. The first three columns represent locus information of the 
25 SNPs that were successfully tested for replication. Columns 4-12 represent the effect size in 
ms, standard error in ms and P-value of those SNPs in each of the QTIGC meta-analysis, in the 
replication cohort (17,692 samples), and in the joint QTIGC-replication meta-analysis.  
 
Locus information  Meta-analysis  Replication  Joint 
Gene  SNP 
Minor 
allele  Beta  SE  P-value  Beta  SE  P-value  Beta  SE  P-value 
Genome-wide significant loci in the joint analysis (joint P<5e-8) 
VCL  rs10824026  A  -0.71  0.13  5.2e-8  -0.72  0.27  4.2e-3  -0.71  0.12  1.5e-9 
SRL  rs889807  T  -0.51  0.10  2.6e-7  -0.53  0.22  7.2e-3  -0.51  0.09  1.2e-8 
TUFM  rs7498491  A  -0.51  0.10  6.2e-7  -0.54  0.21  5.5e-3  -0.51  0.09  2.2e-8 
Nominal significant loci in replication (replication P<0.05) 
CAMK2D  rs17531033  C  0.39  0.11  3.7e-4  0.66  0.24  2.8e-3  0.44  0.10  1.1e-5 
TNNC1  rs352139  T  0.44  0.10  1.3e-5  0.42  0.21  2.1e-2  0.44  0.09  1.5e-6 
PREP  rs7760812  A  -0.59  0.14  2.0e-5  -0.51  0.29  4.1e-2  -0.57  0.12  4.2e-6 
CDH13  rs8046873  T  0.80  0.17  4.6e-6  0.75  0.45  4.9e-2  0.79  0.16  1.1e-6 
Loci at P>0.05 in replication 
MB  rs17722827  A  1.00  0.20  4.4e-7  0.24  0.53  3.3e-1  0.91  0.19  1.0e-6 
HSP90AA1  rs10143509  A  -0.76  0.15  5.8e-7  0.48  0.60  7.9e-1  -0.69  0.15  3.4e-6 
MYO18A  rs8614  A  -0.55  0.13  2.6e-5  -0.37  0.33  1.3e-1  -0.53  0.12  1.5e-5 
RPL27  rs8079855  A  0.41  0.10  8.3e-5  0.32  0.21  6.2e-2  0.39  0.09  2.6e-5 
MAP4  rs777016  T  -0.46  0.11  1.2e-5  -0.13  0.22  2.8e-1  -0.40  0.09  2.9e-5 
AMPD3  rs12279871  A  0.65  0.15  1.4e-5  0.17  0.31  2.9e-1  0.56  0.13  3.3e-5 
DLST  rs2111705  A  0.38  0.10  5.6e-5  0.14  0.25  2.9e-1  0.35  0.09  7.4e-5 
SPTBN1  rs12999048  T  -0.68  0.17  4.8e-5  -0.05  0.46  4.6e-1  -0.61  0.16  1.2e-4 
PRKAR2A  rs990211  A  -0.45  0.12  1.5e-4  -0.25  0.25  1.6e-1  -0.41  0.11  1.2e-4 
PABPC1  rs12114870  T  -2.00  0.48  2.7e-5  2.16  2.03  8.6e-1  -1.78  0.46  1.2e-4 
ARNT  rs267734  A  -0.50  0.12  2.0e-5  0.04  0.24  5.7e-1  -0.40  0.10  1.7e-4 
ALDOA  rs9924308  A  -0.38  0.10  9.4e-5  -0.11  0.20  2.8e-1  -0.33  0.09  1.7e-4 
EIF3M  rs12801493  A  1.93  0.47  3.8e-5  -0.26  1.08  6.0e-1  1.58  0.43  2.3e-4 
DBT/AGL  rs6682639  T  -0.79  0.23  6.8e-4  -0.76  0.54  7.9e-2  -0.78  0.21  2.3e-4 
FLNB  rs6770059  A  0.68  0.17  7.6e-5  -0.03  0.44  5.3e-1  0.59  0.16  2.5e-4 
PRKAR1A  rs2287301  A  0.38  0.10  1.9e-4  0.14  0.21  2.5e-1  0.33  0.09  2.7e-4 
TUBA8  rs2234338  T  2.90  0.69  3.0e-5  -0.86  1.15  7.7e-1  1.89  0.59  1.4e-3 
RTN4  rs6756933  T  -0.38  0.10  1.8e-4  0.71  0.28  1.0E+00  -0.25  0.10  8.9e-3 
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Figure  3.5  Vinculin  knockdown  prolongs  action  potential  duration  in  zebrafish.  A. 
Morpholino  knockdown  of  zebrafish  vinculin r e s u l t e d  i n  p r o l o n g e d  c a r d i a c  a c t i o n  p o t e n t i a l s  
(APD80 =466±105 msec) compared to carrier injected controls (APD80 = 371±40 msec), P = 
0.04,  n  =  13  independent  samples.  B.  Superimposed  exemplar  traces  are  shown  for  one 
representative sample for Vinculin knockdown (red) and Control conditions (blue). The zebrafish 
knock-downs were the work of Moshe Rav Acha, Stacey N. Lynch and David Milan. 
 
Knockdown of TUFM or EIF3C in zebrafish did not affect the action potential duration (data not 
shown). Based on our integrated proteomic and genetic analysis, we therefore identify three novel 
loci associated with QT interval variation in the general population, and for two of the loci in vivo 
evidence  further  supports  the  specific  gene  we  prioritized  as  being  causal.  Figure  3.6B 
summarizes all the proteins we identified in the proteomics experiments that are encoded by 
genes in loci associated to QT interval variation, emphasizing the three novel loci we identified. 
Our data provides strong evidence that molecular interaction partners of LQTS genes contribute 
to common variation in the QT interval. 
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Figure 3.6 Integrative analysis of cardiac protein complexes and GWAS data. A. Depiction 
of the interactions identified in the proteomics experiments between the bait LQTS proteins (red) 
and proteins encoded by GWS genes (green) as well as proteins encoded by genes that achieved 
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P<1e-4  for  association  to  QT  interval  or  achieved  P<1e-3  and  passed  a  mass-spectrometry 
abundance threshold (yellow). The proteins are plotted according to the best genetic association 
P-value of their corresponding genes in the horizontal direction after taking the negative 10 based 
logarithm of the P-value. Interactions are represented by grey lines. As indicated by the grey 
lines, several of the proteins are detected in more than one independently resolved complex. The 
stipulated red line indicates the threshold for GWS (corresponding to a P-value of 5.0e-8). SNPs 
representing  the  genes  depicted  in  yellow  were  chosen  for  genetic  replication.  B.  Complex 
proteins encoded by genes in GWS loci (green) highlighting the five prioritized genes from loci 
that became GWS after genetic replication in independent cohorts (yellow halo). Remarkably, 
39% of all 38 known GWS loci (35 plus the 3 discovered here) in QT interval variation are 
represented by proteins that physically interact in the protein complexes resolved and illustrated 
here.  
3.4  Discussion 
Our  proteomic  dataset  represents  the  first  analysis  of  the  composition  of  protein  complexes 
involved in rare Mendelian LQTS based on proteins isolated from cardiac tissue. Moreover, our 
approach provides the first systematic overview of functional connections between genes in a 
Mendelian disorder and its analogous common trait using quantitative interaction proteomics. As  
Figure  3.6 i l l u s t r a t e s ,  i n t e g r a t i n g  t h e  L Q T S  p r o t e i n  c o m p l e x e s  w i t h  G W A S  d a t a  s h o w s  t h a t  
genetic variants that contribute to QT interval variation points to the interactors of proteins in 
which  rare  and  highly  penetrant 
Mendelian variants cause LQTS. Remarkably, 15/38 (39%) of all loci now definitively associated 
with QT interval variation span genes that encode components of one or more of the protein 
complexes we dissect (Fibure 3.6B), which suggests that a very large proportion of currently  
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identified  common  genetic  variation  affecting  QT  interval  duration  modulates  the  biological 
systems deciphered here. Of the novel loci we discover, and associated loci we annotate, it is 
interesting to note that three of the genes are involved in Ca
2+ transport (ATP2A2, PLN, SRL). 
Hereby,  in  addition  to  the  well-established i m p o r t a n c e  o f  K
+ f l u x ,  c a l c i u m  s i g n a l i n g  i s  
highlighted  as  an  essential  component  of  cardiac  repolarization  and  common  QT  interval 
variation. SERCA2 (ATP2A2) transfers Ca
2+ from the cytosol to the lumen of the sarcoplasmic 
reticulum. PLN and SRL regulate the transport of Ca
2+ into the sarcoplasmic reticulum, and the 
function of SERCA2 is inhibited by interactions with the former and stabilized by the latter. In 
addition to the proteomic and genetic evidence we provide here, ATP2A2 and SRL harbor rare 
mutations  in  LQTS  patients  [Arking  et  al., in  submission].  Together  with  our  accompanying 
paper, the involvement of calcium signaling in cardiac repolarization is thus evidenced both from 
proteomics  experiments,  sequencing  of  LQTS  patients,  and  meta-analyses  of  genome-wide 
association  studies,  which  all  converge  on  a  cluster  of  physically  interacting  Ca
2+  regulating 
proteins.  The  integration  of  several  independent  and  orthogonal  genome-scale  datasets  on 
genetics  and  proteomics  therefore  provides  new  insights  into  the  molecular  composition  and 
genetic  architecture  of  cardiac  repolarization  in  humans.  More  generally,  the  methodological 
approach we have developed represents a strategy to functionally annotate loci associated with 
QT interval variation, for which the causal gene has not been identified, and to augment and filter 
modestly  associated  common  variants.  Looking  forward,  the  methodological  and  statistical 
framework outlined here may be applicable to a number of other complex traits to elucidate their 
underlying biological systems and genetic determinants.   
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3.5  Methods 
3.5.1  Tissue preparation and immunoprecipitations 
6-8 weeks old male mice of strain C57BL6 were sacrificed by cervical dislocation and 
their hearts were harvested and snap frozen in liquid nitrogen and stored at -80 °C. Heart 
tissue  was  homogenized  on  a  Precellys  24  and  solubilized  in  ice-cold  lysis  buffer 
containing  protease  and  phosphatase  inhibitors.  Tissue  lysates  were  centrifuged  to 
remove insoluble debris. For each tissue preparation produced, lysates derived from 5 
mice were pooled and protein concentrations were measured by Quick Start Bradford 
Dye Reagent (Biorad). Solubilized heart tissue lysate was pre-cleared with Dynabeads 
protein G (Invitrogen) before incubation with primary antibody followed by binding to 
Dynabeads  protein  G,  using  either  anti-Kv7.1  (SC10646,  Santa  Cruz),  anti-Cav1.2 
(AC003, Alomone), anti-Kv11.1 (AC062, Alomone), anti-Cav-3 (ab2912, Abcam), anti-
Snta-1 (ab11425, Abcam) or control IgG (goat IgG: SC2028, rabbit IgG: SC2027, mouse 
IgG: SC2025, Santa Cruz). After washing, bound proteins were eluted with 1x sample 
buffer containing 100 mM dithiothreitol (70 °C, 3 min) and separated by SDS-PAGE (4-
15 % Bis-Tris gels, BioRad).  
3.5.2  In-gel digestion 
Separated proteins were fixed in the gel (40 ml water, 50 ml acetonitrile, 10 ml acetic 
acid, 10 min) and visualized with colloidal Coomassie staining (Invitrogen). Each gel 
lane was excised and separated into four slices that were minced and destained (50 % 25 
mM ammonium bicarbonate, 50 % acetonitrile) in a thermomixer (3 times 20 min, 800  
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rpm, room temperature (RT)). Gel dices were dehydrated (acetonitrile, 10 min, 800 rpm) 
followed by reduction of disulfide bonds (10 mM dithiothreitol in 25 mM ammonium 
bicarbonate, 45 min, RT, 800 rpm) and alkylation of cysteines (55 mM chloro-acetamide 
in 25 mM ammonium bicarbonate, 30 min, 24 °C in darkness, 800 rpm). After washing in 
25 mM ammonium bicarbonate the gel plugs were dehydrated in acetonitrile and proteins 
were digested by trypsin (50 ul 12.5 ng/ul sequencing grade trypsin (Promega) in 25 mM 
ammonium bicarbonate for 1 hour, followed by addition of 100 ul 25 mM ammonium 
bicarbonate, left overnight at 37 °C). Trypsin activity was quenched by acidification of 
the mixture with trifluoroacetic acid to pH~2 and peptides were extracted from the gel 
plugs with 30 % acetonitrile in 3 % trifluoroacetic acid (30 min, 800 rpm) followed by 80 
% acetonitrile in 0.5 % acetic acid (30 min, 800 rpm) and finally in 100 % acetonitrile. 
Organic  solvents  were  removed  by  evaporation  in  a  vacuum  centrifuge.  Extracted 
peptides were purified on STAGE-tips with two C18 filters.  
3.5.3  Mass-spectrometry, LC-MS/MS 
Peptides were eluted from the STAGE tips into 96 well microtiterplates with 2x10 ul 40 
% acetonitrile in 0.5 % acetic acid and the acetonitrile was evaporated using a vacuum 
centrifuge reducing the sample volume to 4 ul. The peptide mixtures were acidified with 
0.1 % trifluoroacetic acid in 2 % acetonitrile to an end volume of 9 ul and analyzed by 
on-line nanoflow LC-MS/MS. Peptide separation was performed by reversed-phase C18 
HPLC on an Easy nLC system (Thermo Fisher Scientific) loading 5 ul samples with a 
constant flow of 750 nl/min onto 15 cm long analytical coloumns, packed in-house with 3 
um C18 beads, and eluting peptides using a 135 min segmented gradient of increasing (5  
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%-80 %) buffer B (80 % acetonitrile in 0.5 % acetic acid) at a constant flow of 250 
nl/min. The effluent from the HPLC was directly electrosprayed into an LTQ Orbitrap 
Velos mass spectrometer (Thermo Fisher Scientific) through a nano-spray ion source. 
The peptide mixture was analyzed by full-scan MS spectra (m/z 300-2000, resolution 
30,000) in the Orbitrap analyzer after accumulation of 1,000,000 ions in the Orbitrap 
within a maximum fill-time of 1.000 ms with the lock mass option enabled to improve 
mass accuracy [131]. For every full-scan the most intense peptide ions were sequentially 
isolated  (up  to  ten  for  every  full-scan)  and  fragmented  by  higher  energy  collisional 
dissociation (HCD) in the octopole collision cell and fragments were recorded by the 
Orbitrap mass analyzer after accumulation of 50,000 ions with a maximum fill-time of 
250 ms and using a normalized collision energy of 40%.  
3.5.4  Mass spectrometry data analysis  
The acquired data was processed by MaxQuant (version 1.1.1.25) (Max-Planck Institute 
of  Biochemistry,  Department  of  Proteomics  and  Signal  Transduction,  Munich)  [132], 
where  peptides  and  proteins  are  identified  by  the  Andromeda  search  algorithm  via 
matching of all MS and MS/MS spectra against a target/decoy-version of the mouse IPI 
database v. 3.68 supplemented with reversed copies of all sequences as well as frequently 
observed contaminants. Maximal MS/MS tolerance was 20 ppm, a maximum of 2 missed 
cleavages was allowed and false discovery rates were set at 0.01 both for peptides and 
proteins. Carbamidomethylated cysteines were set as a fixed modification, whereas N-
pyroglutamine,  oxidation  of  methionine  and  N-terminal  acetylation  were  searched  as 
variable  modifications.  Minimum  peptide  length  was  set  at  6  amino  acids.  Statistical  
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evaluation and filtering of the resulting peptide datasets were performed in MaxQuant as 
previously  described  [132].  Protein  intensities  were  normalized  and  proteins  were 
quantified between control and case experiments by the MaxQuant label-free algorithm, 
resulting in LFQ (label-free quantitation) protein intensities. The downstream analysis 
was  performed  with  Excel  (Microsoft)  and  Perseus  (Max-Planck  Institute  of 
Biochemistry,  Department  of  Proteomics  and  Signal  Transduction,  Munich)  software. 
The  triplicates  of  each  bait  IP  were  analyzed  against  the  five  control  IPs.    Protein 
identifications  were  filtered  for  contaminants  and  reverse  hits.  A  minimum  of  three 
peptide identifications with at least one being uniquely assigned to the particular protein, 
and protein identification in at least three immunoprecipitations were required followed 
by log2 transformation of the LFQ intensities. To perform statistical analysis of the label-
free bait IP experiments versus control IP experiments normal distributed values were 
imputed for missing values using a normal distribution with width 0.3 and a downshift of 
the mean by 1.8 compared to distribution of all LFQ intensities. T-test based comparison 
of bait IPs versus control IPs were performed to identify significant interactors with P-
value threshold set at 0.05 and a bend of the curve value, S0, set at 1 [133]. LFQ protein 
intensity ratios of bait relative to control was plotted against the negative logarithmic P-
value  of  the  t-test  as  was  a  stipulated  line  representing  the  calculated  t-test  based 
significance curve separating specific from non-specific binders. Significant interactors 
of the bait proteins were color coded in yellow and the rest were color coded in blue. For 
the hierarchical clustering, LFQ intensities were Z-scored and average linkage clustering 
was performed using Euclidian distance, and protein LFQ intensities were color-coded 
with blue representing low intensities and yellow representing high intensities. In general,  
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the reporting of our mass spectrometry data acquisition, processing and search results as 
well as sharing of all MS raw files have been done according to the Molecular and 
Cellular Proteomics Guidelines. Raw mass spectrometric files in Thermo Scientific’s 
*.raw format are available for download through Tranche at http://proteomecommons.org 
using the following Hash-key:  
UpjhtcVZMgE8uKwuMa6G2qQokoYYdAs2mxUAYJmrPD6HWggQ+WLr3DoMRQa
M3wyNWHjEmFyJqjIcWxioc9NVGIRub0oAAAAAAAACiA== 
with password LQT1LQT2LQT8LQT9LQT12 
3.5.5  Association analyses 
QT-IGC: The QT-IGC consortium consists of 48 cohorts of European ancestry with QT-
interval and genome-wide genotype data (>100,000 individuals in total). Each cohort 
contributed GWAS results from a linear regression of original QT-interval on genotype 
using RR-interval, age and sex as covariates (individuals with QRS-duration > 120ms or 
history  of  MI  were  excluded).  The  summary  statistics  (betas,  standard  errors  and  p-
values) on 2.5 million SNPs (either directly genotyped or imputed) were then combined 
in  a  meta-analysis  using  the  software  MANTEL.  The  non-genomic-control-corrected 
results were used in this analysis to match what is reported in the accompanying QT-IGC 
study (λGC=1.069). 
To test the joint set of proteins (737 proteins in total, 436 unique proteins) derived 
from all complexes for containing more GWS hits than chance expectation, taking into 
account that multiple GWS proteins were represented in more than one complex, we 
simulated 10,000,000 random selections of 5 complexes (each of the same number of  
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proteins represented in the individual complexes) from all genes in the genome. For each 
random selection of 737 total proteins, we counted the number of GWS hits. We then 
report an empirical p-value for the probability of selecting 22 or more GWS hits (22 
represents the fact that some of the 12 GWS proteins were selected multiple times). To 
derive a p-value for each individual interacome, as described in Supplementary Figure 3, 
we performed a hypergeometric test, since we did not need to account for proteins being 
represented multiple times. 
The joint test for enrichment in association performed on the remaining proteins 
in the complexes (those that did not achieve genome-wide significance) was carried out 
as described in Rossin et al. In order to control for linkage disequilibrium (LD) between 
genes, we broke the genome into LD blocks as defined by recombination hotspots. We 
then  scored  each  block  with  the  best  association  Z  score  achieved  over  that  block 
(association data was from the QTIGC meta-analysis). This score was then corrected for 
the number of SNPs tested in the block using linear regression in R. The residuals from 
the regression were used as the corrected scores for each block, and genes were assigned 
scores according to the blocks they overlap. To test a group of proteins for enrichment in 
association, we compared the unique set of scores derived from the group of proteins to 
the unique set of scores for all genes in the genome using a 1-tailed rank-sum test, with 
the alternative hypothesis being that the group of proteins has higher association scores 
than scores from all genes in the genome.  
3.5.6  Replication genotyping and analysis 
Corhort descriptions:  
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SMART:  The  Secondary  Manifestations  of  ARTerial  disease  study.  SMART  is  a 
prospective  cohort  study  among  patients  aged  18-74  years  who  are  referred  to  the 
University Medical Center Utrecht, The Netherlands, because of atherosclerotic vascular 
disease or for treatment of atherosclerotic risk factors. The objective of the SMART study 
is to determine the prevalence of asymptomatic arterial disease and risk factors in patients 
presenting with a manifestation of arterial disease or known risk factor, and to study 
future  cardiovascular  events  and  their  predictors  in  these  at-risk  patients.  Wet-lab 
genotyping  was  carried  out  by  KBiosciences,  Hertfordshire,  UK,  using  proprietary 
KASPar PCR technique.  
LifeLines: LifeLines is a multi-disciplinary prospective population-based cohort study 
examining in a unique three-generation design the health and health-related behaviours of 
165,000 persons living in the North East region of The Netherlands. It employs a broad 
range  of  investigative  procedures  in  assessing  the  biomedical,  socio-demographic, 
behavioural,  physical  and  psychological  factors  which  contribute  to  the  health  and 
disease of the general population, with a special focus on multimorbidity and complex 
genetics. 
PROSPER/PHASE: All data come from the PROspective Study of Pravastatin in the 
Elderly  at  Risk  (PROSPER).  A  detailed  description  of  the  study  has  been  published 
elsewhere. PROSPER was a prospective multicenter randomized placebo-controlled trial 
to assess whether treatment with pravastatin diminishes the risk of major vascular events 
in elderly. Between December 1997 and May 1999, we screened and enrolled subjects in 
Scotland (Glasgow), Ireland (Cork), and the Netherlands (Leiden). Men and women aged 
70-82 years were recruited if they had pre-existing vascular disease or increased risk of  
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such disease because of smoking, hypertension, or diabetes. A total number of 5,804 
subjects  were  randomly  assigned  to  pravastatin  or  placebo.  A  large  number  of 
prospective  tests  were  performed  including  Biobank  tests  and  cognitive  function 
measurements. Resting 12 lead ECGs were recorded at baseline and annually thereafter 
and were analyzed using the University of Glasgow analysis program. A whole genome 
wide screening has been performed in the sequential PHASE project with the use of the 
Illumina  660K  beadchip.  Of  5,763  subjects  DNA  was  available  for  genotyping. 
Genotyping was performed with the Illumina 660K beadchip, after QC (call rate <95%) 
5,244 subjects and 557,192 SNPs were left for analysis. These SNPs were imputed to 2.5 
million SNPs based on the HAPMAP built 36 with MACH imputation software.  
RS3: The Rotterdam Study III (RS-III) is a prospective population-based cohort study. 
The cohort comprises 3,932 subjects aged 45 years and older, living in the Ommoord 
district  in  Rotterdam,  the  Netherlands.  The  Medical  Ethics  Committee  of  Erasmus 
Medical  Center  approved  the  study  and  written  consent  was  obtained  from  all 
participants. Electrocardiograms were recorder on ACTA electrocardiographs (ESAOTE, 
Florence,  Italy)  and  digital  measurements  of  the  QRS  intervals  were  made  using  the 
Modular ECG Analysis System (MEANS). All RS-III participants with available DNA 
were genotyped using Illumina Human 610 Quad array at the Department of Internal 
Medicine, Erasmus Medical Center following manufacturer’s protocols. Participants with 
call rate < 97.5%, excess autosomal heterozygosity, sex mismatch, or outlying identity-
by-state  clustering  estimates  were  excluded.  After  quality  control  2,082  RS-III 
participants were included. Of these, 1961 participants were included in this study.   
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For the SMART data, we ran a linear regression in Plink to test for association to 
the duration of the QT interval in the same manner as was done in the QT-IGC meta-
analysis  as  well  as  the  other  3  cohorts,  controlling  for  age,  sex  and  heart  rate  and 
excluding individuals with QRS duration > 120 or past history of MI. Association results 
are expressed in terms of a 1-tailed p-value in the replication cohort and a 2-tailed p-
value  when  folded  in  with  the  meta-analysis.  The  meta  analysis  was  done  with  the 
program Metal using effect size estimates and standard errors. These results are reported 
in the main text as Table 3.2. We assessed the results as follows: first, we counted the 
number of SNPs that were nominally significant (P < 0.05) in the replication cohort. 7 
were  nominally  significant.  1.25  SNPs  by  chance  are  expected  to  be  nominally 
significant, and this therefore represents an enrichment at P=0.0003 using a binomial test. 
We then did a sign-test for directional consistency, and found that the effect sizes of 
18/25 SNPs were directionally consistent with QTIGC (P = 0.02). Then, we considered 
the replication p-value in addition to direction of effect by counting the number of SNPs 
that improved the QT-IGC meta-analysis p-value when jointly considered. 11 improved 
the original QT-IGC p-value, whereas on average 7.6 are expected by chance based on 
simulation (P = 0.03). Finally, three novel SNPs reached genome-wide significance when 
folded in with the QT-IGC meta-analysis: rs10824026, P = 1.5e-9; rs889807, P = 1.2e-8; 
rs7498491, P = 2.2e-8.  
3.5.7  Electrophysiology and data analysis:  
Preparation  and  injection  of  cRNA  into  Xenopus  oocytes,  purchased  from  EcoCyte 
Bioscience (Castrop-Rauxel, Germany), were done as described 
18. cDNAs were verified  
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by sequencing. GeneBank accession numbers of the clones used were NM_000238 for 
hKv11.1a and NM_001677 for hATP1B1.  Currents were recorded from three batches of 
oocytes  injected  with  hKv11.1a,  hKv11.1a+hATP1B1  or  hATP1B1  cRNA  with 
hKv11.1a and hATP1B1 injected at a 1:1 molar ratio from a holding potential of −80 
mV. Electrophysiological recordings were performed at room temperature (22°C–24°C) 
3 days after injection in Kulori medium (90 mM NaCl, 4 mM KCl, 1 mM MgCl2, 1 mM 
CaCl2, 5 mM HEPES, pH 7.4) using a two-electrode voltage clamp amplifier (CA-1B, 
Dagan,  Minneapolis,  MN,  USA).  Data  analysis  was  performed  using  Pulse  (HEKA, 
Lambrecht,  Germany),  Igor  Pro  4.04  (Wavemetrics,  Lake  Oswego,  OR,  USA),  and 
GraphPad  Prism  (GraphPad  Software  Inc,  San  Diego,  CA,  USA).  All  values  are 
displayed as mean ± SEM. Current–voltage (I/V) relations were obtained from the step-
protocol by plotting the outward current at the end of the second test-pulse as a function 
of the test-potential. Inactivation kinetics was evaluated by the time constant derived 
from a monoexponential fit to the decaying phase of the current. The voltage-dependence 
of  activation,  inactivation  and  recovery  from  inactivation  was  determined  by  fitting 
normalized currents versus test potentials to a two-state Boltzmann distribution of the 
form I(V) = 1/(1+exp[(V½ − V)/a]), where V½ is the potential for half-maximal activation 
and a is the slope factor.  The number of independent experiments is indicated by n. 
Comparison of the biophysical properties in the presence and absence of hATP1B1 were 
performed using an unpaired t-test with P <0 .05 being considered significant.   
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3.5.8  Zebrafish experiments:  
TuAB or Ekwill wild type zebrafish strains were reared according to standard techniques. 
At  the  single  cell  stage,  fertilized  oocytes  were  injected  with  1-10ng  of  antisense 
morpholino oligos targeting the transcription initiation sites of ATP1B1a 
19, vinculin 
20, 
TUFM  (5’  -  GAATTTTATAACTTACCGGAGAGGC  –  3’)  or  EIF3C  (5’  – 
GTCTTCTCCACAAACTCACTGCTGT – 3’) dissolved in Danieau’s solution (58 mM 
NaCl,  0.7mM  KCl,  0.4  mM  MgSO4,  0.6  mM  Ca(NO3)2,  5.0  mM  HEPES  pH  7.6). 
Controls  were  injected  with  Danieau’s  solution  alone.  Embryo  hearts  were 
microdissected, stained with di-4-ANEPPS (Invitrogen) and imaged on a CCD Camera 
(Cardio-SMQ, Red Shirt Imaging) at 1000 frames per second as previously described 
21. 
Cardiac motion was arrested with the use of 15uM blebbistatin (Sigma), field pacing was 
employed to control beating frequency (Grass S48 Stimulator).  
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4.1  Abstract 
Owing  to  recent  technological  advances,  genome  sequencing  in  medical  genetics  to 
discover disease-relevant variants is now a reality. Though their contribution to disease 
architecture remains unclear, investigators are now beginning to study the role of rare 
single nucleotide polymorphisms (SNPs) in medical genetics. Not surprisingly, a number 
of recent publications have shown that significant analytic challenges exist when trying to 
detect association to such rare events. Recent studies showed that the problem can be 
addressed  by  testing  groups  of  variants  together,  though  each  acknowledges  that  the 
appropriate functional unit over which to group variants is still not clear [148,149]. Since 
genes are well-mapped (at least in comparison to other functional units in the genome), 
grouping rare variants over a gene could be very powerful, but it has become apparent 
that  most  methods  still  cannot  overcome  the  burden  of  multiple  testing,  even  in  the 
setting of testing SNPs within genes jointly[150]. We showed in chapters 2 and 3 that 
common variants associated to complex traits tend to be near genes that relate to one 
another  through  protein-protein  interactions.  We  hypothesize  that  rare  variants 
contributing to risk for disease likely affect modules of proteins in a similar way and that 
studying  rare  genetic  variation  at  the  level  of  biological  pathways  (as  opposed  to 
individual  genes  or  variants)  through  joint  analysis  of  sequencing  data  with  protein-
protein interaction (PPI) data will reveal insight into causal genes and networks affected 
by rare variation. Here, we investigate the role of PPI data in analyzing rare variation. 
First, we show that genes harboring functional de novo variants in autistic patients form 
PPI  networks  by  leveraging  DAPPLE,  a  method  discussed  in  chapter  2.  Second,  we 
extend  this  concept  to  case/control  exome  sequencing,  where  we  simulate  networks  
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affected by rare variation and apply a data-biased random-walks method (herein called 
“DAPPLE/SEQ”) that augments the CALPHA gene-burden test by jointly considering 
PPI and genetic data. In both settings, we provide a principled approach to show that PPI 
has promise in highlighting important genes and networks affected by rare variation that 
may have been otherwise missed in variant testing alone. 
4.2  Introduction  
Advances  in  high-throughput  sequencing  have  now  reached  a  point  where  it  is 
economically feasible and technically possible to study rare (MAF < 5%) and de novo 
genetic variation in thousands of patients. For diseases that are highly polygenic, this task 
poses a significant challenge. It is likely the rare alleles contributing to complex traits are 
of modest effect, as evidenced by the lack of results coming out of linkage studies[2]. 
Unlike common variation, rare alleles of low effect are often too individually infrequent 
for a traditional test of association to be well powered enough to detect association or to 
distinguish  it  from  the  many  neutral  variants  nearby.  Even  more  challenging  is  the 
analysis of de novo variation, which is rarely seen more than once in a single cohort in 
the same gene, let alone at the same position in the genome[151]. 
One of the most important areas for development is how to analyze and interpret 
the incredible amount of genetic data that is emerging. The rarity of individual causal 
single nucleotide polymorphisms (SNPs) and insertion/deletion polymorphisms (indels) 
and  the  number  of  genes  likely  to  be  contributing  to  risk  for  complex  disease 
compounded with the sheer number of rare variants in the human population makes it 
difficult to distinguish causal from neutral variants. For example, results from on-going  
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autism case/control sequencing studies in our lab show that 95% of all genes contain at 
least one rare non-synonymous SNP in 789 people [unpublished data]. To address this 
challenge, a number of burden tests have been developed over the past few years to 
overcome the power limitations in analysis of rare variation. These approaches can be 
categorized  into  three  groups:  collapsing  markers  across  a  region,  weighting  markers 
based  on  functional  categories  and  distribution-based  approaches[150].  Li  and  Leal 
proposed collapsing variants over a region, and Madsen and Browning augmented this 
approach using a weighted-sum statistic, whereby markers are weighted according to 
allele frequency, and the weights are summed over genes[149,152]. Other methods use 
functional measures such as alteration in protein function to weight alleles[153]. More 
recent methods use changes in distributions of rare variants as the test of association, 
such  as  the  binomial  over-dispersion  test  called  CALPHA  for  dichotomous  traits  or 
SKAT  for  continuous  traits[148,154].  Yet,  results  from  GWAS  have  consistently 
revealed that there are likely hundreds of causal genes underlying complex traits, which 
would predict that only a small fraction of cases harbor rare mutations in any one of 
them.    This  may  explain  why  a  recent  study  found  these  methods  to  be  somewhat 
underpowered in the context of simulated and real genetic data[150]. In this case, it is 
clear that more innovative methods for interpreting genome sequence data are required.  
We hypothesize that for complex traits, causal genetic variation affects a common 
but  limited  set  of  underlying  molecular  processes  that  modulate  risk  to  disease.  We 
therefore suggest that it will be necessary to consider rare variants in the context of 
functionally connected genes to detect association. Autism, a pervasive developmental 
disorder  characterized  by  language  delay,  restricted  interests/repetitive  behaviors  and  
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social impairment, is an example where GWAS has as of yet not identified common 
variation contributing to disease; one naturally emerging hypothesis is that the genetic 
architecture of autism may include rare variation. Recent pathway studies revealed that 
rare  CNVs  in  autism  affect  genes  that  share  functional  relatedness  beyond  chance 
expectation;  another  study  detected  abundant  connections  between  established  autism 
proteins via yeast-two-hybrid assays[55,155]. Likewise, we and others have shown that 
loci associated to other complex traits (such as Crohn’s disease, rheumatoid arthritis, 
blood lipid levels and QT-interval variation) include genes that form significant physical 
interaction networks or fall into similar pathways [87]. We propose that this concept be 
applied  more  generally  to  ongoing  sequencing  efforts  in  complex  traits.  To  our 
knowledge, there has been little rigorous testing of the use of PPIs in analyzing rare and 
de novo variation revealed by exome sequencing. 
In our joint analysis of rare variation and PPI data, we will use the publically 
available PPI database InWeb (described in chapter 2) consisting of 169,810 interactions 
across 12,793 proteins. Investigators have rapidly populated databases of such PPIs over 
the past decade, mainly through manual curation of the literature[60,61,64–66,80]. The 
data is noisy – beyond technical false positives, in vitro evidence of binding may not 
recapitulate  in  vivo  binding  due  to  temporal  and  spatial  expression  differences[105]. 
InWeb is a meta-database that addresses many of the concerns about false positives in 
PPI data by assigning a confidence score to each interaction (see chapter 2) [62,106]. 
This chapter will consider two types of rare variation: de novo variants discovered 
through  analysis  of  trios  and  rare  inherited  variants  discovered  through  case/control 
sequencing. The challenge in interpreting de novo variation is that unless the relevant  
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genes are affected in multiple people within a sequencing cohort, it can be difficult to 
pinpoint which genes to follow up on, especially if de novo variation is predicted to play 
a relatively small role in disease etiology. To consider the utility of PPIs in the context of 
de novo variation in autism, we will describe the application of a tailored version of 
DAPPLE to a recent autism de novo discovery sequencing effort. Autism is one of the 
most heritable complex disorders, suggesting that genetics plays a leading role in its 
etiology. Though de novo variation cannot contribute to this heritability, it is likely that 
causal de novo variants affect similar pathways as inherited ones.  
The  other  category  of  variation  discussed  here  is  rare  inherited  variation 
discovered through case/control exome sequencing which may contribute to heritability. 
Whereas de novo variation can be easily fitted to the previously benchmarked method 
DAPPLE,  analysis  of  case/control  rare  variant  data  will  require  significant 
methodological development. The goal of such an analysis is to find sub-networks in the 
InWeb database that are enriched for association to rare variation. Ideally, we would test 
all  possible  sub-networks;  however,  this  naïve  solution  not  only  would  require  a 
astronomical multiple testing burden to overcome but also has been shown to be NP-
hard[156]. Methods to discover “enriched sub-networks” – groups of proteins enriched 
for  both  connectivity  and  an  independent  metric  –  have  been  studied  over  the  past 
decade. Promising approaches include simulated annealing, an adaptation to the Prize-
Collecting  Steiner  Tree  problem  and  data-biased  random  walks  (DBRW)  [156–158]. 
Compared to the former two methods, DBRW is an attractive approach due mainly to its 
technical feasibility.   
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  Komurov et al. have previously shown that DBRW is able to recover enriched 
sub-networks  when  integrating  genetic  and  gene  expression  data[158].  The  method 
approaches  the  problem  by  transforming  the  PPI  database  into  a  transition  matrix, 
whereby the transition probability from one node to the next for a random walker is 
dependent on the association of each node[148]. Clusters of interconnected nodes that are 
enriched  for  the  independent  score  should  be  visited  more  often  than  other  nodes. 
Inspired  by  the  success  of  Komurov  et  al.’s  approach  and  the  practicality  of  its  fast 
implementation, here we adapt this approach to analysis of rare variation associated to 
disease. 
4.3  Results 
4.3.1  De novo variation in autism and the protein complexes implicated 
To  identify  the  role  of  de  novo  exonic  point  mutations  in  autism,  our  group 
sequenced whole exomes of 96 trios (affected offspring and parents) from mostly simplex 
families, followed by a second wave of 77 trios. Neale and colleagues generated a QC 
and analysis pipeline that resulted in 93% of the exome being assayable due to sufficient 
depth of coverage and a 98% validation rate on variants called as de novo. Across both 
waves, they identified 163 coding single nucleotide variants consisting of 101 missense, 
10 nonsense, 2 conserved splice-site and 50 silent mutations. An exome mutation rate of 
1.5e-8 per base per person was estimated, which does not represent a significantly higher 
mutation rate in autistic individuals than expected by chance.  
While no significant evidence that de novo events play a major mechanistic role 
in this sample was observed, it does not preclude the variants from conferring significant  
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autism risk. Recent CNV studies highlight the inescapable fact that hundreds of loci are 
involved  in  autism  and  some  severe  de  novo  mutations  affecting  these  genes  likely 
contribute  to  autism  risk  in  specific  individuals[55].    Therefore,  more  modest 
contributions of de novo variants, such as 10-20% of cases carrying a risk-conferring 
event, could be consistent with the observed data.  That is, while the set of data are not 
significantly different from chance mutation, the subset of genes that harbor de novo 
mutations could be enriched for autism relevant genes. 
Of the group of genes harboring de novo functional (non-silent) mutations (113 in 
total), we asked whether the protein products are unusually connected to each other using 
DAPPLE. The consideration of de novo variation introduces a new bias that the current 
permutation methodology (described in Chapter 2) does not account for: large mutation 
target size. De novo variants are more likely to be observed in larger genes, since more 
coding real estate offers more chances for a de novo mutation. Therefore, we set out to 
test whether the PPI data is non-randomly distributed according to gene size. First, we 
calculated  the  correlation  between  gene  size  (excluding  non-exon  regions)  and  the 
respective protein binding degree in the InWeb database. A significant but very small 
correlation exists (Figure 4.1, R
2 = 0.00148, p = 4.12e-5). Importantly, DAPPLE will 
correct for this type of bias, since it will compare to networks of the same binding degree 
distribution.  
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Figure 4.1 Correlation between gene size and binding degree. To test whether large genes are 
likely to have more binding partners, we calculated the Pearson correlation between gene size 
(defined by exons in kilobases) and binding degree in the InWeb database. We found a small but 
significant correlation (R
2 = 0.00148, p = 4.12e-5). 
We  then  considered  the  possibility  that  a  larger  correlation  structure  exists 
between the size of a gene and the size of its binding partners (ie, big genes bind big 
genes).  Interestingly, we found a larger correlation (Figure 4.2, R
2 = 0.03, p < 2e-16), 
suggesting that the size of a gene is correlated with the size of its binding partners. This 
means that the DAPPLE p-values are confounded (albeit very modestly) by gene size if 
there is a systematic bias in the size of the input genes. This is typically not the case for 
GWAS but will be the case for de novo variation and CNV studies, since they will tend to 
be biased toward larger genes.  
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Figure 4.2 Correlation between gene size and mean neighbor gene size. We found a modest 
and significant correlation between a node’s gene size (defined by exons in kilobases) and the 
mean of its neighbor’s sizes (Pearson R
2=0.0354, p<2e-16). 
To correct for this bias empirically, we generated a list of random de novo point 
mutations  using  a  mutation  rate  model  that  used  fixed  differences  between  humans, 
chimps and baboons to estimate the relative frequency of all possible single-nucleotide 
changes as a function of the bases to the left and right (i.e., all 64x3 possible three base 
changes XY1Z -> XY2Z) and sampled sets of 113[159,160]. The final p-value assigned to 
a network becomes the empirical p-value based on 1000 simulations representing the 
frequency with which an equal or better DAPPLE direct network significance score (each 
based on 10,000 DAPPLE permutations) was observed. 
We  found  22  direct  connections  amongst  23  de  novo  identified  proteins, 
representing significantly more than would be expected by chance (DAPPLE p = 0.0004, 
p<0.001 correcting for gene size bias). The top-scoring proteins are listed in Table 4.1. 
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This  represents  substantial  connectivity  beyond  chance  expectation.  Furthermore,  we 
obtained a set of de novo variants from unaffected siblings of autistic individuals from 
simplex families and found no significant connectivity amongst 87 genes baring non-
synonymous mutations (direct connectivity p=.745).  
 
 
Figure 4.3 Protein–protein interactions for genes with an observed functional de novo event. 
Direct protein connections from InWeb, restricting to genes harboring de novo mutations for 
DAPPLE analysis. Two extensive networks are identified: the first is centered on SMARCC2 
with 12 connections across 11 genes; the second is centered on FN1 with 7 connections across 6 
genes. The P-value for each gene having as many connections as those observed is indicated by 
node color. 
We then considered whether the genes highlighted in DAPPLE were known to be 
haploinsufficient (HI). Since de novo variants only affect one copy of the gene, it follows 
that the functional consequences of a mutation are predicted to be more severe if the gene  
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is  HI.  Huang  et  al.  used  empirical  observations  of  haploinsufficiency  to  generate  a 
probabilistic model that assigns HI probabilities to 12,443 genes that they validated using 
genes  known  to  be  implicated  in  dominant  human  diseases  and  mouse  knock-out 
phenotypes[161]. Using a rank-sum test to compare the haploinsufficiency scores of the 
genes in the de novo set that DAPPLE scored highly (DAPPLE p<0.1) to those that were 
not  scored  highly,  we  found  an  enrichment  in  HI  genes  (p=0.0048;  the  mean  HI 
probability for the DAPPLE proteins was 66.8% whereas the mean overall is 37.6%.)  
 
Table 4.1 DAPPLE and haploinsufficiency scores for de novo network proteins. HI scores are 
probabilities of HI according to Huang et al. 
Gene  Chr 
DAPPLE p-
value 
HI 
score 
SMARCC2  Chr12  0.00099975  0.995 
STAT2  Chr12  0.00778479  0.466 
SMARCC1  Chr3  0.01851351  0.86 
APOC3  Chr11  0.01930591  0.255 
OBSL1  Chr2  0.01950396  0.159 
ELK1  chrX  0.02444871  1 
ZNF292  Chr6  0.03056284  0.888 
CHD1  Chr5  0.05366016  0.815 
RTF1  Chr15  0.06993264  0.595 
BRCA2  Chr13  0.076479  0.976 
ITGA5  Chr12  0.07667119  0.349 
 
Finally, we tested the direct network in Figure 4.3 for being encoded for by genes 
co-expressed in neuronal tissue. Using the same expression analysis describe in Chapter 
2, we tested each of the 126 tissues in the Benita et al. 2010 dataset for higher-than-
expected  expression  of  the  network  genes  [87,108].  Of  the  20  tissues  that  achieved 
p<0.01, 11 were neuronal (Figure 4.4). This is not expected by chance when compared to 
tissue enrichment scores of random direct networks built from simulations of de novo  
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variants using the mutation rate model described (p=0.015). Interestingly, most of the 
other top tissues were related to testes and ovary. These tissues are shown in Table 4.2. 
 
Figure  4.4 E n r i c h m e n t  i n  neuronally e x p r e s s e d g e n e s  i n  de  novo n e t w o r k .   Using  an 
expression dataset of 126 tissues (described in Chapter 2), we tested the set of 23 network genes 
for enrichment in tissue expression by comparing their expression values to the rest of the genes 
in  the  expression  array u s i n g  a  1 -tailed  rank-sum  test.  We  found  that  of  the  top  22  tissues 
(p<0.01), 11 were neuronal. To test the probability of the top 20 tissues containing ≥ 11 neuronal 
tissues, we compared the results of the autism network (purple circles) to tissue enrichment scores 
of random direct networks (grey circles) built from simulations of de novo variants using the 
mutation rate model described (p=0.015). 
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Table 4.2 Tissue enrichment scores for autism de novo network. 11/20 tissues at p<0.01 were 
neuronal in origin (indicated by a *).  
Tissue 
Enrichment P-
value 
Ovary  0.00052348 
Testis germ cell  0.001095922 
Testis seminiferous tubule  0.00173855 
*Dorsal root ganglion  0.002048479 
Uterus  0.003299053 
Uterus corpus  0.003817946 
*Globus pallidus  0.003932643 
*Temporal lobe  0.004376913 
*Parietal Lobe  0.005247557 
Prostate  0.005261165 
Heart  0.005543438 
*Cingulate cortex  0.005597326 
Tongue  0.006592636 
*Pituitary  0.006862346 
Testis leydig cell  0.007583201 
T-regulatory cell  0.008388834 
Testis intersitial  0.008567759 
*Prefrontal cortex  0.008660865 
*Cerebellum  0.008891937 
*Superior cervical ganglion  0.00939216 
 
We therefore provide compelling evidence that a subset of the de novo variants 
discovered in autistic patients code for proteins that are non-randomly related to each 
other  through  physical  interactions.  We  furthermore  provide  two  additional  lines  of 
evidence that this network is biologically relevant, as it is enriched for genes predicted to 
be HI and the participating genes are co-expressed in neuronal tissues, which may be the 
relevant cell type in autism.  
A subset of the proteins highlighted by the network broadly can be described as 
involved in chromatin remodeling and transcription. SMARCC1 and SMARCC2 achieved 
nominal DAPPLE p-values of 0.018 and 0.0009, respectively, and were also highly likely  
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to be HI (86.0% and 99.5%, respectively). These two genes (SWI/SNF related, matrix 
associated, actin dependent regulator of chromatin, subfamily c, members 1 and 2) are 
involved  in  transcriptional  activation  and  repression  of  genes  through  chromatin 
remodeling  as  part  of  the  SWI/SNF  complex.  This  complex  has  been  shown  to  be 
involved in neurogenesis and has been reported to play a role in William’s syndrome, a 
rare  autosomal  dominant  disorder  caused  by  a  large  chromosomal  deletion[162,163]. 
STAT2 (p=0.0078) is itself an activator of transcription, though usually in the setting of 
Type  I  interferon  signaling,  and  ELK1  is  a  transcription  factor  activated  by  MAP 
kinase[164]. Interestingly, chromatin remodeling was also highlighted in a concurrent 
autism de novo study with entirely independent samples and discovered mutations[165].  
  We therefore provide three lines of evidence that a subset of the genes affected by 
de novo variation may be relevant – they are enriched for proteins that physically bind 
each  other,  the  connecting  proteins  are  enriched  for  genes  predicted  to  be 
haploinsufficient, and the connecting proteins co-expressed in neuronal tissue. 
4.3.2  DAPPLE/SEQ: a method to jointly analyze rare variants with PPI data 
  Section  4.3.1  provides  encouraging  evidence  that  protein-protein  interaction 
networks may be of use when studying rare variation, just as has been observed with 
common-variant associations. We hypothesized that analyzing exome-wide case/control 
genetic data in the context of large-scale, proteome-wide protein-protein interaction data 
could  reveal  previously  undiscovered  risk  genes  and  pathways.  This  task  is 
fundamentally distinct from that of de novo variation because we typically do not have 
specific genes to test. Rather, the goal is to look for sub-network enrichment, i.e. pockets 
of connected proteins that are enriched for association to rare variation.  
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After consideration of a number of existing sub-network enrichment approaches, 
we  chose  to  use  a  data-biased  random-walks  algorithm  described  by  Komurov  et  al. 
(described in section 4.2)[158]. The goal of this approach is to identify pockets of the 
InWeb database that are enriched for association via rare variation. The method employs 
a “random walker” who walks throughout the database with each step biased toward 
more associated nodes. Ultimately, the area of the network around which the walker 
spent  more  time  should  be  the  most  associated  and  tightly  connected  cluster.  We 
designed a novel strategy to use this approach to assign PPI-based association scores to 
genes  and  called  this  method  Disease  Association  Protein-Protein  Link  Evaluator  for 
Sequencing, or DAPPLE/SEQ. 
Figure  4.5  shows  the  workflow  of  the  method.  First,  all  genes  are  scored  for 
association using the CALPHA burden test for rare variation. Briefly, CALPHA tests for 
over-dispersion compared to the expected binomial distribution for rare variant counts in 
cases versus controls (thus being robust to a mix of protective and risk variation)[148]. 
Genes that are not assigned a score because they bare no variation are automatically 
assigned a score of p=1. To incorporate protein-protein interaction data, we then calculate 
a transition matrix as defined in Komurov et al., where the random walker is biased 
toward transitioning from less associated nodes to more associated nodes. The transition 
probability between nodes i and j (pij) is defined as  
 
Equation 4.1 
! 
pij =
w j
wk k"Ni # 
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where w = 1/pCALPHA and a ceiling is applied, w>.999 = w.999, to limit the amount of time 
spent on a highly associated node. As implemented by Komurov et al. and according to 
the  Perron-Frobenius  theorem  for  stochastic  matrices,  the  left  eigenvector  of  the  full 
transition matrix associated with eigenvalue 1 is the vector of stationary probabilities – ie, 
the final visitation probabilities (which we will refer to herein as FVP for the full vector 
of gene-wise final visitation probabilities and FVPi as the final visitation probability for 
an individual node)[158]. To further enrich for local pockets of visitation, we look at not 
only FVPi for each node but also the sum of its N neighbors: 
€ 
FVPj
j∈N
∑ = FVPN,i
 
Equation 4.2 
These three steps are shown in Figure 4.5A. To correct for the fact that highly connected 
nodes will be visited more often by chance, we approximated an empirical p-value for 
each FVPi and FVPN,i by simulating random genetic data (20,000 simulations of 2,000 
cases/2,000 controls each, see section 4.3.3 for description of simulation) and calculating 
the expected node-wise distribution of FVPi and FVPN for all nodes. For each node, the 
distribution consists of FVPi and FVPN,i for all nodes of the same binding degree in all 
null simulations. After comparing FVPi and FVPN,i to their respective node-wise null 
distributions, we obtain p1 and p2, the empirically derived gene-wise network p-values for 
FVPi  and  FVPN,i,  respectively  (Figure  4.5B).  The  two  empirical  p-values  are  then 
combined  using  Brown’s  method  of  combining  dependent  p-values  where  the  test 
statistic T is assumed to be chi-squared distributed according to the following:   
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Equation 4.3 
where k=2 and ρ is node-specific and estimated individually for each gene by measuring 
the correlation between FVPi and FVPN,i across many simulations. 
! 
T =
"2(ln(p1)+ln(p2))
c
~ #
2(df = 2k/c)
c =
4k +2$(3.25+.75$)
4k 
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Figure 4.5 Schematic of DAPPLE/SEQ. A. Genes are individually scored for association using 
the CALPHA method. A transition matrix is calculated by merging these scores with PPI data, 
and FVP and FVPN,i are calculated from that transition matrix. B. For each gene i, FVPi and 
FVPN,I  are  compared  to  their  expected  null  distributions  based  on  random  genetic  data.  The 
resultant  empirical  p-values  are  combined  to  generate  a  final  pgene  for  each  gene. C .  The 
distribution of final p-values is then inspected for deviation from null expectation 
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  The final step is to inspect the DAPPLE/SEQ p-value distribution for any genes 
that are deviating from null expectation (Figure 4.5C). The first Q-Q plot shows the gene-
wise  p-values  using  the  CALPHA  test  alone  while  the  second  Q-Q  plot  shows  the 
combined CALPHA and PPI results, where the gene-wise association distribution is now 
deviating from null expectation and genes containing causal variation (see section 4.3.3 
for simulation of risk genes) that are locally interconnected improve in association (red 
squares). The metric of success for DAPPLE/SEQ is therefore its ability to assign p-
values to risk genes that are more significant than the genetic burden test alone.   
4.3.3  Simulating risk networks 
We tested the method on simulated whole-exome rare variant data where genes in 
3 pre-specified networks were assigned causal variation. We used a March 2011 snapshot 
of  sequencing  data  from  an  on-going  autism  case/control  sequencing  study  (52,381 
functional variants in 460 cases and 371 controls) to estimate the frequency distribution 
of rare (<5% MAF) functional alleles (missense, non-sense, splice-site) throughout the 
exome. The combined allele frequency distribution is shown in Figure 4.6.  
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Figure 4.6 Allele frequency distribution for functional alleles. Data from an on-going autism 
exome sequencing project was used to estimate the allele frequency of 52,381 functional alleles 
in the human exome (missense, non-sense, splice-site). 1,662 chromosomes in total (460 cases, 
371 controls) were assayed on average for each variant. Alleles between MAF 0.0012 (i.e., 
observed at least twice in the dataset) and 0.05 were included. 
To assign risk to variants, we used a liability threshold model with multiplicative risk 
according to the following biometrical equations. : 
€ 
µ = a[p
2]+ d[2pq]− a[q
2]
V = (a − µ)
2p
2 +(d − µ)
22pq+(−a − µ)
2q
2
a =
ZAA − Zaa
2
;d = ZAA − a − ZAa
ZG ~ N(1− prevG)
 
Equation 4.4 
where µ is the population mean of the liability distribution, a is half the distance between 
the two homozygotes, p is the major allele frequency, q is the minor allele frequency, AA 
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is homozygous wild-type, aa is homozygous risk, V is the additive genetic variance that 
the SNP contributes to the phenotypic variance and ZG represents the liability Z score for 
a given genotypic category at which the phenotypic cutoff for diagnosis is made. The 
overall prevalence is assumed to be 5%, and prevG represents the prevalence within a 
given  genotypic  category.  We  can  then  apply  Bayes  theorem  to  assign  genotypes  to 
simulated cases and controls: 
 
Equation 4.5 
where P(G) is the genotype frequency (p
2, 2pq or q
2) and prev is the disease prevalence in 
the population. We simulated rare variants for 2,000 cases and 2,000 controls and used 
the CALPHA burden test to score each gene for association.  
We simulated genetic risk in three biologically relevant networks that are already 
known to contain disease-causing genes – a network of average binding degree 2.56 
consisting of 9 Fanconi Anemia proteins[56,101] that share 23 connections (network 1, 
Figure  4.7A),  a  network  of  average  binding  degree  1.00  consisting  of  10  proteins 
associated  to  QT-interval  variation[36]  that  share  10  connections  (network  2,  Figure 
4.7B) and a rheumatoid arthritis[94] network of average binding degree 1.06 consisting 
of 16 proteins that share 18 connections (network 3, Figure 4.7C). All three networks 
achieve a significant DAPPLE direct connectivity p-value (see Chapter 2). We will herein 
refer to these networks as networks 1, 2 and 3, respectively.  
! 
P(G |D) =
P(D|G)P(G)
P(D)
=
(prevG)P(G)
prev 
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Figure 4.7 Plots and properties of three simulated networks. We chose three networks that 
represented  different  properties  of  sub-networks:  network  1  (average  binding  degree  2.56), 
network 2 (average binding degree 1.00) and network 3 (average binding degree 1.06).  
We varied the amount of additive genetic variance assigned to causal genes between 
0.1%,  0.3%,  0.5%  and  1%.  We  saw  this  range  as  containing  the  lower  bound  for 
detection (0.1%) and the upper bound for plausibility (1%). 1% additive genetic variance 
should  produce  a  strong  signal  of  association  and  is  higher  than  the  typical  signals 
observed in GWAS. We therefore assume that low-effect variants discovered through 
exome-sequencing, even when combined across a gene, will rarely exceed this threshold. 
For each gene, risk was distributed over 10-20% of the functional (missense, non-sense, 
splice-site) SNPs therein (or at minimum 1 SNP).  
  In considering the success of the method, we consider genes that did not achieve 
pCALPHA < 2.5e-6. These genes will be candidates for follow-up regardless. Since the field 
is facing a preponderance of results that are above this threshold (hence the need for more 
innovative methods), we will restrict our results to genes that initially did not achieve 
such a high score. On average, the proportion of genes that achieve pCALPHA<2.5e-6 is: 
0.4% (0.1% additive genetic variance), 5.6% (0.3% additive genetic variance), 18.6% 
(0.5% additive genetic variance), 39.6% (1% additive genetic variance).  
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4.3.4  Running DAPPLE/SEQ on simulated risk networks 
The results of running DAPPLE/SEQ on networks 1, 2 and 3 are summarized in 
Figure 4.8 and Figure 4.9. First, we asked whether the method was powered to detect 
significance at pDAPPLE/SEQ<2.5e-6. We found that in all three networks, DAPPLE/SEQ 
assigned genome-wide significant scores to risk proteins previously at pCALHA>2.5e-6. 
The  percent  of  such  proteins  improved  consistently  as  the  average  additive  genetic 
variance assigned to risk genes was increased from 0.1% to 1.0%.  
 
Figure 4.8 Percent of risk genes that rise to genome-wide significance using DAPPLE/SEQ. 
After running DAPPLE/SEQ on ~50 simulated genetic datasets for all three risk networks (2000 
cases, 2000 controls for each simulation), we counted the number of risk genes that earned a 
score that passes the Bonferroni corrected cutoff of 2.5e-6. 95% confidence intervals are shown. 
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We then relaxed our threshold and asked whether more proteins were assigned 
scores in the tail of the DAPPLE/SEQ association distribution as compared to CALPHA 
alone. Figure 4.9 shows the percentage of risk genes (originally at pCALPHA>2.5e-6) that 
achieved  pCALPHA<1e-4  as  compared  to  the  percentage  of  risk  genes  that  achieved 
pDAPPLE/SEQ<1e-4  (i.e.,  the  true  positive  rate  at  p<1e-4).  When  compared  to  the  same 
cutoff  using  CALPHA  alone,  the  true-positive  rate  for  DAPPLE/SEQ  at  p<1e-4  is 
improved  significantly  in  most  cases  if  the  additive  genetic  variance  is  above  0.1% 
(Wilcox rank-sum two-tailed p-values for CALPHA vs. DAPPLE/SEQ at 0.1%, 0.3%, 
0.5% and 1.0% additive genetic variance, respectively, are: network 1: 0.0715, 9.32e-13, 
2.01e-14, 2.19e-16; network 2: 0.0723, 4.53e-8, 1.89e-6, 0.0036; network 3: 0.257, 0.515, 
0.00373, 2.87e-13).  
  148 
 
Figure  4.9 D A P P L E / S E Q  i m p r o v e s  t r u e  p o s i t i v e  r a t e  a t  p < 1 e -4.  We  compared  the  true 
positive rate at p<1e-4 for the CALPHA test versus DAPPLE/SEQ. We found that for additive 
genetic variances greater than 0.1%, the method significantly improves the ability to detect risk 
genes (for 0.1%, 0.3%, 0.5% and 1% additive genetic variance, rank-sum comparison p-values 
are network 1: 0.0715, 9.32e-13, 2.01e-14, 2.19e-16; network 2: 0.0723, 4.53e-8, 1.89e-6, 0.0036; 
network 3: 0.257, 0.515, 0.00373, 2.87e-13). 95% confidence intervals are shown. 
  It is unlikely that the underlying disease etiology for complex traits consists of a 
single, small network. Afterall, what we have learned from GWAS is that complex traits 
are extremely polygenic. We were therefore interested in the behavior of DAPPLE/SEQ 
if  the  disease  etiology  were  due  two  separate  mechanisms.  We  simulated  risk 
simultaneously in network 1 and network 2 (19 proteins in total).  We were encouraged to 
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find the same general trends. First, risk genes previously at pCALPHA > 2.5e-6 became 
genome-wide significant, though the percent of risk genes at this cutoff leveled off after 
0.3% additive genetic variance (Figure 4.10, see discussion for why this might be).  
 
Figure 4.10 Percent of risk genes that rise to genome-wide significance after introduction of 
PPI data for joint networks 1 and 2. We simulated risk on networks 1 and 2 simultaneously for 
~50 datasets (2000 cases, 2000 controls for each simulation) and ran DAPPLE/SEQ. We then 
counted the number of risk genes that earned a score that passes the Bonferroni corrected cutoff 
of 2.5e-6. 95% confidence intervals are shown.  
Second,  a  consistent  increase  in  genes  achieving  pDAPPLE/SEQ<1e-4  was  also 
observed for the joint network (Figure 4.11). When compared to the same cutoff using 
CALPHA  alone,  the  true-positive  rate  for  DAPPLE/SEQ  at  p<1e-4  is  improved 
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significantly  in  most  cases  (Wilcox  rank-sum  two-tailed  p-values  for  CALPHA  vs. 
DAPPLE/SEQ at 0.1%, 0.3%, 0.5% and 1.0% additive genetic variance, respectively, 
are: network 1: 1.31e-10, 3.44e-10, 3.5e-9, 6.78e-9; network 2: 0.435, 3.95e-5, 0.00201, 
0.00494). 
 
Figure 4.11 DAPPLE/SEQ improves p-values for risk genes in a joint model with networks 
1 and 2 are simultaneously associated. We simulated risk simultaneously in networks 1 and 2 
and compared the true positive rate at p<1e-4 for the CALPHA test versus DAPPLE/SEQ. When 
compared to the same cutoff using CALPHA alone, the true-positive rate for DAPPLE/SEQ at 
p<1e-4  is  improved  significantly  in  most  cases  (Wilcox  rank-sum  two-tailed  p-values  for 
CALPHA  vs.  DAPPLE/SEQ  at  0.1%,  0.3%,  0.5%  and  1.0%  additive  genetic  variance, 
respectively,  are:  network  1:  1.31e-10,  3.44e-10,  3.5e-9,  6.78e-9;  network  2:  0.435,  3.95e-5, 
0.00201, 0.00494). 95% confidence intervals are shown. 
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  The false positive rates for all 4 risk networks (network 1, network 2, network 3 
and joint networks 1&2) are shown in Figure 4.12. The reason behind a non-zero false 
positive rate is that sometimes, associated sub-networks will cause close PPI neighbors to 
become highly significant. It is therefore important to consider CALPHA results jointly 
with DAPPLE/SEQ results in evaluating candidates for follow-up. 
 
Figure  4.12 F a l s e  p o s i t i v e  r a t e s  at  p<2.5e-6  for  DAPPLE/SEQ  on  4  risk  networks.  The 
percent of non-risk genes achieving pDAPPLE/SEQ<2.5e-6 for all 4 networks is shown. 1 standard 
deviation is plotted. 
  We then asked whether the method controls for binding degree bias in the data. 
We found that it may be conservative with respect to nodes of high binding degree. As 
discussed in chapter 2, the InWeb database (and PPI databases in general) is affected by 
publication bias: well studied proteins will appear to be more connected than others, even 
if they are not so in the true set of biological connections. As shown in Figure 4.13, there 
is  a  significant  negative  correlation  (r=-0.06,  p=8.6e-10)  and  genes  of  high  binding 
degree  are  rarely  significant,  suggesting  that  DAPPLE/SEQ  is  conservative;  that  is, 
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highly connected nodes are less likely to achieve significance. This likely explains the 
more modest effect observed with network 3, whose mean global binding degree (the 
average binding degree in the InWeb database) is 73.6, while for networks 1 and 2 it is 
25.6 and 45.5. 
 
Figure  4.13 C o r r e l a t i o n  b e t w e e n  DAPPLE/SEQ p -value  and  protein  binding  degree.  A 
representative simulation (0.3% additive genetic variation, network 1) is plotted (proteins at > 3 
standard deviations away in binding degree were removed). r=-0.06, p=8.6e-10. 
4.4  Discussion 
In this chapter, we have provided preliminary evidence that considering functional 
relationships between genes when analyzing rare variants (both de novo and inherited) 
can highlight risk genes that would have been otherwise missed. The results presented 
here  are  extremely  promising  to  the  field,  as  investigators  are  now  looking  for  rare 
variation  that  influences  risk  to  disease  but  are  uniformly  encountering  significant 
analytic  challenges[150].  Based  on  early  results,  most  have  found  that  the  current 
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methods for association analysis (both SNP-wise and gene-wise via burden tests) are 
underpowered due to the extreme rarity of these types of genomic events. For diseases 
where risk is distributed over functional networks – which is likely the case for many 
heritable complex traits, as we have shown in previous chapters – introducing protein-
protein interaction data to the analysis might offer a novel route to identifying risk genes 
and processes. 
The network assembled from the autism de novo variants is extremely promising. 
In sporadic cases of autism (simplex families), one hypothesized genetic etiology is that 
de novo point mutations make contribute to risk in some cases, similar to sporadic CNVs 
[55]. While a large burden of de novo variation was not necessarily observe beyond a 
small excess of non-sense mutations, we show that the genes baring de novo variation in 
autism patients is significantly enriched for proteins that physically connect to each other. 
We show that the network genes are co-expressed in brain and that the genes implicated 
suggest chromatin and transcriptional regulation, as has been recently found by another 
group[165]. This type of analysis therefore might be promising in terms of identifying 
particular  genes  on  which  to  follow  up.  Moreover,  this  network  can  now  serve  as  a 
candidate for future case/control focus, as mechanisms affected by de novo variants that 
contribute to disease may be similar to those affected by inherited variants.  
We have also described a method to extend this concept to rare variants discovered 
through case/control sequencing. Similar to the early days of GWAS, exome sequencing 
studies so far have found very little evidence for strong associations. Almost certainly, 
increasing power should yield more results in the future. However, it may be the case for 
rare variants that distinguishing them from background variation is so difficult that joint  
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consideration of biological process in genetic association studies will be required. While 
the results are based only o  n  simulated  data,  they  serve  as  a  principled  test  of  the 
method  (DAPPLE/SEQ)  and  proof  that  detecting  local  areas  of  PPI  connectivity 
associated to rare variation is possible, even when the additive variance explained by a 
gene is considerably low.  
Interestingly, DAPPLE/SEQ performs much better on networks 1 and 2 than it does 
for network 3. We hypothesize that the method is limited in its detection of association at 
nodes of unusually high binding degree in the InWeb database, likely due to the step that 
controls for visitation bias due to degree. Indeed, Figure 4.13 shows that nodes of higher 
degree  have  systematically  lower  association  scores.  In  future  applications  of  this 
approach,  solutions  to  this  problem  should  be  considered,  such  as  down-sampling  of 
edges for highly-connected nodes. It is also interesting to note that DAPPLE/SEQ is 
slightly  power-limited  in  scenarios  of  multiple  risk  mechanisms  as  additive  genetic 
variance per gene increases (Figure 4.10). The likely driving force is that the method is 
competitive:  nodes  compete  with  each  other  for  visitation.  In  scenarios  of  multiple 
disconnected mechanisms, each one draws visitation time from the next, which might 
impair signal to noise detection. Nonetheless, the approach still out-competes tests of 
genetic association alone. 
It  is  important  to  underscore  that  these  results  are  preliminary.  The  inherent 
limitation to simulations is that it is computationally unfeasible to test the full range of 
possible  parameters.  Future  work  will  include  varying  gene-wise  assigned  risk,  trait 
heritability,  network  size,  network  connectivity  and  percent  of  network  affected.  In 
addition, other functional connectivity datasets can be used – for example, co-expression  
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datasets are well suited for this application. Nonetheless, the results described here should 
serve  as  promising  evidence  that  the  prospective  consideration  of  the  functional 
relationships  between  genes  can  significantly  improve  the  discovery  of  rare  variants 
influencing disease.  
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5  Discussion 
 
This thesis describes three approaches to combine genetic and proteomic data. In 
Chapter 1, we describe an in silico PPI analysis tool to test loci associated to complex 
traits  for  harboring  genes  that  are  significantly  related  through  physical  interactions. 
Abundant evidence is provided to show that this method, called “DAPPLE”, is able to 
detect enriched connectivity in loci associated to two autoimmune diseases, prioritize 
genes in large loci and propose new genes for follow-up based on their connectivity to 
the disease network. We then explore the use of directed experiments in discovering PPIs 
by focusing on the genetics of QT-interval variation. We show that the heart-specific 
protein complexes of 5 known long-QT syndrome proteins are not only highly enriched 
for proteins near common variants associated to QT-interval variation but also able to 
point to novel genes previously not known to affect the QT-interval. We extend this 
concept to rare variation in Chapter 4, which due to its infrequent nature requires novel 
statistical methodological development for analysis. Using a case example of de novo 
variation in autism, we show that DAPPLE can successfully highlight de novo variants 
that  may  be  relevant  to  autism  even  if  no  standard  statistical  methodology  can  be 
employed to identify specific genes on which to follow up. Finally, we implement and 
test a tool (“DAPPLE/SEQ”) to analyze rare inherited genetic variation in the context of 
protein-protein  interaction  data.  Using  simulated  risk  variation,  we  show  that 
DAPPLE/SEQ  significantly  improves  the  ability  to  detect  rare  risk  variants  that  are 
distributed over a network of interacting proteins.  
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Since being published, DAPPLE has been widely used by the community and 
therefore empirically tested as to its applicability to a broad spectrum of complex traits. 
In the first year, it has been used 1,500 times by 350 unique users across the world. For 
example,  Raj  and  colleagues  found  that  Alzheimer’s  disease  susceptibility  loci  under 
natural  selection  form  significant  interaction  networks[166];  Cotsapas  and  colleagues 
showed discrete networks associated with clusters of shared autoimmune susceptibility 
loci[167]; Morris and colleagues identified a network underlying new loci associated to 
Type  2  Diabetes  [manuscript  accepted  at  Nature  Genetics];  and  Irvin  and  colleagues 
identified  a  significant  network  underlying  genes  associated  to  subcutaneous  adipose 
tissue  distribution  in  HIV-infected  men[168].  In  our  own  work,  we  have  observed 
significant underlying connectivity in susceptibility loci for Crohn’s disease, rheumatoid 
arthritis,  blood-lipid  levels,  height,  QT-interval  variation,  autism  (via  de  novo  point 
mutations),  schizophrenia[169]  and  multiple  sclerosis,  among  others.  The  results 
therefore  seem  to  extend  beyond  the  particular  phenotypes  studied  here,  and  more 
generally provide evidence for the concept that loci associated to complex traits code for 
proteins that physically interact with one another.  
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Figure 5.1 Cumulative per-day users of DAPPLE 
   
  The concept of applying protein-protein interaction networks to genes of interest 
is not new, but only recently has it begun to be rigorously employed to human genetics. 
Many groups have also recently integrated proteomics and genetics in creative ways to 
highlight  mechanisms  underlying  complex  traits.  Wang  et  al.  recently  created  a  3-
dimensional structural interface map of human protein-protein interactions, and showed 
that disease-causing mutations are more likely to be at the interaction interface of the 
associated protein, with location within the interface giving specificity to the particular 
disease[170]. Dutkowski and Ideker showed that better predictive models can be made in 
breast and brain cancer metastasis if one combines genetic mutations with the protein 
networks  that  are  affected[171].  Sang  et  al.  used  purification  of  ciliopathy  protein 
complexes to link different ciliopathies to specific mechanisms as well as to discover new 
genes causal of ciliopathy in humans[172]. Though the idea of deciphering the protein-
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binding partners of genes of interest is an old approach, the formal integration of large-
scale networks with human complex trait genetics has been receiving more and more 
attention over the last decade.  
The future of integrative in silico PPI and genetic network analysis will likely 
include more specific and multifaceted snapshots of cellular processes. For example, in 
Chapter 2 and 4 we overlay expression data onto CD, RA and autism networks to make 
sure that the interactions identified were between proteins expressed in the same tissue 
and ensure that the highlighted tissue makes sense in the context of disease (though this 
does not necessarily have to be the case and could offer insight into unexpected biology). 
However, it is likely that a more formal integration of expression data with PPI data will 
be  powerful  and  will  allow  testing  of  tissue-specific  networks,  rather  than  post  hoc 
analysis. In addition to co-expression, other types of connectivity information – such as 
co-regulation and genetic interactions – is going to be useful and represents some of the 
main  foci  of  systems  biology  today  [173–175].  Furthermore,  interactions  do  not 
necessarily need to be represented as binary: here, we binarize the InWeb database for 
ease  of  analysis;  however,  using  the  raw  confidence  scores  might  improve  analysis 
capabilities by calculating weighted distances between nodes rather than restricting to 
one- and two- degree relationships. 
  In  addition,  the  future  will  likely  also  include  dynamic  snapshots  of  cellular 
processes that are relevant to the phenotype being studied. While some interactions are 
stable across different cellular stresses, it is likely that the topology of the underlying 
interaction  landscape  changes  as  perturbations  (genetic,  pharmacologic,  etc)  arise. 
Therefore, it will become important to construct “differential” networks, where edges are  
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qualitatively characterized by how they change under specified conditions. This type of 
analysis would be alike to expression analysis, where measuring differential expression 
with condition is considered the norm[176]. 
  What  has  become  clear  from  extensive  exploration  of  the  public  PPI  data, 
however, is that we cannot rely solely on public databases: directed in vivo experiments 
are warranted. In chapter 3, we focused on 5 proteins and elucidated their heart-specific 
interaction partners. While the members of the complexes significantly overlapped with 
interactions documented in the literature, there were many interactions that are not only 
novel but involve proteins that are relevant to disease and affect the QT-interval when 
tested in Xenapus oocytes and zebrafish. Looking forward, it will likely be extremely 
powerful  to  carry  out  gene-specific  and  tissue-specific  PPI  experiments  rather  than 
relying only on public databases. For example, Sakai et al. recently conducted a yeast-2-
hybrid  screen  of  26  autism-associated  genes  and  found  numerous  novel  connections, 
including the ability to predict new genes that when tested in independent samples were 
affected by CNVs in autistic individuals[155]. The two approaches (public and directed) 
do  not  have  to  be  mutually  exclusive  but  rather  can  be  cooperative,  whereby  public 
databases help generate testable hypotheses and are in turn dynamically augmented by 
specific experiments. 
  Furthermore,  as  proteomic  technologies  continue  to  advance,  proteome-wide 
complex purifications will hopefully become feasible. This will allow for the unbiased 
assaying of the full protein-protein interactome without relying on the literature, which 
suffers from publication bias. Though no approach will be truly unbiased (since certain 
proteins will naturally be easier to assay than others, certain tissues will be easier to  
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culture, etc), it will fill in missing pieces of the interactome that are currently less well-
studied. These pieces likely will provide novel insights into regions of the genome that 
are definitively associated to disease but poorly annotated. 
  The ultimate promise of network-based interpretation of disease is that it might 
help steer therapeutic design.  For example, Berger et al. showed that the sub-network 
surrounding  long-QT  proteins  is  enriched  for  FDA-approved  drug  targets  that  cause 
prolongation of the QT-interval, a known side effect of many drugs[134]. They then went 
on  to  predict  and  validate  drugs  that  affect  the  QT-interval,  illustrating  the  general 
principle that biological networks built from disease-associated genes can point to new 
proteins relevant to therapy. While this study focused on adverse events, a logical next 
step is using networks to point to proteins as novel targets for disease or that are better 
targets than the current ones. The current target-based drug discovery platforms are poor 
at predicting drug efficacy and the full spectrum of side-effects, which is one of the 
reasons that most drugs do not survive the drug development process[177,178]. Moving 
away from target-based design toward network-centered design may help increase the 
efficiency of the therapeutic design process because a more complete consideration of the 
biological context of a drug target will take place. 
  Hopefully, we have provided convincing evidence in this thesis that the field of 
human  genetics  is  ready  to  start  projecting  its  findings  onto  networks  of  gene-gene 
relationships.  Studying  variants  associated  to  disease  in  the  context  of  the  biological 
systems in which they exert their effect is of utmost importance to translating genetic 
findings  to  function  and  ultimately  to  medical  relevance.  The  entire  goal  of  human 
genetics  is,  afterall,  to  unveil  the  pathophysiologic  mechanisms  that  are  currently  
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unknown. To achieve this goal, it will be very powerful to include in our analyses the fact 
that genes and their protein products do not act alone; they are part of complex networks 
of proteins that together produce the phenotypes that we study in human genetics. 
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